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Abstract
Malaria is a widespread and serious disease which affects billions of people. Protein-protein
interactions occurring between host and Plasmodium parasites are critical to the pathogenesis
of malaria and thus represent prime targets for greatly-needed novel therapeutics. Identify-
ing these host-pathogen interactions is challenging, but recent advances in our understanding
of parasite biology and in high-throughput biomolecular interaction detection methods have
paved the way to a number of successes.
In this work I produced a library of recombinant Plasmodium falciparum proteins to screen
for interactions with human receptors in a number of high-throughput assays. Using an estab-
lished ELISA-based protein-protein interaction detection method, I identified an interaction
between P. falciparum merozoite protein 7 (PfMSP7) and human P-selectin (SELP). I used
surface plasmon resonance and flow cytometry approaches to validate this interaction and,
by screening more widely across the MSP7 protein family, identified that SELP-binding is a
conserved property of multiple MSP7s in at least three Plasmodium species. The evolution-
ary conservation indicates that SELP-MSP7 interactions might have an important function
in malaria. Isolating the interacting regions of SELP and PfMSP7 to the secreted, flexible
N-terminus of PfMSP7 and the known ligand-binding domains of SELP led to a hypothesis
that PfMSP7 could prevent the leukocyte recruitment and activation properties of SELP. I used
PfMSP7 to block the interactions between SELP and leukocyte ligands in vitro, providing sup-
port to this hypothesis. Further evidence will be required to determine whether Plasmodium
MSP7 proteins and their interactions with SELP mediate an immunomodulatory mechanism
in malaria, and whether the MSP7 proteins represent useful therapeutic targets.
I also developed a biochemical co-purification assay aiming to detect additional interactions
between recombinant P. falciparum merozoite extracellular proteins and those present in hu-
man serum. This assay was successful in detecting previously-identified interactions but did
not identify novel binding partners for 56 P. falciparum ligands. By expanding the screen or
by decreasing its stringency this method could facilitate the identification of further receptors
for Plasmodium ligands which could in turn, like the interaction between SELP and MSP7s,
aid our understanding of how host and pathogen interact to cause disease.
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Chapter 1
General introduction
1.1 An introduction to malaria
1.1.1 Malaria as a major global health problem
Caused by protozoa of the Plasmodium genus, malaria is a disease that has plagued humanity
since antiquity. Challenges in surveillance make it difficult to quantify the current global
burden of malaria; the World Health Organisation (WHO) estimated the number of clinical
cases in 2010 to be over 200 million, with over one million being fatal, but it is possible that
this is a significant underestimate[136, 359]. Approximately half of the world’s population
live in areas where malaria is endemic and the disease persists particularly in some of the
world’s poorest countries. Sub-Saharan Africa bears the largest burden of this severe disease,
which has its most devastating effects in young children and represents a major barrier to
development[360].
One of the United Nations’ Millennium Development Goals was to bring about a decrease
in the global incidence of malaria by 2015. This has catalysed truly international research
efforts, with an annual investment in excess of $2billion towards combating what was previ-
ously a neglected, understudied disease[266]. Progress has been abundant: half of all sub-
Saharan African households are now thought to own a protective insecticide treated bed-
net[360]; annotated genome sequences are available for a growing number of Plasmodium
isolates[48, 49, 107, 255, 260]; and the world’s first malaria vaccine (albeit only partially ef-
fective) has been developed[244]. Such efforts are estimated to have prevented a quarter of a
billion cases and saved over one million lives[360].
Despite ongoing successes in disease prevention and treatment, there is still a great need to
better understand the pathology of malaria, the biology of Plasmodium parasites and the dy-
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namics of transmission to confront challenges in the future. We still lack an effective vaccine
and are encountering a growing number of drug-resistant parasites. Furthermore, it is possi-
ble that changes in global climate and human behaviours will bring the threat of malaria to
immunologically naïve populations[88].
1.1.2 Plasmodium parasites cause malaria
Apicomplexan Plasmodium parasites are single-celled eukaryotes, over 200 species of which
have been identified. Plasmodium species have parasitised birds, reptiles and mammals long
before the evolution of humans, with the earliest evidence for their existence dating as far
back as 30 million years[267]. Human infection is thought to have originated on multiple
occasions from ape-infecting parasites and is thought to have become prevalent around the
time of the Agricultural Revolution over 10,000 years ago[191, 194, 195], with Plasmodium
DNA still detectable in human remains from Ancient Egypt[182]. These protozoan parasites
were identified by microscopy as the causative agent of malaria in the late 19th century, and
mosquitoes were soon after identified as being responsible for transmitting these parasites to
humans[283].
All Plasmodium species complete a complex life cycle between a vertebrate and mosquito
host, progressing through a series of morphologically-distinct forms, first described over 200
years ago[121](Figure 1.1). Human infection begins when a host is bitten by an infected
Anopheles mosquito. When the mosquito takes a blood meal, Plasmodium sporozoites en-
ter the human host via the skin. These sporozoites migrate to the liver where they replicate
asymptomatically to create thousands of merozoites, which are released into the bloodstream.
Here the parasites undergo further cycles of asexual reproduction. These cycles begin with
the merozoites’ invasion of a red blood cell (RBC), within which they replicate. These new
merozoites cause lysis of the RBC, such that they are released back into the blood where
they rapidly invade a new RBC. A subset of merozoites will develop into gametocytes, which
go on to produce micro- and macro-gametes that fuse as part of sexual reproduction in the
mosquito host. Fused gametes develop into diploid ookinetes, which are able to cross the
mosquito midgut wall and form an oocyst, where sporozoites develop. Once these sporozoites
are released they invade the mosquito salivary gland, allowing them to be transmitted to a new
human host when the mosquito feeds.
At least five Plasmodium species naturally infect humans. P. falciparum is responsible for the
most severe cases of malaria, and for the majority of fatalities. It is found throughout South
East Asia and in parts of South America but is hyperendemic in most of Sub-Saharan Africa,
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with as many as 50% of people infected[310]. P. vivax is thought to cause the largest number
of infections globally, but has been less widely studied, perhaps owing to its lower mortality
rate[219]. Whilst P. vivax infections do occur in Africa, the majority of clinical cases occur
in Central Asia[114]. Infections with P. malariae, or one of the two sub-species of P. ovale
are not known to be as prevalent, but are likely under-reported[44, 322]. These particular
parasites have thus received comparatively little attention in the form of research effort. P.
knowlesi was long-considered a macaque pathogen, but is now recognised to cause disease in
people living in the regions of South East Asia where humans and macaques interact[162].
Mixed infections, whereby hosts are simultaneously infected with more than one Plasmodium
species are also thought to be common[208].
Figure 1.1: Parasite life cycle in the human host
Figure from Invasion of red blood cells by malaria parasites by Cowman and Crabb
(2006)[61]. Reproduced with permission.
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1.1.3 Plasmodium merozoites invade red blood cells
1.1.3.1 Merozoite structure
The blood-stage merozoite form of the parasite has been the most intensively studied, and is
the primary focus of the work described in this thesis. At just over 1µm in length P. falciparum
merozoites are amongst the smallest known eukaryotic cells. Free merozoites have an elliptical
cross section with a projected apical end where secretory organelles - rhoptries, micronemes
and dense granules - are located (Figure 1.2). Parasites also possess a highly specialised en-
domembrane system known as the inner membrane complex (IMC) located just below the
plasma membrane. This structure and its connections to the cytoskeleton are thought to play
critical roles in determining and maintaining the shape of the merozoite, in cell division, and in
mediating its RBC-invasion mechanism[3, 22, 39]. The merozoite surface is covered in a 15-
20nm thick filamentous coat[14] comprised primarily of a number of glycosylphosphatidyli-
nositol (GPI)-anchored membrane proteins and peripherally associated proteins[115, 293].
Amongst these integral membrane proteins are those described as MSPs (merozoite surface
proteins), including PfMSP1, 2, 4, 5 and 10 and a family of cysteine-rich proteins which are-
associated with adhesive properties in P. falciparum[221]. These proteins interact with other
Figure 1.2: Merozoite structure and RBC invasion ligands
Figure from That was then but this is now: malaria research in the time of an eradication
agenda by Kappe et al., (2010)[163]. Reproduced with permission from AAAS.
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parasite proteins, including those from the PfMSP3- and PfMSP7-families, which themselves
do not possess a GPI anchor or transmembrane domain, to tether them to the merozoite sur-
face. The PfMSP1 and PfMSP2 proteins are thought to comprise about two-thirds of the total
protein content of the merozoite surface[115]. PfMSP1 is proteolytically processed such that
four associated PfMSP1 peptides derived from a single precursor are present on the merozoite
surface[28]. A fragment of each PfMSP6 and PfMSP7 are also peripherally associated with
these PfMSP1 fragments to constitute an assembly known as the MSP1 complex[257, 336].
A number of other membrane proteins and peripherally-associated proteins have been identi-
fied as more minor components of the merozoite surface, many of which are delivered from
Plasmodium’s secretory organelles prior to RBC invasion[61, 293].
1.1.3.2 RBC invasion and parasitism
In order to invade a host RBC, the merozoite carries out a number of steps in a defined
sequence, which has been elucidated by microscopy[4, 81]. The invasion process involves
molecular recognition events which cause the initial physical association between the two cell
types. The merozoite then re-orientates such that its apical pole is in contact with the RBC
surface, with which a tighter interaction is then made. Powered by its actin-myosin motor
complex, the merozoite actively drives entry into the RBC, such that this tight junction moves
from the apical to the posterior end of the merozoite[166]. During this invasion process,
merozoite surface proteins and those involved in the tight junction are proteolytically cleaved
and released into the bloodstream[135]. The final result of this process is that the merozoite
ends up in the RBC cytoplasm surrounded in host-derived membrane in what is known as the
parasitophorous vacuole. Whilst inside the RBC, the parasite digests a substantial proportion
of the host cell’s haemoglobin. Some of this haemoglobin consumption provides nutrition for
parasite growth but it is thought that it plays a more pivotal role in regulating the osmotic sta-
bility of the parasitised RBC (pRBC), so as to prevent lysis before the parasite has undergone
asexual reproduction[192]. After merozoites have divided several times, the pRBC, at this
point termed a schizont, ruptures, releasing as many as 32 merozoites into the bloodstream.
Within a matter of seconds, these merozoites invade new RBCs and the cycle repeats. Mero-
zoites are known to progress through their erythrocytic cycle in synchrony, resulting in waves
of RBC rupture, occurring approximately every 48 hours in P. falciparum malaria1. The mech-
anism and function of this synchrony is not fully understood; it could potentially be driven by
the host responses to infection, or conversely be an adaptation of the parasite to overwhelm
1Synchronicity in merozoite invasion/lysis cycles is not observed in all infections, and is less common when
the host is simultaneously infected by Plasmodium parasites with a diverse range of genotypes[334]
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the immune system when merozoites are exposed[127, 176].
Whilst intracellular, P. falciparum is known to modify the surface of the pRBC by traffick-
ing a subset of its own proteins to the membrane. Amongst these is PfEMP1[214], deriving
from a family of around 60 highly variable proteins, encoded by var genes. PfEMP1 is a
critical component of ’knob’ structures on pRBCs which enable them to adhere to vascular
endothelia[62], thus avoiding passage to, and destruction by, the spleen. This process is re-
ferred to as cytoadherence or sequestration and is thought to account for the much of increased
morbidity associated with P. falciparum infections compared with other Plasmodium species.
PfEMP1 is also thought to mediate platelet-mediated clumping of pRBCs[259] and ’rosetting’
whereby pRBCs aggregate with uninfected RBCs[54].
1.1.4 Malaria can have life-threatening sequelae
The first symptoms of infection with Plasmodium parasites occur after an incubation period
of at least one week. Although malaria is often described as being characterised by a periodic
fever in the human host, it usually presents as a combination of symptoms including, but not
limited to, fever, chills, headaches, nausea and malaise. In uncomplicated infections these
symptoms can be temporarily debilitating but usually resolve within a few weeks. However,
a proportion of infections do progress to severe, life-threatening syndromes. Severe Malarial
Anaemia (SMA) is defined by the WHO as having detectable parasitaemia and a hematocrit
lower than 15%, indicating that RBC counts are at least half healthy levels[248]. SMA is re-
sponsible for a large proportion of childhood deaths in malaria-endemic regions[84]. Anaemia
results not only from the direct parasite-driven lysis of pRBCs but primarily from the destruc-
tion of uninfected RBCs[150], by macrophage-mediated phagocytosis or clearance by the
spleen[179]. Respiratory distress, renal failure and septic shock-like symptoms can develop
in a subset of cases and are responsible for a small proportion of fatalities.
Certain sequelae are particular to P. falciparum malaria. Cerebral malaria, thought to occur
in about 1% of clinical P. falciparum cases[360], is characterised by neurological impair-
ment and can lead to coma and death. Adherence of pRBCs in the brain is thought ob-
struct blood flow through cerebral microvasculature, which might deprive the brain of oxy-
gen. At the same time, the pro-inflammatory cytokines produced as part of the anti-parasite
immune response are thought to destabilise the blood-brain barrier, exacerbating the neuro-
logical impairment[142]. Pregnant women are at particular risk from P. falciparum malaria.
Parasites express a specific PfEMP1 variant that is able to bind to placental CSA, which causes
the adherence of pRBCs to blood vessels in the placenta[344]. This blocks the flow of nutrients
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to the developing foetus and as such can negatively affect the outcome of the pregnancy.
Although re-infection is common in malaria-endemic regions, those who recover from P. fal-
ciparum malaria and remain unexposed do not develop any further symptoms. However, re-
currence of disease can be observed many years after exposure to P. vivax or P. ovale, the
parasite remaining dormant in the liver in a form known as the hypnozoite[57].
1.1.5 Natural immunity to malaria provides incomplete protection from
Plasmodium infections
Immunity to malaria is enigmatic. Even people living in endemic regions are not thought to
develop true sterile immunity to malaria. However, provided they are continually exposed,
people gradually develop a level of protection against life-threatening disease, even when
parasites are detectable in their blood (Figure 1.3). This slow development of immunity is
widely considered to be the result of strain-specificity in immune responses[153], such that
apparent immunity results from the generation of a repertoire of strain-specific responses to a
diverse range of Plasmodium parasite infections[70]. This would explain why the majority of
deaths occur in infants and why protection from severe disease appears to wane in the absence
of continual exposure.
1.1.5.1 Innate and adaptive immune responses
The immunological basis of protection against malaria is still unclear and has been investi-
gated at multiple stages of the parasite lifecycle. Whilst the induction of anti-sporozoite an-
tibodies has been shown to provide protection against disease[165, 269, 301], the sporozoite
stage has not been clearly demonstrated to be a target of protective antibody responses in nat-
ural infections. Since blood-stage infection is so commonly observed it is often assumed that
naturally-induced immune responses against sporozoites are largely ineffective at preventing
disease. This might result from the low number of sporozoites transmitted by the mosquito2,
which provides a scarcity of antigen against which the immune system can respond. There
is also a body of evidence suggesting that sporozoites drive the suppression of anti-parasite
immune response from the moment they are injected into the skin[130].
The mechanisms by which the host controls blood-stage Plasmodium parasites have been in-
vestigated extensively, however a unified picture of which responses are protective has not yet
emerged. Antibody responses have long been recognised as important in controlling infection,
since the observation that immunoglobulins prepared from adults living in endemic areas could
2Studies in rodent models suggest a median of about 18 sporozoites are injected per bite[212]
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Figure 1.3: Acquisition of immunity to malaria
Data collected from a population living in an endemic region of P. falciparum transmission
show that immunity to severe disease is acquired during infancy, but infections still persists
into adulthood.
Figure from Immunity to malaria: more questions than answers by Langhorne et al.,
(2008)[185]. Reproduced with permission.
have a therapeutic effect on children suffering from malaria[58]. A dependence on antibody to
limit parasitaemia has been corroborated by studies in B-cell deficient mice, that are unable to
clear P. chabaudi from the blood[184]. Antibody may function to control infection in several
ways; by directly binding to merozoite antigens marking the parasite for antibody-dependent
cell mediated killing and phagocytosis[149, 252], by binding to merozoite antigens to prevent
them from invading RBCs[29], or by binding to PfEMP1 on pRBCs to induce their clearance
from the bloodstream[37]. A broad range of parasite-specific antibodies are detectable in the
serum of P. falciparum-exposed individuals, but it is still unclear as to which confer protection
from severe disease[91]. PfMSP2, PfMSP3, PfMSP7, PfSEA1, PfAMA1, PfGLURP and Pf-
SERA9 are amongst a growing number of candidate proteins against which antibody is thought
to protect individuals in specific populations [124, 145, 243, 251, 273, 311]. More thorough
analyses of a larger range of candidate antigens will be required to develop a complete picture
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of naturally-protective antibody responses.
Antibody-independent mechanisms also play a role in the host immune response to infec-
tion by Plasmodium parasites. A number of PAMPs (pathogen-associated molecular pat-
terns), including GPI (by which merozoite surface proteins are anchored to the membrane)
and haemozoin (produced from the parasites’ digestion of RBC haemoglobin), are thought
to bind to Toll-like receptors (TLRs), and stimulate both CD4+ and CD8+ T-cells to produce
pro-inflammatory cytokines[56, 93, 236]. These cytokines include Interferonγ (IFNγ) and Tu-
mour Necrosis Factor α (TNFα), which are thought to contribute to parasite killing in the
early stages of infection[92, 231, 232]. However, the activation of an inflammatory immune
response in malaria has more often been associated with a negative outcome for the host, the
over-production of cytokines being considered highly immunopathological[199].
1.1.5.2 Genetic resistance to malaria
The human race has evolved alongside Plasmodium parasites since antiquity, and its selective
pressures have left their mark on the human genome, such that resistance to certain strains of
malaria can be afforded by host genetic factors. Notably, a number of blood disorders are com-
monly associated with protection against malaria. The HbS variant of the HBB gene - which
encodes RBC β -globin component of haemoglobin - has arisen on multiple independent occa-
sions and been maintained in malaria-endemic populations, even though homozygotes suffer
from life-threatening sickle-cell disease. This risk is balanced against the ten-fold reduced in-
cidence of P. falciparum malaria in heterozygotes[1]. A number of other variants in the HBA
and HBB globin genes are also found in malaria-endemic regions, again affording a degree of
protection from malaria at the expense of sub-optimal haemoglobin functionality[55, 97, 226].
Similarly, a number of RBC enzyme deficiencies are thought to have been maintained in pop-
ulations as they prevent Plasmodium parasites from surviving intracellularly. The most com-
mon example is glucose-6-phosphate dehydrogenase (G6PD) deficiency which is observed in
African and Mediterranean populations that have evolved with P. falciparum infections[198].
Interestingly, it is thought that the parasite has adapted to produce its own G6PD, counteracting
the host’s once-innate defence[341]. Similarly P. vivax transmission in Africa was thought to
be restricted by the lack the FY Duffy blood group antigen, which was thought to be required
by the parasite for entry into the RBC[222]3. However it is now recognised that P. vivax iso-
lates from Madagascar are able to invade Duffy-negative RBCs indicating that parasites have
once again evolved to overcome this restriction[217]. Recent large-scale genome-wide studies
linking host genotypes with disease outcomes have helped to clarify the role of these host loci
3P. knowlesi is also thought to require Duffy antigen to enter RBCs
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believed to affect malaria susceptibility and have identified many more host genes that might
also contribute[151, 202].
1.1.6 Blood-stage P. falciparum parasites are highly adept at immune-
evasion
Part of the reason why long-lasting, sterile immunity to malaria is has eluded mankind may
lie in the ability of the parasite to overcome the defences of the host immune system. The
largely intracellular habitat of the parasite within RBCs shields Plasmodium parasites from
the onslaught of immune effector cells and molecules present in the blood. RBCs are one of
the few cell types that do not present intracellular antigen on their surface via MHC Class
I molecules, further hiding parasite-derived antigens from immune surveillance. The spleen
mechanically filters damaged RBCs from the blood and thus might be expected to bring about
the destruction of pRBCs. However, P. falciparum-infected RBCs adhere to endothelia (as
described in 1.1.3.2) so as to avoid passage to the spleen. PfEMP1 protein, displayed on
the surface of the pRBC, is critical for this adhesion process and is one of the few parasite
proteins that is directly exposed to immune effectors in the blood for more than a matter of
seconds. P. falciparum has evolved a sophisticated mechanism to prevent PfEMP1 from recog-
nition by the immune system. It only expresses one of a diverse range of approximately 60
PfEMP1-encoding var genes at any one time, such that antibodies raised against one PfEMP1
variant will be ineffective against parasites that display another[295]. Though their role in
disease is less well-characterised, antigenic switching of this kind has also been observed in a
number of pRBC surface proteins belonging to other multi-gene families. These include the
rif family[178] and stevor family which has been recently implicated in RBC invasion and
rosetting[238].
Plasmodium parasites are also thought to actively subvert the functioning of the immune sys-
tem; this may be particularly important in protecting free merozoites from destruction when
they are exposed between cycles of RBC lysis and invasion. There have been many reports that
Plasmodium parasites can impair the maturation of antigen-presenting dendritic cells (DCs),
possibly preventing them from stimulating parasite-killing activity in T-cells[197, 315, 340]. It
has been suggested that the haemozoin, produced by the parasites’ digestion of haemoglobin,
can mediate the observed suppression of DC function[223]. A parasite-encoded homologue
of human macrophage migration inhibitory factor (MIF) might also affect the function of
antigen-presenting cells (APCs), stimulating them to produce cytokines that drive the prema-
ture maturation of CD4+ T-cells such that their anti-parasite specificity is rapidly lost and does
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not contribute to immunological memory[320].
Whilst there is increasing evidence that certain naturally-induced antibodies do protect hosts
from infection (Section 1.1.5.1), there are a number of mechanisms by which parasites are
thought to suppress the generation of an effective, long-lasting antibody response. Memory
B-cell populations studied from people living in areas of high malaria transmission are con-
sidered under-responsive and potentially impaired in their ability to combat infection with P.
falciparum[143]. Many merozoite antigens display a great deal of sequence diversity between
isolates[18], indicating that they are under strong balancing selection exerted by the human
immune system. Alongside the antigen-switching behaviour exhibited by P. falciparum pro-
teins on the pRBC surface, this variability impairs the effectiveness of antibody repertoires
generated during previous infections to neutralise new infecting strains of the parasite. The
inability of the immune system to respond effectively to a malarial challenge, and the lack of
long lasting immunological memory present obstacles to making an effective vaccine.
1.1.7 Current anti-malarial measures
1.1.7.1 Chemotherapeutic agents
A wide range of anti-malarial drugs has been developed and used both as treatments and
as prophylaxis in immunologically naïve travellers to malaria zones. 4-Aminooquinolines,
such as chloroquine, are safe and affordable drugs that have been effective against all species
of Plasmodium known to affect humans. They form a complex with a waste product of
haemoglobin digestion that is toxic to the parasite, and prevent its degradation to haemozoin[245].
Arylaminoalcohols (structural relatives of aminoquinolones) and artemisinin derivatives have
been used for hundreds of years. There has been much speculation over the mechanism of
action of these drugs; arylaminoalcohols (such as quinine) have been suggested, like amino-
quinolones, to prevent the detoxification of haem degradation products. Artemisinin is thought
to cause oxidative damage to the parasite but the precise targets are unclear[220]. More re-
cently, drugs that target the parasite respiratory chain or biosynthetic pathways have been
developed[356]. A number of antibiotics also have an antimalarial activity, acting on the
prokaryote-derived apicoplast organelle (see Figure 1.2) upon which the parasite relies for
fatty acid and isoprenoid biosynthesis[353]. However these antibiotics are not used as stand-
alone treatment as they have a delayed-killing effect, dependent on the parasites’ completion
of an erythrocytic cycle[66]. In an effort to prevent the spread of drug resistance, many of these
classes of drugs are used in combination with one another, and new anti-malaria compounds
are being sought actively. Of note, nearly two million chemicals were recently screened for
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anti-parasite activity, which has led to the identification of novel drug targets and many chem-
ical starting-points for potential new drugs[104, 129].
1.1.7.2 Environmental management
There is currently no widely-available vaccine, so prevention of malaria in people living in en-
demic regions has relied solely on environmental management aimed at preventing infectious
bites from occurring. Interventions that target mosquito vectors have been a major contributor
to the eradication of the disease from many areas of the world, notably the USA where a rel-
atively short campaign saw the eradication of malaria by the 1950s. This elimination process
has involved the use of insecticides and the destruction of the stagnant-water habitats where
mosquitoes breed. For the areas of the world where infected Anopheles vectors still persist,
the WHO advocate that at-risk people sleep under an insecticide-treated bed net (ITN) and
that indoor surfaces are regularly sprayed with insecticides (indoor residual spraying, IRS).
They estimate that almost 60% of sub-Saharan African households have now been supplied
with ITNs and that 135 million people (about 4% of the at-risk population) are protected by
IRS[360]. In the small number of areas, often urban areas, where mosquito breeding sites
are easily-identifiable, accessible and few, biological or chemical agents are sometimes used
to eliminate developing larvae[247]. Innovative vector control strategies have been emerg-
ing in recent years. These include the generation of genetically-modified mosquitoes that are
resistant to infection[204] or that produce predominantly male offspring, so as to drive a pop-
ulation crash[102]. Interventions of this kind rely on the large-scale generation and release of
genetically-modified insects, which is currently a logistical challenge.
1.1.8 Threats to the elimination of malaria
1.1.8.1 Antimalarial drug resistance
Whilst prophylactic drug treatment for malaria is effective for travellers who visit malaria
zones, the lifelong treatment of the billions at risk from malaria would not be practicable.
The spread of drug-resistant parasites threatens the utility of these preventative and curative
treatments. Chloroquine, once the first-line treatment for P. falciparum malaria, was consid-
ered to be a highly effective treatment until the emergence of resistant strains in the 1960s.
Resistance is thought to have evolved in at least four independent incidences and has now
spread such that chloroquine treatment failure rates are high in almost every country studied
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to date4, approaching 100% in a number of areas[246]. Similar emergences of drug-resistant
parasite strains have led to an over-reliance on artemisinin-based therapies, but in recent years
resistance to this drug has also been identified[225]. The use of combination therapies has
been an important step in preventing the spread of antimalarial resistance, however multi-
drug resistant strains are emerging, which is a serious concern. Adaptations in transporter
proteins which allow the parasite to expel these drugs from their sites of action include mu-
tations in the pfcrt gene and amplification of the pfmdr1 gene, and have become particu-
larly widespread[170, 246]. This does not necessarily mean that our repertoire of antimalarial
drugs is now useless; just ten years after the withdrawal of chloroquine treatment in Malawi,
chloroquine-sensitive parasites dramatically re-emerged such that treatment failure rates re-
turned to negligible levels[188]. However the potential for chloroquine-resistant parasites to
re-surface under the selective pressure of drug treatment is all too clear.
Many existing treatments, such as quinine and artemisinin, are derived from naturally occur-
ring remedies discovered hundreds of years ago. We can no longer rely on chance discoveries;
an in-depth knowledge of the molecular biology of the parasite will better inform the rational
design of new drugs and the combinations of treatments that will best guarantee long-term
treatment success.
1.1.8.2 Insecticide-resistant mosquitoes
Whilst the use of insecticides has been arguably the biggest contributor to a recent reduction in
the global incidence of severe malaria, and is still effective in most areas, it is widely believed
that the spread of resistant mosquitoes will threaten the continuation of this decline. Four
main classes of insecticides are used against malaria, and mosquitoes resistant to each of them
have been identified[11, 271]. Furthermore, almost all ITNs are treated with pyrethroids,
against which there are the largest number of reported cases of resistant mosquitoes. It is
estimated that if pyrethroids lose their efficacy over half of the benefit of current vector control
programmes would be lost, resulting in over 100,000 additional deaths every year[249]. These
concerns make the establishment of new preventative measures an urgent priority.
1.1.8.3 Challenges of vaccine development
Although antimalarial drugs and vector control have been highly effective in preventing malaria,
the ideal for long-term prevention would be an effective and widely-available vaccine. More
than 40 P. falciparum malaria vaccine formulations have reached the clinical trial stages of
4Chloroquine is still effective in some regions of Central America
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development[300]. Two of the most-developed are based on sporozoite-stage antigens; al-
though natural immunity is not thought to rely on targeting sporozoites, the induction of a
neutralising anti-sporozoite response could result in sterile immunity, which would be the
gold-standard of efficacy for a vaccine. RTS-S/AS01E is a vaccine based on the P. falciparum
circumsporozoite protein (PfCSP). However, phase III clinical trials on this vaccine indicated a
only partial efficacy, which declined to below 20% protection within four years[244]. ‘Leaky’
vaccines that do not provide sufficient protection have the potential to drive evolution of more
virulent vaccine-resistant parasites[15], so an alternative is desperately needed. A whole-
sporozoite vaccine, which may evoke a broader, more effective immune response against pre-
erythrocytic parasites, is another initiative which has recently been tested. Whilst some early
results are promising, there is scepticism about whether the production of such a vaccine
(which involves the dissection of individual infected mosquitoes) would be scalable[86].
A growing number of blood-stage P. falciparum antigens are being developed as potential
vaccines. These include a range of merozoite surface proteins such as PfMSP1, PfMSP3 and
PfAMA1, but as yet none have shown high efficacy in field trials[82, 242, 308, 329]. Sequence
diversity in blood-stage antigens may represent a major driving force behind low reported
rates of protection mediated by vaccines of this kind. Immunisation against one variant of a
particular antigen results in allele-specific immunity, such that individuals are only protected
against parasites displaying that particular antigen variant. This means that vaccines using
polymorphic blood-stage antigens will need to include a diverse range of protein variants, or
focus on functionally-important conserved epitopes, to induce cross-strain immunity[80, 256].
Transmission-blocking vaccines that target the sexual stages of the parasite could be a useful
tool in the global eradication of malaria. Pfs25, an ookinete surface antigen, is thought to
be a suitable vaccine antigen[126]. However vaccines of this type require almost complete
coverage to be effective, and voluntary uptake stands to be low since vaccination does not
directly protect the recipient. Vaccines based on multiple antigens, perhaps from multiple
life-cycle stages, may induce a broader, more effective immune response and help prevent the
emergence of vaccine-escaping Plasmodium strains[200]. With emerging drug resistance and
no certainty of a cost-effective vaccine in the immediate future, it will be important to develop
new strategies for controlling the incidence and impact of malaria. The rational design of
such interventions will demand a deeper understanding of parasite biology at the molecular
level[125].
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1.1.9 Research resources
The study of the molecular biology of the malaria parasite has been greatly aided by a grow-
ing number of resources and data sets. Perhaps the most influential development in recent
decades has been the sequencing of Plasmodium genomes. Genomes of P. falciparum[107], P.
vivax[49], P. knowlesi[260], the rodent parasite P. yoelii[48] and P. reichenowi[255]- a chim-
panzee parasite very closely related to P. falciparum - are published. Draft assemblies have
been produced for many isolates, including those from the rodent parasites P. berghei and
P. chabaudi[132], the macaque pathogen P. cynomolgi[323] and the avian parasite P. galli-
naceum. Genome sequencing is becoming more routine, such that thousands of P. falciparum
genomes[203, 225] and a smaller number of P. vivax genomes[52, 140, 218, 235] have now
been analysed, allowing deeper insights into the genetic variation that exists in nature. An-
notated sequences are freely available and are constantly being improved[254, 343]. Com-
plementing these genomes, transcriptome data has been generated for a number of different
species at different stages of their lifecycles[32, 189, 253, 289, 355], and large proteome data
sets are also published[98, 187, 270].
We are now able to culture Plasmodium parasites in isolated RBCs, which provides an in vitro
system to study phenotypes of blood stage parasites. The first attempts to grow P. falciparum,
P. vivax and P. malariae in human blood were made over a century ago[21], but it was not
until the 1970s that the continuous growth of a P. falciparum strain could be achieved[335].
Since then P. knowlesi and a number of additional strains of P. falciparum have been success-
fully grown in culture[228], though we still lack the capacity to sustain the growth of P. vivax
along with many P. falciparum field isolates outside of a host. P. falciparum cultures have
been used extensively as a source of parasites for a range of studies into processes such as
gene expression, protein localisation and RBC invasion[330]. Genetically manipulating these
Plasmodium parasites, particularly by knocking-out genes-of interest, allows the functions of
candidate genes to be determined. For instance the roles of hypothesised RBC invasion lig-
ands have been investigated using cultured P. falciparum parasites that have been genetically
altered to be deficient in PfEBA175, PfMSP7 and a range of other proteins[77, 78, 159]. Sys-
tematic approaches that can facilitate stable genetic modifications in P. falciparum, P. vivax, P.
knowlesi, P. berghei and P. yoelii have been developed, making the study of candidate genes
possible in in vitro and in vivo systems [50, 228, 230, 265, 371].
Appropriate animal models of malaria are required to study the course of infections in vivo
and represent a valuable research resource. Plasmodium species that naturally infect African
rats have been adapted to grow in laboratory mice and now represent the most common animal
models of human malaria. Model systems using P. chabaudi, P. berghei or P. yoelii parasites
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have been used with some success to study P. falciparum protein orthologues, such as the
prospective immune evasion ligand PfPMIF[9] and PfTRSP, a putative hepatocyte invasion
ligand[180]. However these systems are somewhat limited in their utility to study proteins that
do not have orthologues in rodent malaria parasites, or to examine aspects of human malaria
pathology that are not accurately replicated in rodent models. The P. berghei mouse model
of cerebral malaria has been widely criticised, as the hallmark human symptom of pRBC se-
questration does not appear to be replicated in brain microvasculature, though its pathological
effects are perhaps substituted by leukocyte sequestration[43]. This makes the model inappro-
priate for the study of cytoadhesive interactions and anti-cytoadhesion therapies, and it also
appears to have had limited power in predicting the efficacy of human vaccines; for instance
antibodies against PbCSP protected mice from infection[269], yet immunogenic, human vac-
cines based on PfCSP have not shown the same success[120, 244]. To overcome some of these
issues, adapted model systems are being developed, such as mice infected with P. berghei para-
sites expressing P. falciparum proteins[119] and chimeric mouse models that can carry human
erythrocytes to support the growth and study of P. falciparum[154]. For studies that require
the closest possible proxy for human infection, Aotus monkeys can be used as a host for P.
falciparum and P. vivax[139]. However, there is widespread ethical objection to the use of
non-human primates in research, such that their use is restricted to very specialised facilities
and for experiments on only the most promising therapeutic targets.
To complement the data generated about Plasmodium parasites, there has also been a focus
on the biology of the human host and mosquito vector. Tens of thousands of human genomes
have been sequenced to date and these data are continually enhancing our understanding of
the host factors underlying susceptibility to malaria (see 1.1.5.2), and provide an insight into
how host and pathogen interact to cause disease.
1.2 Protein-protein interactions in malaria
1.2.1 Parasites interact directly with their human host
To establish disease, pathogens interact extensively with their hosts. Systematic screening ap-
proaches have identified a myriad of potential interactions between viral proteins and those of
their hosts[45, 68]. In fact, one study suggests that all ten major proteins of human influenza
viruses make interactions with multiple host factors[303]. With much larger genomes, the
host-pathogen interactomes for bacterial and protozoal diseases are not as well characterised,
but still over 60 such interactions are known in Salmonellosis alone[297]. Plasmodium’s com-
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plex life cycle means that it interacts with a broad range of human and vector environments.
Plasmodium parasites invade a range of different cell types at different points in the life cycle,
and these processes are known to involve a series of protein-protein interactions (PPIs).
1.2.1.1 RBC invasion
RBC invasion by the merozoite is the most comprehensively studied process where host and
Plasmodium cells interact. PPIs occurring at around a 20-30nm membrane-membrane dis-
tance, are thought to mediate the initial recognition between the cells. As the primary compo-
nent of the merozoite surface, PfMSP1 has been implicated in mediating this initial interac-
tion, perhaps with the abundant Band 3 protein on the erythrocyte surface[116]. A number of
other inter-cell receptor-ligand pairs have been identified as part of the merozoite-RBC recog-
nition process. Amongst these, P. falciparum erythrocyte-binding-like (EBL) family proteins
PfEBA175, PfEBL1 and PfEBA140 are thought to bind RBC surface glycophorins A, B and
C respectively[201, 207, 306]. A family of reticulocyte binding-like homologue (RH) pro-
teins also have known RBC ligands, with PfRH4 and PfRH5 interacting with CR1 and BSG
respectively[64, 328]. There are thought to be multiple pathways by which the the merozoite
can enter the RBC, such that there is a substantial degree of redundancy in P. falciparum’s
invasion ligands. This allows the parasite to infect hosts regardless of polymorphisms in their
RBC receptors[78]. The interaction between PfRH5 and BSG appears to be particularly fun-
damental to the invasion process, as blocking this interaction with antibodies or recombinant
proteins completely inhibits invasion in a wide range of P. falciparum isolates in vitro[64].
1.2.1.2 pRBC/host interactions
PfEMP1 has at least 20 hypothesised ligands which facilitate the sequestration of pRBCs
away from innate immune destruction[285]. These include a range of endothelial ligands in-
cluding CD36, Thrombospondin, ICAM-1, SELP and EPCR, with some variants able to bind
placental CSA[17, 23, 24, 279, 302, 338]. Certain PfEMP1 variants are known to mediate
rosetting phenotypes via their interactions with CR1[284], AB blood group antigens[47], hep-
aran sulphate-like molecules[54] or possibly CD36[134], which has also been implicated as
the host ligand responsible for platelet-mediated pRBC clumping[259]. A range of known
PfEMP1 ligands are present on the surface of leukocytes, such that pRBCs may interact with
immune effector cells via direct PPIs. pRBC binding to macrophage CD36 has been suggested
to lead to phagocytosis and parasite clearance [210], however there is conflicting evidence that
this pRBC/CD36 interaction subverts the functioning of DCs and causes the suppression of
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immunological memory[340].
1.2.1.3 Sporozoite/host interactions
A number of sporozoite proteins are implicated in the parasites’ migration from the skin to the
liver, and in the invasion of hepatocytes. The major sporozoite surface protein, PfCSP, as well
as PfTRAP are thought to be important hepatocyte invasion ligands, both suggested to bind
to highly sulphated heparan sulphate proteoglycans (HSPGs) on the hepatocyte surface[100,
280]. PfTRSP-depleted parasites are unable to invade hepatocytes[180] and antibodies against
ligands including PfSPATR, PfSTARP and PfEMP3 inhibit hepatocyte invasion [96, 128, 180].
Despite this range of potential invasion ligands, the identification of hepatocyte receptors has
proved difficult. A recent model for cellular invasion by Toxoplasma gondii, another intracel-
lular Apicomplexan parasite, hypothesises that the parasites insert their own invasion receptors
into the host membrane[25]. This phenomenon is also thought to occur in P. falciparum-
mediated RBC invasion where the interaction between PfAMA1 and RBC-targeted PfRON2
is thought to be critical[183]. If Plasmodium sporozoites also behave in this way, this may
account for why host receptors for cell traversal and hepatocyte invasion have not been char-
acterised.
1.2.1.4 Identification of novel interactions can provide important insights into parasite
biology
Of over 5,000 potential protein-coding genes identified from the P. falciparum genome[107],
we understand the functions of surprisingly few. To understand the intricacies of how Plas-
modium parasites manipulate their hosts and gain access to a range of cell types, it will be
invaluable to identify the interacting proteins of pathogen and host. The identification of these
interactions will help us to understand the disease process at a molecular level and could
help elucidate new targets for therapeutics. The most interesting proteins in these respects
are perhaps those at the cell surface of, and secreted from, the parasite as they make direct
contact with host cells and are directly exposed to host proteins and immune effectors. For
example, by identifying receptor-ligands pairs in cell invasion, we could design safe, spe-
cific antibody or small-molecule inhibitors to target these processes and prevent the parasite
from accessing the host cell. Blocking PPIs involved in cell invasion has shown promise for
the treatment of viral infections[72, 298] and is being investigated as a therapeutic target for
malaria[316, 354]. Similarly, specific drugs that could rapidly prevent the adhesive properties
of pRBCs could be a valuable clinical tool[348]. Vaccines too could be based on antigens
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that participate in pathological host-pathogen PPIs, inducing long-lasting antibody responses
that can block these interactions. An understanding of the interactions that allow the parasite
to evade the immune system will also contribute to the development of successful vaccines,
advising their rational design to elicit the most effective immune response in the host.
1.2.2 Interaction discovery
1.2.2.1 Studies on candidate proteins
The majority of the known interactions involved in RBC invasion have been discovered fol-
lowing the observation that isolated Plasmodium ligands bind to the RBC surface. The identity
of the receptors for each of these ligands has been inferred or narrowed-down based on the sen-
sitivity of the interactions to enzymatic treatment of the RBC, or by the inability of ligands to
bind RBCs naturally lacking specific receptors5. For example, the first of these RBC-binding
ligands to be discovered, PfEBA175, could not bind to neuraminidase-treated RBCs, which
implicated a sialylated protein as the receptor[46]. PfEBA175 was also unable to bind MkMk,
Tn or En(a-) RBCs which do not express glycophorin A (GYPA) on their surface, thus leading
to the identification of GYPA as the receptor[250, 307].
Similarly, the PfEBA175-related proteins PfEBL1 and PfEBA140 were shown to bind specif-
ically to erythrocytes displaying glycophorins B and C respectively[196, 207]. Likewise a
recombinant protein corresponding to a conserved sequence block from PfMSP1 bound to the
RBC surface, but could not bind to the surface of RBCs from spherocytosis patients[138],
which lack one of a number of cytoskeletal proteins including Band 3 and spectrin. A seg-
ment of the Band 3 protein, believed to contain the PfMSP1 binding domain was subsequently
shown to block the interaction between PfMSP1 and the RBC surface[116]. PfRH4 was
shown to interact with the erythroctyte surface in a neuraminidase-resistant but trypsin and
chymotrypsin-sensitive manner. This restricted the potential receptor for PfRH4 to only a
handful of proteins, including CR1, antibodies against which were shown to block the binding
of PfRH4 to the erythrocyte surface[328]. Similarly, some of the known pRBC/endothelial
interactions were initially identified following the observation that pRBCs could bind to a
number of cell lines displaying human endothelial surface proteins[299, 339]. Anti-CD36
antibodies were able to prevent this adhesion, leading to CD36’s eventual identification as a
PfEMP1 ligand[17, 20]. Affinity purification methods have also been applied to the discovery
of PPIs involved in malaria. This involves creating an isolatable binding reagent based on a
protein-of-interest, incubating this reagent with the potential ligand and demonstrating that
5Since RBCs are anucleate it has not yet been possible to engineer cells lacking receptors of interest
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the ligand co-purifies with the binding reagent. For instance, the earliest evidence that SELP
might be an endothelial receptor for PfEMP1 came from an experiment where PfEMP1-coated
beads were incubated with recombinant SELP. SELP could be detected on the surface of these
beads, but not negative control beads, by Western blotting[302].
1.2.2.2 Screening approaches
The cell-binding approaches described in Section 1.2.2.1 have relied upon prior knowledge
and hypothesis-driven rationale on which to select candidate Plasmodium or host proteins
for study. The identification of the full repertoire of host-pathogen receptor-ligand inter-
actions will require exhaustive, high-throughput, unbiased screening approaches. In recent
years computational analyses have been used to infer novel host-pathogen PPIs occurring in
malaria. New candidate interactions have been predicted based on both structural similarities
with experimentally-determined interactions and correlation of the gene expression data for
host and parasite[278, 362]. These approaches often generate a large number of candidate
interactions, which require experimental validation, and refinement is still needed to reduce
the false positive and false negative discovery rates.
The yeast-two-hybrid (Y2H) system has been systematically applied to discover nearly 3000
candidate Plasmodium-Plasmodium PPIs[181], and has also been used to screen for PPIs oc-
curring between Plasmodium proteins and those expressed in the human liver and brain[345].
Whilst Y2H screening has provided a wealth of candidate interactions, and has been used in
combination with computational approaches to help define the Plasmodium-Plasmodium PPI
network[275], it is again limited by high rates of false positives and negatives. The cloning
steps used to generate bait and prey libraries mean that only fragments of much larger proteins
are screened and that a proportion of proteins will not be represented in the screening library.
By expressing Plasmodium proteins in a heterologous system such as yeast, it is likely that
a proportion of the protein fragments will be not be folded in their native conformation. Im-
provements in the efficiency of recombinant protein production have enabled high-throughput
screening between libraries of full-length proteins, which has led to the identification of two
more erythrocyte-merozoite PPIs (see 1.2.3).
Another set of approaches has screened Plasmodium proteins against cells that have been
transfected to display human receptors-of-interest on their surface. An expresssion-cloning
screening approach where COS cells were transfected with endothelial ligands was used to
discover ICAM1 as another receptor for pRBCs[24]. More recently a much larger scale
microarray-based reverse transfection system has been used to screen PfEMP1 against over
2500 potential human cell surface receptors, leading to the identification of EPCR as a pRBC
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receptor[338].
1.2.2.3 In vitro validation and kinetic analysis of interactions
Many of the methods used to identify interactions (discussed in 1.2.2.1) are equally appro-
priate for use in generating evidence to validate the occurrence of an interaction predicted by
computational or in vitro screening approaches. For example, for an interaction involving an
isolated or recombinant RBC receptor, it would be useful to demonstrate that its binding part-
ner could interact with the RBC surface in a manner dependent on the presence and availability
of the RBC receptor. Conversely, for interactions discovered between a Plasmodium ligand
and the RBC surface, it would be useful to validate the identity of the expected RBC receptor
by demonstrating that the interaction can take place between isolated proteins. In either case, a
routine test of interaction specificity is to demonstrate that the interaction can be blocked by an
agent known to bind to either of the interacting proteins (for example, a monoclonal antibody
or known ligand, as described in many of the above references[20, 64, 116, 302]). Affinity
purification studies are another common approach used to validate interactions. Such exper-
iments can be designed to validate interactions between recombinant proteins (for example
between PfMSRP proteins and PfMSP1[215]), but it is preferable to design these experiments
such that one binding partner can be used to co-purify, or ’pull down’, its interacting protein
from its native source, such as a parasite lysate or RBC membrane preparation, as has been
demonstrated for the interaction between PfMSP1 and PfMSP7[160].
A number of methods that measure biophysical properties of binding proteins can be used to
validate interactions. Specific binding interactions usually display saturable binding kinetics
and thus these methods can be adapted to estimate interaction affinities. Surface plasmon
resonance (SPR) is a widely used biophysical analysis method that can be used to determine
kinetic parameters of interactions occurring between isolated proteins. The technology uses
light directed at a metal-coated surface, which is reflected back onto a detector. Some of the
light causes electrons to resonate at the chip surface (these electrons are surface plasmons),
which results in a loss of intensity of the reflected light at a particular angle of detection. The
surface plasmons travel parallel to the metal surface so are sensitive to the presence of other
molecules along their path. Thus the binding of molecules to the surface of the chip can be
quantified by measuring the shift in the angle where the dip in intensity of the reflected light
can be detected. PfRH4/CR1 and PfRH5/BSG binding have been studied in this way, and as
such have provided useful, quantitative information about the affinity and half-lives of these
interactions[64, 328, 347].
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1.2.3 Identifying new interactions: Approaches in the Wright Lab
Whilst hypothesis-driven studies on candidate proteins and a growing number of screening ap-
proaches have yielded a myriad of candidate PPIs for further investigation, the identification of
additional host receptors for Plasmodium proteins has been impeded by technical difficulties.
The first of these challenges is to produce sufficient quantities of correctly folded recombinant
Plasmodium proteins, particularly since the genome of Plasmodium falciparum is predomi-
nated by A-T base pairs[107], which can be problematic for cloning and protein expression.
The next hurdle to identifying host-pathogen PPIs is the low sensitivity of interaction detec-
tion methods; extracellular protein-protein interactions are often transient and of low-affinity
and therefore not readily detected by classical biochemical purification techniques, which usu-
ally require stringent washing steps. In the laboratory where the work described in this thesis
was carried out, we aim to overcome these challenges using a specialised protein expression
system and a high-throughput interaction screening platform.
1.2.3.1 A mammalian expression system for Plasmodium proteins
By developing a high-throughput mammalian expression system based on the transient trans-
fection of cells from the Human Embryonic Kidney line (HEK293 cells), we have been able to
express a library of 62 merozoite cell surface and secreted proteins[65, 369]. This has acted as
a valuable resource both to discover novel interactions and to use in in vitro assays to help de-
termine their function. The details of this expression system are described in Section 2.1, but
one of its key features is the use of codon-optimisation to overcome the A-T nucleotide bias
that impairs routine molecular biology procedures. This process makes Plasmodium protein
ectodomains much more amenable to expression in mammalian cells. Using this system, pro-
teins can be pentamerised via the inclusion of a cartilage oligometric matrix protein (COMP)
sequence in expression constructs[333]. These pentameric proteins have further increased our
capacity to discover and study PPIs by increasing the avidity and stability of the interactions
in which they participate (Figure 1.4B).
1.2.3.2 AVEXIS
Avidity-based extracellular interaction screening, or AVEXIS, is a technique developed in the
Wright laboratory as a sensitive, high-throughput method for the discovery of protein-protein
interactions[40]. Ectodomain regions of receptor proteins are expressed in HEK293 cells,
such that protein libraries can be systematically screened against each other. One ectodomain
library can be presented as an ordered array of ‘bait’ proteins immobilised on microtitre plates.
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Figure 1.4: AVEXIS as a highly sensitive interaction screening method
Figure from Large-scale screening for novel low-affinity extracellular protein interactions by
Bushell et al., (2008)[40]. Reproduced with permission.
A. Diagramatic representation of the AVEXIS method. Biotinylated bait proteins (blue) are
arrayed on the surface of a streptavidin-coated plate and incubated with pentameric prey pro-
teins (red). Interacting prey proteins are captured by the immobilised baits and remain bound
following a wash step. The β -lactamase activity of the prey hydrolyses nitrocefin, inducing a
yellow-to-red colour change.
B. Pentamerisation of the prey proteins increases the avidity and stability of the
Cd200/Cd200R interaction.
C. The specificity of Cd200/Cd200R interaction detection is shown, as an antibody against the
bait protein can prevent the binding of the prey.
D. Example of an interaction screen: hits from the screen produce a red colour.
To detect interactions, these plates are probed with another library of pentamerised, enzyme-
tagged ectodomain ‘prey’ proteins (Figure 1.4A). This approach has been used previously in
this laboratory to identify receptor-ligand interactions involved in malaria. By screening a
panel of merozoite proteins against a library of erythrocyte receptors, two novel interactions
were identified and subsequently validated; SEMA7a was identified as a receptor for PfM-
TRAP and BSG as a receptor for PfRH5[19, 64]. Both of these interactions are transient,
with micromolar affinities calculated in SPR experiments; this demonstrates that AVEXIS is a
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highly sensitive method, appropriate for the detection of low-affinity interactions.
1.3 Scope of this thesis
This thesis focuses on the use of existing methods and the development of novel methods
for identifying host-pathogen protein interactions in malaria. In screening for interactions,
P. falciparum merozoite surface protein 7 (PfMSP7) was identified as a potential ligand for
human P-selectin (SELP) and the biochemistry of this interaction was characterised in detail.
This work is summarised in three results chapters as follows:
Chapter 3: Identification and validation of an interaction between SELP and PfMSP7
This chapter describes the use of AVEXIS to test for novel interactions occurring between
recombinant proteins from the P. falciparum merozoite and proteins from, but not restricted
to, the human platelet. A novel interaction was identified between PfMSP7 and human SELP.
These recombinant proteins were shown to be biochemically active and this interaction could
also be observed in SPR experiments and in a flow cytometry-based assay developed as part of
this project. Evidence is also presented that suggests that recombinant PfMSP7 oligomerises
in solution, that this is a property of the protein’s N-terminus, and that this oligomerisation
might be important for its interaction with SELP.
Chapter 4: Biochemical investigations into the conservation and function of the interac-
tions between Plasmodium MSP7s and SELP This chapter describes the biochemical and
functional characterisation of the interactions between SELP, PfMSP7 and related proteins.
AVEXIS was used to isolate the binding domains as the C-type lectin and/or EGF-like do-
mains of SELP and the N-terminus of PfMSP7, and to screen more widely for interactions oc-
curring between mammalian selectins and Plasmodium MSP7-family proteins. This revealed
that SELP-binding is a conserved feature of multiple members of the P. falciparum MSP7
family. At least one P. vivax MSP7 protein also bound to SELP in vitro and the SELP/MSP7
interaction looked to be conserved in the P. berghei mouse model of infection. These data sug-
gest that SELP-binding might be an important, previously unidentified, role for the PfMSP7
N-terminus and its numerous paralogues. The possibility that the PfMSP7/SELP interaction
might play a role in RBC invasion was investigated and largely ruled-out. In in vitro binding
experiments PfMSP7 could block the interaction that SELP makes with its known ligands, and
can thus be implicated as having an immunomodulatory role.
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Chapter 5: Development of a biochemical co-purification assay to detect interactions
between Plasmodium merozoite proteins and human serum proteins This chapter de-
scribes the rational design of a biochemical co-purification procedure whereby recombinant
P. falciparum merozoite proteins are immobilised on superparamagentic beads and used to
isolate binding partners from normal human serum. The assay was optimised so as to balance
maximal capture of interacting protein against minimal contamination with abundant non-
specifically interacting serum proteins. The assay was shown to be very effective at detecting
the high-affinity interaction between PfMSP3.4 and human IgM, which is an abundant serum
component. The possibility that transient, low affinity interactions can also be detected by
this approach was also demonstrated using the interaction between PfRH5 and BSG. A panel
of over 50 merozoite proteins were screened for interactions with serum proteins using this
method, though no novel interactions were identified.

Chapter 2
Materials and Methods
2.1 Protein production
2.1.1 Plasmid preparation
All plasmids used for protein expression were based on pTT3 which contains an ampicillin re-
sistance marker for selection, an EBV origin of replication to allow amplification in HEK293E
cells, and a series of promoter and leader elements to enhance expression[79] (Figure 2.1A).
For the expression of mammalian proteins, the endogenous signal peptide was cloned into
the vector, whereas the coding sequences of Plasmodium proteins were cloned downstream of
the leader sequence of the mouse variable κ light chain (Figure 2.1B)1. Plasmodium protein
sequences were codon-optimised for expression in mammalian cells using Life Technologies’
GeneArt Service[240]. Since N-linked glycosylation is uncommon in Plasmodium (and preva-
lent in HEK cells), N-X-S/T glycosylation site-encoding motifs in Plasmodium constructs
were mutated to N-X-A-encoding DNA, prior to gene synthesis.
1N-terminally truncated mammalian proteins were also cloned downstream of this leader sequence, without
their endogenous signal peptide
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Depending on the intended use of the recombinant protein, a selection of different C-terminal
tags were incorporated (Figure 2.1C). All secreted proteins were produced as fusions with rat
Cd4 domains 3 & 4 (Cd4), which is likely to increase the proteins’ solubility and hence ex-
pression, and also means that they could be detected via the use of a mouse anti-rat Cd4 OX68
monoclonal antibody[35]. For proteins that were to be biotinylated, an Escherichia coli BirA
biotin ligase substrate motif was included[36, 40]. A six-histidine tag[141] and/or 3xFLAG®
(Sigma) were also included for protein purification and detection. Pentamerisation of proteins
was achieved via the inclusion of a pentamerisation domain from cartilage oligometric matrix
protein (COMP)[333]. Pentameric proteins were also tagged with a β -lactamase reporter that
could be used as a proxy to normalise the amount used in assays (as described in 2.3.1.2). To
produce GFP-tagged proteins on the surface of cells, a transmembrane (TM) domain from rat
Cd200 was included, along with an eGFP reporter[60].
All plasmid DNA sequences were validated by in-house capillary sequencing. Details of the
expression plasmids used as part of this work can be found in Tables 2.4 & 2.5.
2.1.1.1 PCR
Several mammalian protein-coding sequence inserts were cloned from cDNA. PCR primers
were designed so as to introduce NotI and AscI sites 5’ of the signal peptide and 3’ of trans-
membrane domain respectively. 1µg cDNA for human SELE, SELL and SELPLG (encoding
PSGL1), as well as mouse Selp (Origene), were used as templates. The reaction was per-
formed using 1U KOD Hot Start DNA polymerase (Novagen) in the manufacturer’s buffer
supplemented with 1.5mM MgSO4, 1µM primers and 0.2 µM dNTPs. The thermocycler was
programmed to carry out an initial five-minute denaturation step at 95°C followed by 25 cycles
of denaturation for 15 seconds at 95°C, primer annealing at between 60 and 65°C for 30 sec-
onds and elongation at 72°C for one minute. A final elongation step at 72°C was then carried
out for five minutes before purifying the fragments using a QIAquick PCR Purification Kit
(QIAGEN). In order to make truncated protein fragments of SELP and PfMSP7, similar PCR
methods were applied using existing plasmids as templates. A list of primers can be found in
Table 2.1 and details of the boundaries of the SELP and PfMSP7 fragments are provided in
Tables 2.2 and 2.3.
2.1.1.2 Restriction-ligation cloning
New plasmids for these studies were constructed using restriction-ligation cloning methods.
Vectors and inserts were digested for two hours at 37°C (most commonly using NotI and
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AscI, NEB) and the resulting fragments were resolved by agarose gel electrophoresis. Bands
were visualised under ultraviolet light and extracted using a QIAquick Gel Extraction Kit
(QIAGEN). 20ng of vector and 60ng of insert were used in ligation reactions with T4 ligase
(Roche) which were performed at 16°C for 3-12 hours. A 45-second 42°C heat shock was used
to transform chemically-competent E. coli cells (Agilent) with the ligation products. Cells
were plated out on LB-agar containing 100µg/mL ampicillin for selection. Positive clones
were cultured overnight in liquid LB and plasmids were prepared for use at 1mg/mL using
a PureLink HiPure Plasmid Maxiprep kit (Life Technologies). In-house capillary sequencing
was used to verify the success of cloning new plasmids.
2.1.2 Protein expression using HEK293 cells
All recombinant proteins were produced in a mammalian expression system based on the tran-
sient transfection of cells from the Human Embryonic Kidney (HEK293) line. The majority
of proteins were expressed using HEK293E cells which are stably transformed with Epstein
Barr Virus Nuclear Antigen (EBNA1), so as to increase the number of plasmids maintained
in transfected cells during protein production. HEK293F cells, which do not possess this
EBNA1-based amplification system, were used for the expression of GFP-tagged recombi-
nant proteins targeted to the cell surface.
2.1.2.1 Cell culture
HEK293 cells were maintained in suspension in 50mL Freestyle medium (Life Technologies)
at 37°C, 70% humidity, 5% CO2 and 120rpm orbital shaking. When HEK293E cells were
grown, the medium was supplemented with 1% FCS (Life Technologies) and 50µg/mL G418
antibiotic (Sigma).
2.1.2.2 Transfection
24 hours prior to transfection, 50mL fresh medium was seeded with cells to give a final den-
sity of 2.5x105 cells/mL. For each transfection, 2mL of Freestyle medium, 25µg of expression
plasmid and 50µg polyethylenimine (PEI) transfection regent were mixed and incubated to-
gether at room temperature for 10 minutes. The mixture was added to the 50mL culture which
was then returned to the incubator. In order to produce biotinylated proteins, cells were seeded
into Freestyle medium containing the same FCS and G418 supplements along with 100µM D-
biotin (Sigma). During the transfection procedure, 2.5µg of a plasmid encoding a secreted
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form of E. coli biotin ligase (BirA) was added alongside the expression plasmid. The BirA en-
zyme catalyses the addition of D-biotin to recombinant protein produced with a biotinylation
site at their C-terminus (Figure 2.1C).
2.1.2.3 Collection
After four to six days of incubation post-transfection, secreted proteins were collected from the
culture supernatant. Cellular material was removed following centrifugation at 3220g for 10
minutes and the resulting supernatant was filtered using 0.2µm filters. The filtered supernatants
were stored at 4°C with 50µg/mL polymixin B antibiotic (Sigma). To remove free D-biotin,
supernatants containing biotinylated proteins were transferred to 10kDa MWCO Snakeskin
dialysis tubing (Thermo Scientific) then dialysed against 4.5L of HBS (0.14M NaCl, 10mM
HEPES, 5mM KCl, 2mM CaCl2, 1mM MgCl2) at 4°C. To ensure sufficient D-biotin removal,
the HBS was replaced seven times over two days.
2.2 Protein purification and quantification
2.2.1 Immobilised metal ion affinity chromatography
6xHis tagged proteins were enriched from cell culture supernatants using 1mL HisTrap nickel
columns and ÄKTAxpress purification apparatus (GE Healthcare). To decrease non-specific
protein retention in the columns, 10mM imidazole and 200mM NaCl were included in the
input protein sample. The HisTrap column was equilibrated with binding buffer (0.5M NaCl,
40mM imidazole, 20mM sodium phosphate buffer, pH7.4), loaded with the input protein,
then washed with binding buffer. Elution buffer (0.5M NaCl, 0.4M imidazole, 20mM sodium
phosphate buffer, pH7.4) was then flowed through the column and 0.5mL eluate fractions
were collected by the apparatus. The ÄKTAxpress readout estimates the absorbance of the
output samples at 280nm and was used to identify fractions with a high protein yield, which
were then visualised and quality-checked using SDS-PAGE (see 2.2.4). The elution buffer
was replaced with HBS during subsequent size-exclusion chromatography (see 2.2.2) or by
dialysis (see 2.1.2.3) using 3.5kDa MWCO D-tube Dialysers (Novagen).
2.2.2 Size-exclusion chromatography
To remove protein aggregates from IMAC-purified proteins, fractions were further purified by
size-exclusion chromatography (SEC), using a Superdex Tricorn 200 10/600 GL or Superdex
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200 Increase 10/300 GL gel-filtration column (GE healthcare). Columns were connected to
an ÄKTAxpress system which was used to pre-equilibrate the column with HBS buffer prior
to the injection of the sample. After the protein was loaded onto the column, HBS buffer was
pumped through the column at a flow rate of 1mL/min and 0.5mL fractions were collected
once the void volume of the column was reached. Protein content of the eluting solution was
inferred by the absorbance at 280nm, measured in real time by the ÄKTAxpress instrument.
2.2.3 Determination of protein concentration
The approximate total protein content of recombinant protein solutions was measured us-
ing their absorbance at 280nm, determined using a benchtop spectrophotometer or Nanodrop
(Thermo). The extinction coefficients of proteins of interest were calculated in silico allowing
the estimation of protein concentration using the Beer-Lambert law.
2.2.4 SDS-PAGE
NuPAGE SDS-PAGE reagents, including 4-12% pre-cast gradient gels (Life Technologies)
were used for protein gels. All proteins were denatured proir to electrophoresis. Gels were
stained with colloidal Coomassie blue G250 (Fisher) or SYPRO Orange (Sigma), according to
the manufacturer’s instructions. SYPRO-stained gels were visualised using a Typhoon phos-
phoimager.
2.2.5 Western blotting
Following SDS-PAGE, proteins were transferred from the gel to a PVDF (GE Healthcare)
membrane. The transfer was carried out using NuPage transfer buffer (Life Technologies)
supplemented with 10% methanol, an XCell II blot module (Novex) and 40V voltage for
two hours at room temperature. To reduce non-specific streptavidin or antibody binding, the
membrane was then blocked by incubation with HBS containing 2% BSA overnight at 4°C.
To detect biotinylated proteins, the membrane was incubated in 25mL HBS containing 0.2%
BSA and 25ng/mL streptavidin-HRP conjugate for one hour at room temperature. When
rabbit polyclonal antibodies were used to detect proteins, 25mL HBS containing 2% BSA and
1µg/mL antibody were incubated together overnight at 4°C then incubated with the membrane
for one hour at room temperature. The antibody-stained membranes were then transferred
to 25mL HBS containing 200ng/mL HRP-conjugated anti-rabbit secondary antibody for one
hour. All membranes were washed with HBST for at least one hour at room temperature. 1mL
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SuperSignal West Pico enhanced chemiluminescent HRP substrate (Thermo) was applied to
the membrane, which was then used to expose Hyperfilm (GE Healthcare).
2.2.6 Polyclonal antibody production and purification
His-tagged Cd4-tagged PfMSP7 was expressed and purified as described in 2.2.1. Approxi-
mately 1mg of the protein was sent to Cambridge Research Biochemicals and used to immu-
nise one rabbit. 50mL of the harvest bleed was filtered through a 0.2µm filter then purified
using a 1mL HiTrap Protein G HP column (GE healthcare) and the ÄKTAxpress apparatus.
The Protein G column was equilibrated with 20mM sodium phosphate buffer (pH7.0), loaded
with the input protein, then washed with sodium phosphate buffer. Bound antibody was eluted
using 0.1M glycine HCl (pH2.7) buffer. 0.5mL fractions were collected and neutralised by the
addition on 60µL 2M Tris-HCl (pH 9.0). The purified antibodies were dialysed against PBS
and tested for reactivity against recombinant PfMSP7 and Cd4 domains 3 & 4 bait proteins by
ELISA (see 2.3.1.1).
2.3 AVEXIS
Avidity-based extracellular interaction screening (AVEXIS) was performed as directed in
Bushell et al. (2008), with some alterations[40]. In brief, 100µL bait proteins, normalised
as described in 2.3.1.1, were captured on a 96-well streptavidin-coated plate, which was incu-
bated at room temperature for one hour. The plate was then washed three times with HBST
and once again with HBS. 100µL normalised prey protein was then added to the wells and
incubated at room temperature for 90 minutes. Washes were performed as before and 60µL
nitrocefin substrate was added to the wells. Absorbance at 485nm was used to quantify the
colour changes after one hour, unless otherwise stated.
2.3.1 Standardisation
To standardise the amounts of cell culture supernatants to be used in AVEXIS, ELISAs were
carried out on serial dilutions of bait proteins and the nitrocefin hydrolysis rates of serial
dilutions of prey protein were also assessed[40]. If necessary, proteins were concentrated
using Vivaspin 20 spin concentrators (Sartorius-stedim) or diluted with HBS containing 1%
BSA.
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2.3.1.1 ELISA
100µL two-fold serial dilutions of biotinylated proteins were captured on a streptavidin-coated
plate (Nunc). After one hour the plate was washed three times with HBS containing 0.02%
Tween (HBST), then once with HBS alone. OX68 is a mouse monoclonal antibody with a high
affinity for the CD4 tag, and 100µL of a 1.4µg/mL solution was used as the primary antibody.
After a further hour’s incubation, the plate was washed again and 100µL of anti-mouse IgG
coupled to alkaline phosphatase (Sigma A4656, 1:5000) was added to the wells. Following
another hour’s incubation and washing, 100µL of 1µg/µL phosphatase substrate (Sigma) was
added. Substrate hydrolysis was assessed after 30 minutes by measuring absorbance at 405nm
on a PHERAstar plus instrument (BMG Labtech).
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Figure 2.2: Standardisation of bait proteins by ELISA
Typical ELISA profiles for biotinylated bait protein supernatants. The arrows indicate the
dilution of each protein that was used in subsequent AVEXIS-based assays. Serial dilutions
of cell culture medium were used as a negative control, to demonstrate the signals observed
were due to the presence of the transfected protein only.
The shapes of the ELISA curves were used to assess protein abundance. If the plate is saturated
with biotinylated protein a consistent, high A405 at low dilution factors is expected, with this
signal decreasing at higher dilutions of the protein (as gradually less bait is bound to the plate).
In reality ’humped’ ELISA profiles were often observed (Figure 2.2), for which there could be
a number of explanations. Perhaps the most likely explanation when supernatants are used is
that the dialysis process has not removed all the available biotin, such that free biotin competes
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with biotinylated proteins for the strepatavidin, an effect which is not observed upon dilution
as competition for biotin-binding sites decreases. For particularly highly-expressed or purified
proteins the curves’ shapes may reflect the ’over-crowding’ of the plate at low dilutions, such
that so much protein is captured on the plate that this impedes access of the OX68 antibody to
the Cd4 tag (a manifestation of the prozone effect[42]). It might also be that other abundant
proteins in the cell culture supernatant interfere with the specific capture of the biotinylated
bait. For AVEXIS, bait proteins were used at the lowest dilution at which absorbance was
maximised, so as to balance high levels of protein capture against over-crowding of the bait
on the plate surface (indicated in Figure 2.2). Bait proteins that did not show a saturable
ELISA signal were spin-concentrated then tested again by ELISA.
2.3.1.2 Nitrocefin hydrolysis assay
To assess their β -lactamase activity, 20µL serial dilutions of prey proteins were prepared in
96-well plates. The absorbance at 485nm was measured every minute for 15 minutes after the
addition of 60µL 125µg/mL nitrocefin (Calbiochem) to each well. Prey proteins were used at
the concentration where nitrocefin hydrolysis was saturated after ten minutes (Figure 2.3).
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Figure 2.3: Standardisation of prey protein by measuring nitrocefin hydrolysis
A. A typical nitrocefin-hydrolysis assay for a single prey protein supernatant.
B. Nitrocefin hydrolysis activity of three P. vivax MSP7 protein supernatants at their chosen
concentration for use in AVEXIS. The absorbance at 485nm saturates after approximately ten
minutes.
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2.3.1.3 Data presentation
AVEXIS data in this thesis is predominantly displayed as 485nm absorbance readings (A485).
The nitrocefin substrate itself has a measurable A485, so to more clearly delineate binding
signals from A485 measurements where no colour change occurs, a reference value was sub-
tracted from each reading. This reference value, usually around between 0.05-0.2 was the
mean A485 of the Cd4 bait controls for each prey protein.
2.4 SELP-ligand interaction blocking
2.4.1 sLeX-SELP interaction blocking
To create a sLeX-based binding reagent whose presence could be detected by measuring enzy-
matic activity, biotinylated sLeX (Glycotech) was incubated with a streptavidin-alkaline phos-
phatase conjugate (strep-AP, Sigma). To determine the optimum ratio of the two components,
a series of binding reagents were created by incubating a range of concentrations of sLeX with
a fixed amount of strep-AP for one hour2. The reagents were then used in an AVEXIS-like
assay. SELP bait was immobilised on the surface of a 96-well strepatividin-coated plate and
incubated with serial dilutions of the reagent. After one hour the plate was washed three times
with HBST and once with HBS before 100µL 1mg/ml phosphatase substrate (Sigma) was
added. To produce the most avid binding reagent from the sLeX and strep-AP, it is important
to maximise the amount of sLeX bound to the AP-conjugate. However, if too much ’free’
unconjugated sLeX is present this could bind SELP independently of sLeX-AP, decreasing the
405nm absorbance (A405) signal observed as a result of SELP binding. Therefore the ratio
at highest sLeX:strep-AP ratio (approximately 5:1) where A405 was still high was used in
subsequent assays.
To determine whether PfMSP7 could block the interaction between SELP and sLeX, SELP bait
was immobilised on a 96-well strepatividin-coated plate and incubated with serial dilutions of
purified pentameric PfMSP7 for one hour. The plate was washed three times with HBST and
once with HBS. The wells were then incubated with sLeX-AP binding reagent for one hour,
washed and incubated with phosphatase substrate. The absorbance at 405nm was measured
after 30 minutes and was used to assess the levels of sLeX binding to SELP.
2each strep-AP molecule is expected to bind approximately two sLeX-bio molecules
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2.4.2 THP1 binding assay
THP1 cells were maintained in continuous culture at a density of 105-106 cells/mL in 50mL
RPMI 1640 supplemented with 10% FBS and 2mM L-glutamine at 37°C and 5% CO2. Sat-
urating quantities of biotinylated proteins were used to coat the wells of a streptavidin-coated
microtitre plate as described in 2.3. An anti-PSGL1 (LS-B2507 clone, LSBio) antibody was
used as a positive control, to which cells should bind provided they have maintained their
expression of PSGL1 receptors on their surface. These immobilised bait proteins were incu-
bated with 104 THP1 cells diluted in HBS+1%BSA for one hour. Plates were washed gently
by removing the liquid from the wells using a pipette and adding 150µL HBS. Four such
washes were performed before counting the cells that remained adhered to the surface using
a light microscope. To block interactions between SELP bait and THP1 cells, immobilised
baits were incubated with CLB-thromb/6 anti-SELP antibodies (Santa Cruz biotechnology) or
purified PfMSP7 pentameric prey each diluted in HBS+1% BSA for 90 minutes, after which
plates were washed four times with HBS prior to the addition of cells.
2.5 Surface plasmon resonance
All SPR experiments were performed using a Biacore T100 instrument in combination with
SA or CAP chips (GE Healthcare). Both chips use the biotin-streptavidin interaction to capture
bait proteins onto their surface. When coating the SA chip, the surface was first ’activated’ by
three one-minute 30µL/min injection of a 1M NaCl/50mM NaOH solution. CAP chips couple
biotinylated proteins onto their surface by means of a DNA-based intermediate, or CAPture
reagent. To prepare the surface of the CAP chip for the immobilisation of biotinylated bait
proteins, the manufacturer’s regeneration solution was injected over the chip surface three
times for 60 seconds at a flow rate of 20µL/min followed by a 60-second injection of the
HBS running buffer and a five-minute 2µL/min injection of CAPture reagent. In each case,
approximately 150 response units (RU), as measured using the Biacore T100 Control software,
rat Cd4 domains 3&4 negative control bait was loaded into the first flow cell at a flow rate of
10µL/min. Molar equivalents of each bait protein were loaded into subsequent flow cells.
After loading the flow cells, any remaining biotin-binding sites were saturated by injecting a
1nM biotin solution over the chip surface until no further binding responses were observed.
All analyte proteins were purified by IMAC and subsequent SEC, and injected over the surface
of the chip at a flow rate of 20µL/min for one minute. Binding responses were recorded and
subsequently analysed using the Biacore T100 Evaluation software.
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2.6 Flow cytometry
2.6.1 Labelling RBC surface proteins
To detect receptors present on the RBC surface, cells were washed, stained with monoclonal
antibodies and a fluorescent secondary then analysed by flow cytometry. O-negative RBCs
were prepared by centrifugation of 4mL whole blood and 10mL RPMI 1640 at 1800g for 5
minutes. The supernatant, and white blood cells from the top of the pellet, were removed and
the remaining RBC diluted to 50% hematocrit with RPMI 1640. These RBCs were diluted
25-fold to 2% hematocrit in PBS containing 2% heat-inactivated FCS. 10µL, approximating to
106 cells, were stained on ice for 30 minutes using 1µg primary antibody in a total volume of
100µL PBS/FCS buffer. To remove unbound primary antibody, RBCs were twice pelleted by
centrifugation at 450g for 3 minutes then resuspended in 100µL PBS/FCS. A 100µL 1:1000
dilution of Alexa 488-conjugated anti-mouse IgG1 secondary antibody (Abcam) was incu-
bated with the cells on ice for 30 minutes. The washing steps were repeated and the cell pellet
was resuspended in 250µL PBS prior to acquisition by flow cytometry using a BD FACSCal-
ibur instrument. The Alexa488 was excited using the 488nm blue laser and its emission was
detected using 530/30 filter. 20000 events were counted and the output was analysed using
BD FACS Diva and FlowJo (TreeStar) analysis software.
2.6.2 Detecting protein-protein interactions on the surface of HEK cells
HEK293F cells were transfected (as described in 2.1.2.2) to express GFP-tagged receptors on
their surface. Successful transfection was verified by fluorescence microscopy. 24 hours post-
transfection, 1mL aliquots of 106 cells were incubated with 5µg pentameric FLAG-tagged
reporter proteins for 1 hour at 4°C, with gentle orbital shaking. Cells were pelleted by cen-
trifugation for five minutes at 200g and resuspended in an HBS buffer supplemented with 1%
BSA and 1mM CaCl2. This wash step was repeated before 5µg Cy3-conjugated anti-FLAG
antibody (Sigma) was added and incubated at 4°C for one hour. To remove any unbound
antibody, the cells were washed three times prior to flow cytometry. A BD LSR Fortessa in-
strument and FACS Diva software were used to record 10,000 events. The 488nm blue laser
was used to excite eGFP, whose fluorescence was detected using a the 530/30 filter. Cy3 was
excited via a 561nm yellow laser and fluorescence detected using a 582/15 band pass filter.
FlowJo v10 (Tree Star) was used for further analyses. Where appropriate, cells were pre-
incubated with 10µg mouse monoclonal IgG1 antibodies for one hour at 4°C, then washed as
before, prior addition of the FLAG-tagged prey. These antibodies included the CLB-thromb/6
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anti-P-selectin clone and the OX102 anti-rat Cd200R clone (BioLegend).
2.6.3 Platelet staining
Whole blood was isolated from healthy donors on the morning of the experiment. Platelet-rich
plasma (PRP) was prepared by isolation of the supernatant following centrifugation of 2mL
whole blood for six minutes at 200g. When optimising the platelet-staining protocol, 10µL
blood or PRP was incubated with 20µL anti-SELP FITC-conjugated antibody or without 10µM
ADP agonist in HBS buffer (total volume 50µL). Following a 30-minute incubation the mix-
ture was fixed using 0.5mL formyl saline for ten minutes. A subset of samples were washed
twice; the washing process involved centrifugation of fixed blood products for ten minutes
at 1000g, after which they were resusupended in 0.5mL HBS. When staining platelets with
FLAG-tagged reporter protein, 10µL PRP was incubated with 10µM ADP, 0.1-20µM reporter
proteins in a total volume of 50µL for one hour, then fixed using 0.5mL formyl saline for ten
minutes. Platelets were then washed and incubated with FITC-conjugated anti-FLAG anti-
body (Sigma) for 30 minutes prior to an additional wash step and analysis by flow cytometry.
Stained platelets were examined using a FC500 flow cytometer (Beckman Coulter). FITC was
excited using the 488nm blue laser and detected using the 525/40nm filter. 5000 platelets were
counted and the data analysed using FlowJo.
2.7 Biochemical co-purifications
Avid merozoite protein reagents were created by conjugating biotinylated IMAC-purified pro-
teins, or biotinylated proteins derived directly from dialysed transfected HEK293E cell-culture
supernatant (prepared as described in 2.1.2.3), to streptavidin-coated superparamagnetic beads
(Sigma). For each experiment, 100µL beads were washed three times with 1mL PBS using a
magnet to isolate beads. Beads were resuspended in 1mL PBS and incubated with merozoite
proteins for 30 minutes with rotation. To demonstrate that sufficient protein was provided
to saturate the beads, ELISAs were performed on the supernatant as described in 2.3.1.1. If
biotinylated protein could be detected then beads were deemed to be saturated. To remove
unbound biotinylated protein, the beads were washed three times with 1mL PBS then resus-
pended in 100µL. Human serum (Sigma) was filtered through a 0.2µm filter before use to
remove any aggregated protein before incubation with protein-coated beads for one hour at
4°C. Beads and their bound proteins were isolated using a magnet and washed five times with
ice-cold PBS. Proteins remaining associated with the beads were eluted in 100µL 1% SDS for
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five minutes. 25µL of the eluate was used in SDS-PAGE (see 2.2.4) and the gel was stained
with SYPRO Orange (Sigma). See Figure 5.2 for a schematic representation of the method.
2.7.1 Mass spectrometry
SDS-PAGE-resolved elutants from co-purification assays were fixed with 40% methanol and
2% acetic acid for one hour and stained with a colloidal Coomassie (Sigma) overnight at 4°C.
The background was cleared using 25% methanol for two hours then the gel was washed in
water. Bands for analysis were isolated, then de-stained by incubation with an equal mixture
of 50mM Ammonium Bicarbonate pH8.5 and acetonitrile (AmBic/CH3CN) for 30 minutes at
37°C and 600rpm shaking. The AmBic/CH3CN was replaced and incubation repeated until
the blue colour of the stain was removed. De-staining was completed by incubating the gel
pieces with 1mL CH3CN for 30 minutes at 37°C, removing the liquid and allowing any re-
maining CH3CN to evaporate. To digest any proteins in the bands, gel pieces were covered
with 500µL AmBic containing 1µg/mL trypsin (Roche) and incubated for two hours at 37°C,
then overnight at 25°C whilst shaking at 600rpm. The resulting peptides were then extracted
from the surrounding liquid. Peptides were eluted from the gel by successive incubations of
the gel pieces with a 50%CH3CN/ 0.25% formic acid (Sigma) mixture. Pooled supernatants
from each elution were dried completely to leave peptides, which were later resuspended in
40µL 0.5% formic acid prior to mass spectrometry, which was performed by the in-house mass
spectrometry team. Peptides were analysed by LC-MS/MS on an Ultimate 3000 RSLCnano
System (Dionex) coupled to a LTQ FT Ultra (Thermo Fisher) hybrid mass spectrometer. The
raw mass spectrometry data was processed in Proteome Discoverer (V1.4) (Thermo Fisher)
using Mascot v2.4 (Matrix Science) to assign protein sources for the detected peptides. The
protein databases were a database of human proteins downloaded from Uniprot (as of Febru-
ary 2013) and a database of common contaminants. The reported protein/peptide list used a
Mascot ion score cut-off of 30 with 0.05 as significance threshold.
2.7 Biochemical co-purifications 53
Figure 2.4: HEK293F cell-surface binding assay
A. Cells are transfected with recombinant receptor proteins with a cytoplasmic eGFP tag
B. Cells are incubated with FLAG-tagged pentameric Plasmodium proteins
C. Cells are washed to remove unbound pentamers
D. Cells are incubated with Cy3-conjugated anti-FLAG antibody.
E. Cells are washed to remove unbound antibody and are analysed by flow cytometry.
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SELP region Amino acids Sequence
’Full length’ 1-771 MANC.....IQEA
SELP->CTL 1-162 MANC.....YTAS
SELP->EGF 1-208 MANC.....EYVR
SELP->S3 1-385 MANC.....EAIS
SELP->S6 1-570 MANC.....CEAI
SELP_EGF domain 159-208 YTAS.....EYVR
Table 2.2: SELP protein fragment boundaries
Truncated SELP proteins were produced comprising the regions indicated in Figure 4.2A us-
ing expression plasmids constructed using the primers detailed in Table 2.1. The amino acids
from the endogenous SELP protein sequence (P16109 in Uniprot), alongside the four cor-
responding N-terminal and C-terminal amino acids for each construct, are shown here. The
EGF domain was expressed downstream of the mouse variable κ light chain signal peptide.
All proteins were expressed with a C-terminal rat Cd4 domains 3&4 tag.
PfMSP7 region Amino acids Sequence
’Full length’ 28-351 TPVN.....LNTM
MSP7_N 28-176 TPVN.....VKAQ
MSP722 177-351 SETD.....LNTM
MSP719 195-351 EVQK.....LNTM
Table 2.3: PfMSP7 protein fragment boundaries
Expression plasmids for recombinant PfMSP7 protein fragments, as depicted in Figure 4.5A,
were produced using the primers detailed in 2.1. The amino acids from the PfMSP7 protein
sequence (PF3D7_1335100) and the four N-terminal and C-terminal PfMSP7 amino acids
included in each construct are indicated here. All PfMSP7 constructs were expressed down-
stream of the mouse variable κ light chain signal peptide and included the C-terminal rat Cd4
domains 3&4 tag.
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Chapter 3
Identification and validation of an
interaction between SELP and PfMSP7
3.1 Introduction
This chapter describes the screening of Plasmodium falciparum merozoite cell surface and se-
creted proteins for interactions with human platelet proteins, and the subsequent identification
and biochemical validation of an interaction between P. falciparum merozoite surface protein
7 (PfMSP7) and human P-selectin (SELP).
3.1.1 Rationale for screening
Extracellular host-pathogen protein-protein interactions are vital to the pathogenesis of dis-
ease and represent potential anti-malarial drug and vaccination targets (Section 1.2.1.4). High-
throughput, unbiased screening approaches such as AVEXIS (Section 1.2.3) are powerful tools
to identify novel interactions of this nature[40]. AVEXIS has had proven success with the dis-
covery of, amongst others, the interaction between BSG and PfRH5, which is essential for
parasite entry into RBCs and is thus an ideal and specific target for therapeutics[64]. This
interaction was discovered via the screening of a library of recombinant P. falciparum mero-
zoite cell surface and secreted proteins[65] against a panel of proteins from the RBC surface.
In this work I screened a subset of the same merozoite protein library against proteins from
the human platelet. A library of almost 200 recombinant platelet proteins had already been
created in our laboratory, and within this library there are a large number of potential target
proteins with which merozoite proteins could interact during disease. Platelets are implicated
in both exacerbating disease and protecting the host, with reports that they are directly capa-
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Platelet protein name Uniprot Accession Number
PECAM1 P16284
SELP P16109
APLP2 Q06481
BSG P35613
CD59 P13987
ESAM1 Q96AP7
FURIN P09958
GP6 Q9HCN6
ICAM2 P13598
PRNP P04156
SCARF Q14162
TMED1 Q13445
LAMP2 P13473
MET P08581
Table 3.1: Platelet bait proteins selected for AVEXIS screening
ble of killing merozoites[211, 264] but are also responsible for the pathological clumping of
pRBCs[259] and potentially contribute to the development of cerebral malaria[263]. Hence,
detecting interactions between parasite and platelet proteins could contribute to our under-
standing of these processes at a molecular level. Many of the proteins in this platelet library
are not restricted to the platelet surface, appearing on many other cell types with which Plas-
modium parasites interact, for example endothelial cells and leukocytes. A large number are
also released into the bloodstream as soluble proteins, many of which are important players in
the immune response[346]. Hence interactions between proteins from the platelet and mero-
zoite libraries could form part of a range of processes occurring in malaria, including cellular
adhesion, platelet-mediated parasite killing and parasite-mediated immune evasion.
3.1.2 Selection of proteins for screening
For an initial screen I shortlisted high-expressing proteins from each library. These included
14 platelet bait proteins (see Table 3.1), each with evidence linking them to a role in im-
mune functionality. For example, PECAM1, CD59, FURIN and PRNP have been impli-
cated as regulators of T-cell maturation and functionality[146, 148, 168, 331], which Plasmod-
ium parasites may suppress[224, 320]. PECAM1 and CD59 are also thought to affect B-cell
development[148, 168] and thus have a role in the humoral immune response that protects the
host from chronic or repeated infections, commonly observed with P. falciparum. APLP2 and
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Merozoite protein name PlasmoDB identifier
MSP1 PF3D7_0930300
MSP2 PF3D7_0206800
MSP4 PF3D7_0207000
MSP5 PF3D7_0206900
MSP10 PF3D7_0620400
Pf12 PF3D7_0612700
Pf38 PF3D7_0508000
ASP PF3D7_0405900
AMA1 PF3D7_1133400
MTRAP PF3D7_1028700
MSP3 PF3D7_1035400
MSP7 PF3D7_1335100
Pf41 PF3D7_0404900
Rh5 PF3D7_0424100
PF10_0323 PF3D7_1033200
AARP PF3D7_0423400
MSP3.4 PF3D7_1035700
Pf12p PF3D7_0612800
PF11_0373 PF3D7_1136200
PF14_0293 PF3D7_1431400
Table 3.2: Merozoite prey proteins selected for AVEXIS screening
LAMP2 are important regulators of antigen presentation[337, 373], FURIN and SCARF par-
ticipate in signalling pathways that modulate the production of parasite-killing cytokines[305,
331], and CD59 has a well-characterised role in the complement cascade[168]. A subset of the
selected proteins (PECAM1, SELP, ESAM, ICAM2, SCARF, MET) can also be found on the
surface of endothelial cells, and of these PECAM1, SELP and ICAM2 have been associated
with the recruitment of leukocytes to sites of inflammation[111, 148, 206]. Unsurprisingly for
a group of platelet proteins, many also have known roles in haemostasis[7, 148, 152, 234], an
important process to blood-dwelling pathogens[318]. I included BSG in the shortlist primar-
ily to use as a positive control, known to interact with PfRH5[64]. However, BSG is also an
interesting candidate to screen in its own right as it has been implicated as playing roles in
cellular adhesion, leukocyte migration and RBC longevity[368], all of which could affect the
survival of Plasmodium parasites in their host. The initial selection of merozoite prey proteins
was more arbitrary; I chose 20 proteins from the library that were known to express at medium
to high levels (see Table 3.2).
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3.1.3 A brief introduction to SELP and PfMSP7
SELP, also known as GMP-140, PADGEM, CD62(P) and LECAM3, is a 140kDa glycoprotein
expressed on the surface of activated platelets and endothelial cells. The protein is comprised
of a C-type lectin domain, EGF-like domain and nine short consensus repeats as shown in
Figure 4.2. Via its N-terminal C-type lectin domain, SELP binds to glycoprotein ligands such
as leukocyte cell surface PSGL1 via sialyl Lewis-X (sLeX) tetrasaccharide moieties on their
surfaces. This property allows SELP to be an endothelial ligand to which leukocytes loosely
adhere, or ’roll’ in the early stages of inflammation. It thus contributes to the recruitment of
leukocytes to vessel walls[71, 229].
The PfMSP7 gene encodes a 40kDa precursor protein, and it is this full length protein that
was used in the original screen. The precursor is believed to be proteolytically processed
then exported from the merozoite. PfMSP7 interacts with PfMSP1 and a fragment from the
C-terminus is retained on the merozoite surface, as part of the PfMSP1 complex (see Figure
3.1)[258]. The biological roles of these proteins, and those in their broader protein families,
will be discussed in detail in Chapter 4.
3.2 Results
3.2.1 PfMSP7 and SELP interacted in an AVEXIS screen
To identify novel host-pathogen receptor-ligand interactions involved in the pathogenesis of
malaria, I made use of the P. falciparum merozoite and human platelet protein expression
constructs that were available in our laboratory. I shortlisted a panel of proteins from each
library to screen against each other by AVEXIS, so as to identify interactions that merozoite
proteins could be making with host immune effector targets. For this screen I produced 14
high-expressing human proteins with a known role in immune functionality as biotinylated
’baits’ and 20 high-expressing merozoite proteins as pentameric β -lactamase-tagged ’preys’.
Interactions were identified by observation of a colour change in the nitrocefin substrate; when
a merozoite prey protein binds to one of the arrayed baits its β -lactamase enzyme cleaves the
yellow substrate to produce a red binding signal, which can be quantified by measuring the
solution’s absorbance at 485nm (see 2.3 and Figure 1.4A). Of the merozoite prey proteins
shortlisted for screening (see Table 3.2), I excluded three from the analysis; PfASP because
it produced a binding-like signal when screened against the Cd4 negative control bait, and
Pf12p and PF14_0293 as they did not produce any observable colour change when screened
against the OX68 positive control bait. The remaining 17 merozoite proteins interacted with
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Figure 3.1: PfMSP7 is proteolytically processed
Figure from Extensive proteolytic processing of the malaria parasite merozoite surface protein
7 during biosynthesis and parasite release from erythrocytes by Pachebat et al. (2007)[258].
Reproduced with permission.
A. The PfMSP7 precursor protein is proteolytically processed in multiple steps. PfMSP7 is
initially cleaved to release a 20kDa fragment from its N-terminus, then the 33kDa fragment
remaining from the C-terminus of the precursor is N-terminally cleaved to leave a 22kDa
fragment. This 22kDa fragment from the C-terminus of PfMSP7 is displayed on the surface
of the merozoite as part of the MSP1 complex. In isolates containing glutamine at position
194 this fragment is cleaved again at the merozoite surface to leave a 19kDa fragment in this
complex
B. The full-length PfMSP7 precursor protein is thought to associate with PfMSP1 soon after
translation, after which PfMSP7 and PfMSP1 are processed concurrently.
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the OX68 bait and not with the Cd4 tag bait, and were thereby judged to have been appropri-
ately standardised for screening (Figure 3.2A). This original small-scale screen yielded two
hits: the known interaction between PfRH5 and BSG (Figure 3.2C) and a potentially novel
interaction between PfMSP7 and SELP (Figure 3.2B).
To further validate interactions discovered by AVEXIS we aim to demonstrate the interactions
in both bait-prey orientations. PfMSP7 bait protein and SELP prey were seen to interact by
AVEXIS, although the colour change observed was significantly slower than that seen when
the assay was performed using in the reciprocal bait:prey orientation (where PfMSP7 is used
as the prey, see Figure 3.3A). The PfMSP7 bait was not able to capture and retain sufficient β -
lactamase-tagged SELP prey to saturate nitrocefin hydrolysis within one hour. Whist AVEXIS
is not a quantitative assay, this result implies that the SELP prey/PfMSP7 bait interaction is
not as strong as the PfMSP7 prey/SELP bait interaction. This could mean that the arrangement
of proteins where SELP is pentamerised and PfMSP7 is arrayed on a surface is not optimal
for the observation of the interaction1. SELP is thought to dimerise on the surface of platelets
and endothelial cells, and this dimerisation has been shown to be important in increasing the
avidity of the interactions SELP makes with its known ligands[16, 274]. It is possible that this
SELP arrangement is replicated more accurately when the proteins are arrayed (as baits) as
opposed to pentamerised via their COMP sequence (as preys).
3.2.2 The recombinant SELP and PfMSP7 proteins were biologically ac-
tive
When working with recombinant proteins, especially those produced in heterologous expres-
sion systems, it is important to ensure that they are correctly folded so as to be biologically
active. Fortunately, both SELP and PfMSP7 have previously-identified interacting partners
which can be utilised to assay the functionality of our recombinant proteins. I was able
to demonstrate that PfMSP7 prey binds to a recombinant PfMSP1 bait by AVEXIS (Figure
3.3A) and that SELP bait binds an alkaline phosphatase (AP)-conjugated sLeX reagent2 (Fig-
ure 3.3B), indicating that both recombinant proteins are functional and active. SELP was
unable to bind to a recombinant PSGL1 in either bait:prey orientation, though this may be
explained by a lack of essential post-translational modifications on the PSGL1 surface, since
1This is not an unusual phenomenon for AVEXIS. In fact in a large scale screen for interactions between
zebrafish receptors only 56 of the 100 of heterophilic interactions identified could be observed in both bait-
prey orientations[205]. These included a handful of known interactions, including those between Robo and Slit
proteins involved in Drosophila development[34, 167].
2This sLeX-AP reagent was created by saturating streptavidin-AP (Sigma) with biotinylated sLeX (Glycotech)
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Figure 3.2: SELP bait interacted with PfMSP7 prey
All bars represent reference-subtracted AVEXIS signals as described in Section 2.3.1.3
A. AVEXIS signals when 17 P. falciparum merozoite prey proteins were screened against
controls. Each prey protein included in the analysis produced a strong signal upon screening
against positive control bait (OX68 antibody) and minimal signal when screened against the
negative control (rat Cd4 tag region)
B. AVEXIS signals when SELP bait was screened against merozoite preys. SELP bait inter-
acted with PfMSP7, but not with any other merozoite preys.
C. AVEXIS signals when additional platelet bait proteins were screened against the merozoite
proteins. The signals observed for five of the 14 baits are shown. The only other signifi-
cant signal observed was when BSG bait was incubated with PfRh5 prey. This is a known
interaction.
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Figure 3.3: Recombinant, soluble SELP and PfMSP7 preparations were biochemically
active
A. AVEXIS signals when PfMSP7 and SELP preys were screened against known ligands.
PfMSP7 prey bound to PfMSP1, as well as SELP, bait. SELP prey bound to sLeX and PfMSP7.
Both prey proteins were also screened against OX68 positive control bait (+) rat Cd4 tag re-
gion negative control bait (-). Bars represent means +/- SD, n=3.
B. Alkaline phosphatase(AP) mediated substrate activity when streptavidin-AP conjugates
were incubated with SELP bait. A sLeX conjugate bound to SELP bait. The bait did not
bind the streptavidin-AP used to create the conjugate.
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co-transfection of a fucosyltransferase may be required to ensure that sLeX is incorporated
into the molecule[291]. It is also worth noting that both PfMSP7 and SELP proteins were ex-
pressed at high levels, which is in itself a good indicator that the proteins are correctly folded
prior to secretion.
3.2.3 The SELP/PfMSP7 interaction could be blocked by an anti-SELP
mAB
To provide further evidence for the correct folding of SELP, I tested the binding of the re-
combinant protein to a commerically-available anti-SELP monoclonal antibody (mAB). The
antibody bound to recombinant SELP by ELISA. However the binding of this CLB-thromb/6
antibody was not affected by denaturation of the recombinant SELP bait (Figure 3.4B), in-
dicating that the CLB-thromb/6-binding epitope is not conformation-sensitive. This means
that the binding of the antibody cannot be used as an indicator of correct protein folding. To
provide more evidence for the specificity of the SELP/PfMSP7 interaction, I showed that the
binding of the antibody to immobilised SELP bait blocks the binding of PfMSP7 prey (Fig-
ure 3.4A). This result may indicate that there is some overlap between the binding sites for
CLB-thromb/6 and PfMSP7 on SELP, and/or may result from the steric effect of the antibody,
impeding access of PfMSP7 pentamers to their binding sites. Additionally, this result means
that this particular antibody clone could be a useful reagent to block the interaction in further
studies.
3.2.4 PfMSP7 bound to recombinant SELP at the cell surface
To demonstrate that PfMSP7 can bind to SELP at the cell surface, and to verify the inter-
action in a different experimental system, I developed a flow cytometry-based binding assay
(described in Figure 2.4). By transfecting HEK293F cells with plasmids encoding protein
ectodomains fused to a transmembrane domain and green fluorescent protein (GFP), I was
able to over-express receptors at the cell surface with a cytoplasmic GFP tag (Figures 2.1C
& 3.5A). I incubated the transfected cells with pentamerised, FLAG-tagged proteins and then
with a Cy3-conjugated anti-FLAG antibody. I then used flow cytometery to distinguish fluo-
rescent populations. I used the interaction between rat Cd200 and Cd200R proteins to optimise
the experimental parameters of the assay, expressing Cd200R at the cell surface and incubating
the cells with Cd200 pentamer. I observed a strong correlation between GFP signal and Cy3
fluorescence, indicating that Cd200 protein bound specifically to transfected cells, at levels
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CLB-thromb/6
OX68
Figure 3.4: An anti-SELP mAB blocked the SELP/PfMSP7 interaction
A. ELISA using CLB-thromb/6 to detect recombinant SELP. The CLB-thromb/6 binding epi-
tope on SELP is not conformation-sensitive, since boiling the protein for ten minutes with 1%
SDS prior to capture did not affect the result.
B AVEXIS signals resulting from the interaction between SELP bait and PfMSP7 prey,
blocked by incubating the bait protein with CLB-thromb/6, a mAB against SELP. The in-
teraction was not blocked with OX68 mAB, which binds to the Cd4 tag region of SELP.
Error bars represent means +/- SD, n=3.
proportionate to the receptor concentration (Figure 3.5B). The interaction could be blocked by
pre-incubating cells with OX102 anti-Cd200R monoclonal antibody, indicating that the Cd200
pentamers are binding to the cell surface specifically via their interaction with the transfected
Cd200R.
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Figure 3.6: PfMSP7 pentamers bound specifically to SELP at the cell surface
A. Flow cytometry dot-plots when SELP-eGFP transfected cells were incubated with pen-
tameric FLAG-tagged PfMSP7 bound to cells expressing GFP-tagged SELP on the cell sur-
face. FLAG-tagged PfMSP7 interacted with eGFP-positive cells (left), but not those that were
blocked by an anti-SELP mAB (right).
B. Dot plots of three negative controls. All negative control samples behaved as expected;
Cd200R positive cells did not bind the PfMSP7 pentamers (left), SELP-transfected cells did
not interact with Cd200 (centre) and mABs not directed against SELP could not block the
SELP-PfMSP7 interaction (right).
5,000 events within forward and side-scatter parameters that facilitate counting of HEK cells
are displayed.
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Similarly, I could detect a specific interaction between SELP receptors and PfMSP7 pen-
tamers (Figure 3.6). PfMSP7 prey did not bind to untransfected cells, or cells transfected
with Cd200R-GFP. The CLB-thromb/6 anti-SELP monoclonal antibody that I earlier found to
block the interaction (Section 3.2.3) could also block the interaction between the PfMSP7 and
SELP-transfected cells. Antibodies against Cd4 or BSG (which is present on the HEK cell
surface) did not block the interaction (Figure 3.6B). This further demonstrates that PfMSP7
bound to the cell surface specifically via its interaction with SELP. I was unable to express
sufficient PfMSP7 at the cell surface to perform the assay using SELP prey.
3.2.5 Recombinant PfMSP7 formed metastable oligometric complexes
in solution
To isolate monomeric PfMSP7 for use in surface plasmon resonance studies, I purified the
6xHis-tagged protein by immobilised metal ion affinity chromatography (IMAC) and then
separated the elutant by size-exclusion chromatography (SEC). I observed high batch-to-batch
variability in the elution profiles from each SEC experiment and observed multiple peaks in the
majority of profiles (see Figure 3.7A). SDS-PAGE analysis on the eluted fractions confirmed
that each peak contained only PfMSP7 proteins, indicating that PfMSP7 exists in multiple
oligometric states (Figure 3.7B). The gel filtration column is calibrated using a series of glob-
ular protein standards, allowing the estimation of the molecular mass of proteins based on
their elution volume. However, the volume at which a protein elutes is dependent on its size
and conformation, not its molecular mass alone, such that elution volume more accurately
reflects the hydrodynamic volume (VH) or radius of gyration (Rg) of the eluting species[319].
In most cases the slowest-eluting fractions had a VH equivalent to a globular protein with a
molecular mass of at least 100kDa; if these proteins correspond to PfMSP7 monomers this
would imply that PfMSP7 adopts a more extended conformation than globular proteins of an
equivalent (~60kDa) mass. The earliest-eluting PfMSP7 fractions, with VHs equivalent to a
globular protein hundreds of kDa in mass, are certainly higher-order PfMSP7 complexes. The
degree to which the PfMSP7 preparations oligomerise did not appear to be related to protein
concentration or the length of time the protein had been stored.
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3.2.5.1 The flexible N-terminus of PfMSP7 was responsible for self-oligomerisation
PfMSP7 undergoes proteolytic cleavage to leave a 22 or 19kDa fragment from the C-terminus
on the surface of the merozoite and fragments as part of the MSP1 complex, and N-terminal
fragments that are thought to be degraded or lost from the merozoite (Figure 3.1)[158, 258].
To determine whether a particular portion of the molecule is responsible for the formation of
metastable oligomers, I expressed and purified the 22kDa fragment of MSP7 (MSP722) and the
remaining portion from the N-terminus (referred to hereafter as MSP7-N). and analysed both
proteins by size-exclusion chromatography (SEC) (Figure 3.8A & C). Each of three indepen-
dent PfMSP7-N preparations exhibited very different SEC elution profiles. This was similar
to the behaviour I observed when analysing full-length PfMSP7 (Figure 3.7) and suggested
that the N-terminus was the source of this potential oligomerisation activity and variability
in the SEC elution traces. Corroborating this, three SEC profiles of PfMSP722 preparations
were very similar to one another (Figure 3.8B & C). They showed a single predominant peak,
which could theoretically correspond to a monomeric protein, and a smaller peak comprising
oligometric protein, indicating that this C-terminal region is not the source of the variable
oligomerisation behaviour observed in PfMSP7.
3.2.5.2 ’Intrinsic disorder’ in PfMSP7
Oligomerisation of P. falciparum merozoite surface proteins has been reported previously,
with SEC elution profiles for PfMSP2, PfMSP3 and PfMSP3 fragments yielding multiple
peaks with large predicated hydrodynamic radii[2, 118, 144]. It is thought that both PfMSP2
and PfMSP3 proteins self-assemble into amyloid like filaments, and it has been hypothesised
that these assemblies promote binding to RBC surfaces prior to invasion[144, 372]. To investi-
gate whether the same sort of oligometric self assembly may be occurring in PfMSP7, I looked
for amino acid sequences that might promote this behaviour. I did not identify any regions of
similarity to the leucine-zipper region or aggregation motif that are speculated to be involved
in PfMSP3 self-assembly, or with the N-terminal region of PfMSP2 which is thought to be re-
sponsible for its oligomerisation[144, 366]. The formation of amyloid fibrils, similar in their
structure to those seen in PfMSP2 and PfMSP3, is associated with flexible regions in compo-
nent protein monomers[370]. By running the PfMSP7 amino acid sequence through the sev-
eral algorithms that predict flexible or ’disordered’ regions in protein structure, I identified that
the PfMSP7 sequence is very likely to contain disordered regions, particularly towards its N-
terminus (Figure 3.8D)[95]. The four algorithms PrDOS[147], Disprot[363], Disopred3[157]
and IUPred[73] predict 44-75% of the amino acid residues comprising MSP7-N to be part
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of disordered regions, whereas the percentage for MSP722 is only 18-22% (see Figure 6.1C).
This suggests that the N-terminus of PfMSP7 is intrinsically disordered.
In recent years there has been growing recognition that a large proportion of proteins, partic-
ularly those in eukaryotes[350]3, lack the ordered, globular domain structures that are com-
monly associated with binding or catalytic functions[361]. These proteins are characterised by
flexible structures, which have been shown to adopt more ordered conformations upon bind-
ing to their (often numerous) ligands. This property has been associated with the ability of
proteins to perform multiple functions and to bind multiple targets, and could contribute to the
tendency of PfMSP7 to self-associate[332].
3.2.6 PfMSP7 binding to SELP was observed using SPR
Surface plasmon resonance (SPR) is a leading method for determining the kinetic parameters
of a protein-protein interaction. I attempted to use this approach to determine equilibrium
binding measurements for the interaction between monomeric PfMSP7 and SELP. Upon in-
jecting PfMSP7 analyte over immobilised SELP bait, I observed a clear binding response,
indicating that the two proteins interact directly (Figure 3.9). Fitting the association curves
to different binding models indicated that complex, multivalent binding of PfMSP7 to SELP
took place, which was anticipated given the observed tendency for PfMSP7 to oligomerise
(see 3.2.5). Where I observed multiple peaks in SEC elution profiles, I often observed signifi-
cantly greater binding signals when PfMSP7 complexes of larger molecular mass (but equiv-
alent amount of PfMSP7 molecules) were injected over SELP (Figure 3.9B). The binding of
a larger complex will in itself increase the SPR signal which is inherently sensitive to the size
of the binding analyte, though given the magnitude of this increase it could be speculated that
these larger complexes are also binding more avidly. More detailed kinetic data are required
to confirm this. In all cases where PfMSP7 species were injected, dissociation of PfMSP7
analyte appeared to be very slow, suggesting that this is a highly avid interaction (Figure 3.9).
Whilst these data validate the interaction between SELP and PfMSP7, their binding charac-
teristics meant that the interaction was not particularly amenable to kinetic analysis. Firstly,
binding did not saturate rapidly, such that a long injection time, and consequently a large vol-
ume of PfMSP7 analyte would be required to perform equilibrium binding analyses. Unfortu-
nately I was unable to generate sufficient purified PfMSP7 analyte to perform these analyses.
3and as much as half of those in Plasmodium species [94]
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Figure 3.8: PfMSP7-N showed similar oligomerisation behaviour to full-length PfMSP7
A. SEC elution profiles from 3 independent PfMSP7-N preparations. As observed with full
length PfMSP7 there is great batch-to-batch variabilty, with profiles showing multiple peaks.
B. SEC elution profiles from 3 independent PfMSP722 preparations. These profiles are much
more consistent, with one predominant peak and a smaller peak containing higher order com-
plexes.
C. SDS-PAGE analysis of each of the indicated Cd4 domain-tagged PfMSP7-N or PfMSP722
peaks confirms that each contains PfMSP7 fragments of the expected size. It is possible that
the peak 1, with the smallest predicted VH, from the PfMSP7-N SEC elutant did not contain
PfMSP7 proteins.
D. Protein disorder scores predicted by four different algorithms IUPred, Protein disorder
prediction system (PrDOS), Disprot and Disopred3. The N-terminal region of PfMSP7 is
predicted to be significantly disordered, which may account for the formation of metastable
oligomers in solution.
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Figure 3.9: PfMSP7 bound specifically to SELP in SPR experiments
A. SPR signals when a range of PfMSP7 concentrations from a predominantly monodisperse
SEC peak were injected over SELP bait. A representation of the SEC elution profile of the
PfMSP7 analyte used in this particular experiment is shown on the left.
B. SPR signals when 3µM PfMSP7 protein from indicated SEC fractions was injected over
SELP. Larger binding responses were observed when larger PfMSP7 complexes were injected.
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Figure 3.10: Purified SELP bound to SPR chips
A. SEC elution profiles from five independent SELP preparation. Predominantly broad,
monodisperse peaks were observed.
B. SPR responses recorded when the indicated concentrations of SEC-purified SELP were in-
jected over four baits for 60 seconds. In each case comparable and highly significant binding
to positive controls (sLeX tetrasaccharide), negative controls (rat Cd4 tag), PfMSP7 and even
blank flow cells was evident.
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Secondly the interaction was fairly resistant to washing with a range of regeneration solu-
tions, including 0.2-1M NaOH, 1-3M Glycine HCl (pH1.5), 5M NaCl and 4M MgCl2. This
made it difficult to fully regenerate the SELP-coated surface, which adversely affected the
reproducibility and reliability of successive analyte injections.
To overcome the difficulties in analysing multivalent PfMSP7 binding to SELP, I prepared
SEC-purified SELP analyte to inject over immobilised PfMSP7. Encouragingly, the SEC
elution profiles of SELP proteins were consistent between experiments, traces showing broad
but monodisperse peaks (Figure 3.10A). However, injecting SELP analyte in SPR experiments
proved problematic as it appeared to bind non-specifically in every flow cell (Figure 3.10B).
This suggested that SELP was binding to the carboxymethylated dextran surface of the SPR
chip. Selectins have been reported to bind dextrans, but only in a sulphated form[133], so it is
currently unclear as to why this binding activity was observed.
3.3 Discussion
3.3.1 Multiple biochemical assays indicate that PfMSP7 and SELP in-
teract, but oligomerisation of PfMSP7 may be required
The work described above shows that recombinant PfMSP7 and SELP proteins interact re-
producibly in multiple assay systems (Figures 3.3, 3.9 & 3.6). Pentamerised PfMSP7 inter-
acts with monomeric SELP in AVEXIS, with nitrocefin hydrolysis saturating in just minutes,
significantly faster than all positive controls. Flow cytometry-based assays also show that
PfMSP7 pentamers can bind specifically to SELP expressed at the cell surface. We can also
see a large SPR signal when injecting purified PfMSP7 over SELP. In AVEXIS, PfMSP7 bait
binding to SELP prey appears to be significantly weaker (Figure 3.3A), indicating that there
may be a requirement for a higher-order spatial arrangement of either protein. SEC experi-
ments show that recombinant PfMSP7 readily self-associates (Figure 3.7) and the higher-order
oligomers appear to exhibit increased SELP-binding ability in SPR experiments (Figure 3.9B).
Especially given the predicted flexibility of the N-terminus (Figure 3.8D), it is not unlikely that
PfMSP7 proteins would oligomerise in vivo, and there is a precedent for doing so provided by
PfMSP2 and PfMSP3[118, 366], whose oligomerisation is thought to increase the proteins’
ability to participate in binding interactions[2, 144].
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Figure 3.11: Purified SELP bait interacted non-specifically in another AVEXIS screen
AVEXIS data from a platelet-platelet protein interaction screen showed that SELP bait inter-
acts non-specifically with a range of platelet preys.
Data courtesy of Dr Yi Sun.
3.3.2 Recombinant SELP is prone to non-specific interactions, but mul-
tiple lines of evidence support the validity of its interaction with
PfMSP7
In the course of this project, unrelated research within the group showed that purified recombi-
nant SELP bait proteins exhibit ’promiscuous’ binding behaviour in AVEXIS. In these experi-
ments, purified recombinant bait proteins from a platelet protein library were screened against
the same library expressed as purified prey proteins. A large proportion of the platelet prey
proteins produced a binding signal when screened against SELP bait, which was amongst the
‘noisiest’ of the bait library (Figure 3.11). Similar results were observed in a microarray-based
AVEXIS-like interaction screen using the same proteins[321].
These AVEXIS data, coupled with the observation that recombinant SELP binds to the sup-
posedly inert SPR chip surface (Figure 3.10B), raised legitimate concerns about the meaning-
fulness of my biochemical data about the SELP-PfMSP7 interaction. In both instances where
this promiscuous binding was observed the recombinant SELP protein was purified by IMAC,
so it is possible that purification increases the propensity of SELP to bind non-specifically.
In light of these concerning observations, I avoided using purified protein where possible and
took measures to ensure that the SELP proteins used in all PfMSP7 interaction assays were
correctly folded and functional, for instance by demonstrating that they bind to sLeX (Fig-
ure 3.3). Even though these assays increase our confidence that the recombinant protein is
folded and active, the possibility remains that a proportion of the proteins in each preparation
are locally unfolded and responsible for non-specific interactions. To ultimately exclude the
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possibility that the interaction we observe is the result of non-natively folded SELP proteins,
I would ideally demonstrate that the interaction takes place between naturally-occurring pro-
teins, which will be folded and post-translationally modified as they would be in vivo. The cell
surface expression of SELP can be induced in platelets and endothelial cells, so I attempted
to stain the surface of activated platelets and human umbilical vein endothelial cells (HU-
VECs) with FLAG-tagged PfMSP7 pentamers. Attempts to stain PMA-activated HUVECs
with either anti-SELP antibodies or PfMSP7 were unsuccessful, both when using microscopy
and flow cytometry as detection methods. It is possible that the surface expression level of
SELP in this cell line was insufficient. The activation of platelets leads to a very significant
increase in surface SELP, which I was able to detect by flow cytometry (Figure 3.12A). In ini-
tial attempts to stain platelets with PfMSP7, I incubated activated platelets with FLAG-tagged
PfMSP7 pentamers followed by a fluorescently conjugated anti-FLAG monoclonal antibody.
These experiments were ultimately unsuccessful, as the antibody itself bound the platelets at a
level that was unaffected by the presence of PfMSP7, positive control or negative control pen-
tamers (Figure 3.12B). Before pursuing in vivo experiments to investigate the function of the
interaction, it will be important to improve this platelet-based assay or otherwise demonstrate
that PfMSP7 can bind to native SELP. Data presented in Chapter 4 support there being an
important, conserved role for this interaction in a number of Plasmodium species, and provide
more evidence for the validity of the interaction discussed here.
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Figure 3.12: Platelet staining assays were optimised but unsuccessful due to antibody
binding to the platelet surface
A. Flow cytometry histograms of FITC flourescence when platelets were incubated with con-
jugated anti-SELP antibody. SELP was detected on the surface of activated platelets within
whole blood or platelet rich plasma (PRP). Washing the blood or PRP by centrifugation did
not impair sample quality.
B. Histograms of FITC fluorescence when platelets were incubated with or without FLAG-
tagged pentameric EphrinB2 positive control proteins and then with a FITC-conjugated anti-
FLAG antibody. It was not possible to discern EphrinB2 binding to platelets(right) as the
anti-FLAG antibody appeared to bind directly to platelets(left).
5,000 events within forward and side-scatter appropriate for counting platelets are displayed.

Chapter 4
Biochemical characterisation of the
interactions between SELP and
Plasmodium MSP7s
4.1 Introduction
Following the identification and validation of an in vitro interaction between human P-selectin
(SELP) and Plasmodium falciparum merozoite surface protein 7 (PfMSP7), this chapter de-
scribes further biochemical characterisation of this interaction, and expands this characterisa-
tion to encompass the broader families of each protein.
4.1.1 The Plasmodium MSP7 family
4.1.1.1 MSP7s in a genomic context
The Plasmodium MSP7 and MSP7-related protein (MSRP) genes have been defined by ho-
mology to the PfMSP7 gene, first identified as the origin of the 22kDa MSP7 protein fragment
found on the surface of the P. falciparum merozoite[215, 227, 257, 327]. These multi-gene
families comprise variable numbers of protein-coding genes located very close to one another
on one chromosome of each Plasmodium species with an available genome sequence. The
genomes of rodent parasites P. berghei, P.chabaudi and P. yoelii contain three MSP7 family
protein-coding genes, the genome of P. falciparum contains at least six and that of P. vivax
contains eleven annotated MSP7 genes (Figure 4.1)[108, 137, 158, 227]. The persistence of
this large multi-gene family across the Plasmodium genus suggests that its members play an
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Figure 4.1: MSP7 gene organisation and nomencalture in different Plasmodium species
Screenshot from PlasmoDB of the genomic locus containing the MSP7 family. The MSP7
genes in P. falciparum, P. vivax and P. berghei are annotated with the nomenclature used to
refer to them in the text of this thesis. This nomenclature reflects each gene’s description in
PlasmoDB at the time of writing with the exceptions of P. vivax MSP7s and P. falciparum’s
putative MSRP6 and MSRP7 genes, which are identified as part of this family in Garzón-
Opsina et al. (2010)[108] and named as such in Heiber et al. (2013)[137]. The above labelling
of the P. vivax MSP7s follows that used in Kadekoppala & Holder’s 2010 review of the MSP7
gene family[158]. MSP7 proteins expressed as part of this work are coloured in green.
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important biological role. There is currently no evidence at the DNA level to suggest func-
tional divergence between MSP7 paralogues, indicating that they might be redundant. The ex-
pansion in the number of MSP7 genes in some species relative to others is therefore not fully
understood, although it has been suggested that the number of family members has been fixed
in each species at the optimal number or gene ’dosage’ for the niche they each occupy[108].
Gene duplication events are thought to be responsible for the presence of multiple MSP7-
family genes in each species. These genes share a similar structure and organisation, though
sequence conservation is moderately low; in P. falciparum for instance, there is about 38 –
54% overall amino acid similarity between paralogues. Increased amino acid similarity is
observed towards the C-termini of the MSP7-family proteins in all species, indicating that
this region may be particularly important to the proteins’ functionality[158, 227]. There is
some evidence to suggest that the 3’ end of the PfMSP7 gene and the central regions of at
least two P. vivax MSP7 genes are under balancing selection, potentially to maintain antigenic
diversity as a result of increased immune selection pressure[5, 110, 286, 326]. In contrast,
most of the individual MSP7-family genes in P. falciparum and a number of MSP7 genes in
P. vivax are highly conserved, with few SNPs observed between isolates[109, 158, 286, 326].
Taken together the genetic information implies that the different MSP7-family proteins have
the potential to carry out similar functions but are differentially exposed to selective pressures.
4.1.1.2 MSP7 protein expression
Transcripts for all MSP7-family proteins have been detected in blood-stage P. falciparum para-
sites, with a general increase in expression seen towards schizogony[160, 216]. However, only
PfMSP7, PfMSRP1 and PfMSRP2 proteins have been detected experimentally. These three
proteins have been detected by immunoflourescence in trophozoites[215], whilst PfMSP7 and
PfMSRP1 have been detected in the detergent-resistant membrane fractions of schizonts[293].
Immunoblotting of trophozoite and schizont lysates detected PfMSP7 and PfMSRP2, but none
of the other P. falciparum MSRP proteins[160]. Both PfMSP7 and PfMSRP2 have been
shown to undergo proteolytic cleavage by subtilisin-like proteases[160, 173, 258, 304] (see
Figure 3.1). Whilst the C-terminal fragments of PfMSP7 that are known to be associated
with PfMSP1 on the the merozoite surface, the eventual destinations of most of the other
PfMSP7 and PfMSRP2 fragments are currently unclear[304]. A 173 amino acid fragment
from the N-terminus of PfMSP7 has been expressed with a GFP tag in P. falciparum parasites.
The fragment could be visualised in the parasitophorous vaculolar space, indicating that this
PfMSP7 fragment could be secreted from merozoites[158]. Although PfMSRP2 is thought
to be processed in a similar manner as PfMSP7[160, 304] there is some debate as to whether
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it associates with PfMSP1 or forms any part of the MSP1 complex[160]. A biochemical pu-
rification assay where GST-tagged PfMSP1 was incubated with recombinant PfMSPRP1 and
PfMSRP2 indicated that both PfMSP7 family proteins bind to PfMSP1[215], but these interac-
tions have not been shown to occur in parasites[160]. Antibodies against PfMSRP2 as well as
N- and C-terminal regions of PfMSP7 have been detected in the serum of individuals living in
malaria-endemic areas[158, 258, 349], indicating that these protein fragments are exposed to
the immune system1. Although their native gene products have not been identified in vitro or
in vivo, GFP-fusions of MSRP5 and putative MSRP6 and MSRP7 proteins have been detected
outside of the merozoite, indicating that they are secreted[137].
Comparatively little is known about the destinations of P. vivax MSP7 proteins. At least
eight are transcribed in late schizonts[32], and the protein with highest amino acid similarity
to PfMSP7 (labelled as PvMSP7_2 in Figure 4.1) has been characterised to some extent; like
PfMSP7 it is expressed and proteolytically processed, and at least one of the cleavage products
is thought to localise to the merozoite surface in schizonts[227]. In rodent parasite P. yeolii all
three MSP7 family proteins have been detected and are thought to bind PyMSP1. PyMSP7 and
PyMSRP2 co-localise with PyMSP1 at the merozoite surface and are thought to induce a low
level of protective immunity when administered as vaccines in mouse models[216]. Similarly
P. berghei MSP7 localises with PbMSP1 at the merozoite surface, though immunoprecipita-
tion experiments indicate that, unlike PfMSP7, PyMSP7 and PvMSP7_2, PbMSP7 does not
undergo proteolytic processing[327].
4.1.1.3 PfMSP7 and PbMSP7 are associated with RBC invasion, but may perform ad-
ditional functions
The P. falciparum MSP1 complex is comprised of four fragments of the PfMSP1 precursor
protein and a peripherally-associated fragment of each of PfMSP6 and PfMSP7; the complex
forms a major component of the thick, fibrillar coat of the merozoite and has hence been stud-
ied intensively as a target for vaccines and therapeutics. The MSP1 complex is known to be
required for merozoites to invade erythrocytes. Antibodies against PfMSP7 can block inva-
sion, either by preventing interactions that the MSP1 complex makes with the RBC surface
or by preventing the maturation and/or shedding of the MSP1 complex[164, 357]. PfMSP7-
knockout parasites still process PfMSP1 and present its peptides on the merozoite surface as
normal. Similarly, knockout parasites are still able to survive and invade RBCs in in vitro and
in vivo models, indicating that MSP7 itself is not essential. However, these knockout parasites
1Of particular note, naturally-acquired antibodies against PfMSP7 were shown to be protective against severe
disease in a cohort of Tanzanian children[273].
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do show a slight impairment in their invasion capacity when compared to wild-type. As-
says using in vitro P. falciparum cultures show a 30% reduction in invasion when PfMSP7 is
deleted[159] whilst P. berghei deletion mutants grew more slowly in vivo and demonstrated a
preference for invading reticulocytes[117, 313, 327]. Adding to the evidence that PfMSP7 has
an important, though not essential, role in RBC invasion, protein levels are seen up-regulated
nearly eight-fold in W2mef strains switching to sialic acid-independent invasion[174]. Plas-
modium parasites are known to enter RBCs via multiple invasion pathways so it is possible that
PfMSP7 is involved in one or more of these. Based on its known localisation to the merozoite
surface, it is reasonable to assign PfMSP7’s role in invasion to its C-terminal 19 or 22kDa
fragment within the MSP1 complex, although peptides corresponding to the N- and C-termini
have been reported to bind to the RBC surface, potentially via an interaction with Band 3, and
inhibit invasion by up to 50%[106].
Evidence from rodent infections implies that PbMSP7 may play an immunomodulatory role.
PbMSP7-knockout parasites caused significantly fewer deaths in both a mouse model of
chronic infection and an aged rat model. The delay in parasite growth and corresponding
slower generation of anaemia in the PbMSP7-knockout infected mice was not sufficient to
explain these results, leading the authors to suggest that the presence of PbMSP7 impaired the
host’s ability to respond effectively to the infection[117]. In mouse strains that are susceptible
to experimental cerebral malaria (ECM) PbMSP7-knockout parasites were unable to induce
the ECM phenotypes observed in mice infected with wild-type parasites, critically demon-
strating a reduced ability to damage the blood-brain barrier. Again these results could not be
explained by the growth impairment of the knockout parasites, indicating that the mechanism
by which ECM is induced relies on the presence of the PbMSP7 protein[313]. The signifi-
cance of the these results to human infections is currently unclear2 but these data indicate that
at least one MSP7 protein may possess functions that do not directly relate to RBC invasion
alone.
4.1.1.4 The P. falciparum MSRPs have no known function
The presence of multiple MSP7 family proteins in Plasmodium species suggests that they
might be functionally redundant. However, experiments in P. falciparum knockouts do not
suggest that MSRPs can provide compensatory functions for PfMSP7’s role in RBC invasion.
MSRP transcript abundances remain comparable between wild type and PfMSP7 knockout
lines, with the exception of PfMSRP5, whose transcription appears to be increased two-fold.
2especially given the differences in MSP7 processing and localisation between human- and mouse-infective
Plasmodium species[215, 216, 227, 258, 327]
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The consequence of this up-regulation is unclear, as the protein itself has not been detected
at the RBC surface, nor elsewhere in parasite lysates[159]. All P. falciparum MSRPs can be
individually deleted without any impairment of the parasites’ ability to invade RBCs[160].
However, to date there have been no reported incidences of the generation of viable parasites
of any species lacking all MSP7 family proteins.
4.1.2 The human selectins
4.1.2.1 The selectin proteins
Lectins are a group of carbohydrate-binding proteins, known for their roles in mediating
cellular recognition and attachment events via their interactions with specific sugars. Se-
lectins are classed among the C-type lectins, which were originally characterised by their
calcium-dependent binding properties[75]. There are three genes encoding selectin proteins
in humans. They are clustered on chromosome one and are thought to have arisen by gene
duplication events occurring before the divergence of humans and mice[351]. Each of the
proteins are structurally very similar, all type I membrane proteins sharing a conserved N-
terminal C-type lectin and EGF-binding like domain then a variable number of short consen-
sus repeats[156] (see Figure 4.2A). E-selectin (SELE) is expressed on endothelial cells whilst
L-selectin (SELL) is expressed on the surface of leukocytes[26, 27, 324]. P-selectin (SELP) is
localised to the alpha-granules of platelets and the Weibel-Palade bodies of endothelial cells.
Upon activation, these bodies fuse with the membrane of their respective cell type, resulting in
the rapid translocation of SELP to the surface membrane[209, 317]. All three selectins can be
detected as soluble proteins in the bloodstream, a splice variant of SELP lacking a transmem-
brane domain being the source of much of this circulating protein[76, 237, 296]. Selectins
exhibit calcium-dependent binding to a number of extracellular glycoproteins. This binding
activity is mediated predominantly by the C-type lectin-like domain which interacts with sLeX
tetrasaccharides[87, 99]. Despite their shared ability to bind sLeX sugars, the glycoprotein
ligand-binding specificity of each selectin differs based on subtle structural differences be-
tween the full length proteins[186, 325]. Leukocyte P-selectin glycoprotein ligand 1 (PSGL1)
is the best characterised SELP ligand[229, 239, 291, 292]. SELE can also bind PSGL1 but is
thought to bind preferentially other leukocyte ligands to mediate rolling interactions[8, 365].
SELL has been shown to interact with PSGL1 with a much lower affinity and has a range
of other mucin-like ligands[282, 314]. A low affinity interaction, in the millimolar range, is
thought to occur between selectins and isolated sLeX[268] but the interactions selectins make
with their glycoprotein ligands are substantially stronger. It has been hypothesised that an
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initial electrostatic interaction occurs between sLeX and its binding site, following which the
selectin molecule makes further contacts with the protein ligand, resulting in a higher affinity
interaction[312]. The C-type lectin-like domain has been most heavily implicated in mediat-
ing binding behaviour in the selectins, as it is the region with which calcium ions, sLeX and
a range of small-molecule interaction inhibitors bind and it is structurally fairly isolated from
the EGF-like domain[113, 123, 133, 312]. However, crystallographic evidence from the struc-
tures of SELP’s EGF and C-type lectin-like domains in complex with a peptide from PSGL1
suggests that the EGF-like domain may play a role in high-affinity ligand binding[161, 312].
4.1.2.2 SELP-ligand interactions are important in inflammation and blood coagulation
Selectins have a well-characterised role as vascular adhesion molecules, each mediating in-
teractions between leukocytes and endothelial cells[26, 112, 193]. Endothelial selectins and
their ligands are necessary for the loose binding, or ‘rolling’, of leukocytes as they are re-
cruited to vessel walls in the very early stages of inflammation[71, 190, 206, 239]. This is
an important process in controlling infection, as evidenced by the recurrent, and often severe,
bacterial infections suffered by selectin-deficient mice and patients with Type II Leukocyte
Adhesion Deficiency, in which selectin ligands are sub-optimally glycosylated for binding to
selectins[38, 89]. More recently it has been discovered that the leukocyte-endothelium interac-
tions mediated by SELP might have a more profound effect on inflammation than by leukocyte
recruitment alone. Firstly, it is thought that SELP selectively recruits pro-inflammatory Th1
(T-helper-1) cells in preference to Th2 cells, which can down-regulate inflammation[10, 30].
Secondly, leukocyte PSGL1 binding to endothelial SELP is also thought to trigger signalling
pathways that prime cells for enhancing inflammatory responses. For instance this binding
promotes phagocytosis in monocytes and leads to an enhanced production of a range of cy-
tokines, including TNFα[83, 352], which is thought to be particularly important for parasite
killing in the early stages of malaria[276]. Conversely, it is thought that circulating soluble
SELP can prevent these interactions and help to limit the inflammatory response[76, 103, 358].
Roles for SELP in blood coagulation and haemodynamics have also been identified. SELP can
induce monocytes to produce tissue factor[51], which both induces signalling in white blood
cells and initiates the chain of interactions in the clotting cascade. Since this discovery, SELP
has been characterised as a pro-coagulant molecule[7], the interaction between platelet SELP
and PSGL1 being important in the formation of thrombi[90].
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4.1.2.3 SELP is known to contribute to malarial pathology
As a key part of the inflammatory response, platelets and endothelia are activated which leads
to raised levels of soluble and membrane-bound SELP in human and murine malarial hosts.
Selectins on the surface of endothelial cells have been implicated in the sequestration of
pRBCs. SELP and SELE have been independently identified as receptors for PfEMP1 on
the pRBC surface and are thought to help the initial adhesion, or rolling, of pRBCs[241, 302].
These comparatively weak interactions are thought to aid pRBC sequestration by facilitating
a stronger interaction between CD36 and PfEMP1[302]. pRBC rolling is reduced in a Selp
knockout mouse[53] though no decrease in overall cytoadhesion is observed. Selp-deficient
mice have been shown to be substantially less susceptible to ECM compared with wild-type
control mice[59]. Complementing this observation, it has also been shown that Selp levels are
increased in the brain vessels of mouse strains that are susceptible to ECM, whereas resistant
BALB/c strains do not show this accumulation. Tissue specific Selp-knockout mice have been
used to isolate endothelial (rather than platelet) Selp as the key contributor to the observed
cerebral pathology; the incidence of ECM was decreased in mice deficient in endothelial Selp,
whilst those lacking platelet Selp were not protected[59]. Plasmodium species’ use of SELP as
an endothelial receptor may explain these observations, though more recent research suggests
that SELP can compromise the stability of the blood-brain barrier in certain situations[155],
a state which is thought to precipitate cerebral malaria[233]. More research is needed to de-
termine whether SELP has a pathological role in human malaria, and, if so, whether this is
mediated by a direct host-pathogen interaction.
4.2 Results
4.2.1 Characterisation of PfMSP7 binding to selectins
4.2.1.1 The C-type lectin and EGF-like domains of SELP were required to bind PfMSP7
In Chapter 3, I described the identification of an interaction between SELP and PfMSP7. To
identify the region of the SELP protein that interacts with PfMSP7, I made a series of biotiny-
lated C-terminally truncated SELP proteins based on the protein’s domain structure (Figure
4.2A). I then screened these baits against PfMSP7 prey using AVEXIS. All truncated proteins
were able to bind to full length PfMSP7, except the smallest fragment which comprised only
the C-type lectin (CTL) domain (Figure 4.2B).
The smallest binding fragment contained the CTL and EGF domains, indicating that both
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Figure 4.2: The CTL and EGF domains of SELP were essential for PfMSP7 binding
A. Schematic representation of the truncated SELP bait proteins used for domain mapping ex-
periments, with C-terminal truncations made after the CTL, EGF, third short consensus repeat
(SCR) or sixth SCR domain. The EGF domain, without the CTL domain, was also produced.
Domain boundaries were determined using Pfam and are detailed in Table 2.2.
B. AVEXIS signals when truncated SELP baits were screened against PfMSP7 prey. All
SELP bait protein fragments containing both the CTL and EGF domains bound PfMSP7 prey.
PfMSP7 prey was also screened against OX68 positive control bait (+) rat Cd4 tag region neg-
ative control bait (-). Bars represent means +/- SD, n=3.
C. AVEXIS signals resulting from the interaction of SELP bait and PfMSP7 prey in the pres-
ence of EDTA. The interaction between SELP bait and PfMSP7 prey was blocked completely
by around 30mM EDTA. The rat Cd200/Cd200R interaction was unaffected by EDTA. Error
bars represent means +/- SD, n=3.
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domains in combination, or the EGF domain alone, are minimally required for binding. To test
whether the EGF domain alone could bind, I expressed the single domain as a bait protein and
tested it for binding to PfMSP7 prey (Figure 4.2B). I saw no indication of binding, suggesting
that both CTL and EGF domains are minimally required for binding, and that the binding
site(s) for PfMSP7 is located within this region. The interactions SELP makes with its known
ligands are typically dependent on the coordination of calcium by its CTL domain. To test
whether PfMSP7 binding is also calcium-dependent, I incubated the proteins with varying
concentrations of EDTA, a divalent cation chelator. By performing the AVEXIS-based binding
assay in the presence of EDTA I observed that the interaction could be blocked by about 30mM
EDTA, which is in line with published experiments where EDTA has been used to block
SELP binding[172] (Figure 4.2C). This indicates that the conformation of the CTL-domain is
important for PfMSP7 binding.
4.2.1.2 PfMSP7 bound to SELP and interacted weakly with SELL
SELP is one of the three human selectin proteins. These three selectins have a conserved
structure, and a high degree of amino acid similarity within their shared domains (Figure
4.3A) so it is very plausible that PfMSP7 could bind to other selectins besides SELP. To deter-
mine whether this occurs, I sub-cloned SELL and SELE ectodomains from cDNA, expressed
both as biotinylated bait proteins (Figure 4.3B) and screened them against PfMSP7 prey us-
ing AVEXIS (Figure 4.3C). I observed a degree of nitrocefin hydrolysis when SELL bait was
used in the screen, indicating that some PfMSP7 prey was bound. Unlike when OX68 (posi-
tive control) and SELP baits were used, this nitrocefin hydrolysis did not saturate within one
hour. This indicates that SELL can capture PfMSP7, but cannot capture as much of this prey
protein as SELP can, implying that the interaction involving SELL is weaker. When I used
all three selectins in SPR experiments with a PfMSP7 analyte, I only observed binding in the
flow cells containing SELP (Figure 4.3D), which might indicate that PfMSP7/SELL binding
phenomenon seen by AVEXIS is not biologically significant.
4.2.1.3 Naturally-occurring SNPs within SELP’s binding domain did not affect binding
to PfMSP7 without compromising protein function
Sequencing and genotyping have elucidated a number of SNPs occurring in the human SELP
DNA sequence, and they have been catalogued in the dbSNP database. Using this resource, I
identified four non-synonymous SNPs within SELP’s CTL and EGF domains (highlighted in
Figure 4.3A). Searching the 1000 human genomes data revealed that all of these variants are
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Figure 4.3: Limited evidence for SELL and SELE binding to PfMPS7
A. T-COFFEE amino acid sequence alignment of CTL and EGF domains of SELL, SELL,
SELP and mouse Selp. Vertical lines indicate the boundaries of each domain as delineated by
Pfam. Residues highlighted in red or green are those that are recorded in dbSNP as known
variants in human SELP.
B. Selectin baits were successfully expressed and biotinylated. Single bands of expected sizes
were observed by Western blotting using streptavidin-HRP.
C. PfMSP7 prey bound to SELP and SELL baits in AVEXIS assays. OX68 was the positive
control bait (+) and the rat Cd4 tag region was the negative control bait (-). Bars represent
means +/- SD, n=3.
D. PfMSP7 analyte did not bind SELL or SELL in SPR experiments.
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very rare in all populations. I created expression constructs using site-directed mutagenesis
and produced all four variants as bait proteins (Figure 4.4A, B). I then screened these variant
proteins for binding to PfMSP7 prey. All variants bound indistinguishably from the wild-type
SELP reference, with the exception of the A156T variant (Figure 4.4C). This variant did not
bind the anti-SELP monoclonal antibody that was able to block the SELP-PfMSP7 interaction
(Figure 4.4D). These results indicate either that A156, which lies at the boundary between the
CTL and EGF-like domains, is an important part of the binding region for both the antibody
and PfMSP7, or that mutation of this residue significantly affects the folding or conformation
of the SELP protein. This particular residue is conserved in the protein sequences of all three
human selectins and mouse Selp (Figure 4.4A, highlighted in red), perhaps suggesting that it
has an important role in the correct functioning of the protein. To determine whether the A156
mutant was still a functional protein, I tested whether the mutant SELP prey protein could
bind to immobilised sLeX (Figure 4.4E). No sLeX-binding activity could be detected using
this mutant, thus indicating that the variant probably does not fold to form a protein that can
carry out the normal in vivo binding roles of SELP.
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4.2.2 Characterisation of SELP binding to Plasmodium MSP7-proteins
4.2.2.1 The N-terminus of PfMSP7 bound to SELP
To determine which fragment of the full-length PfMSP7 precursor protein binds to SELP, I
expressed the merozoite surface-resident C-terminal fragments (PfMSP719 and PfMSP722)
and the remaining N-terminal region of the protein (PfMSP7-N) as prey proteins to screen
against full-length SELP (Figure 4.5A). PfMSP7-N but neither of the C-terminal PfMSP7
fragments bound to SELP. This suggests that the functions of the N- and C-termini are dis-
tinct; PfMSP722’s role in the MSP1 complex is separate from PfMSP7-N’s SELP-binding
function. Interestingly, all protein fragments showed some binding to PfMSP1 prey. MSP719
and MSP722 are thought to bind PfMSP1 within the MSP1 complex, but it is unclear whether
the N-terminus of PfMSP7 associates with PfMSP1 outside of the merozoite cell, or solely
during intracellular protein maturation. It is possible that the binding site in PfMSP7-N inter-
acts only within the parasite with the unprocessed form of PfMSP1, since the N-terminus of
PfMSP7 is not detected in the MSP1 complex.
4.2.2.2 SELP-binding was a characteristic of multiple members of the P. falciparum
MSP7 family
MSP7 has at least five paralogues in P. falciparum, each with a similar overall structure but
divergent sequence[158]. To determine whether these paralogues share a conserved SELP-
binding function, I expressed them as prey proteins to screen against SELP bait (Figure 4.6A).
PfMSRP2 and PfMSRP5 bound to SELP, though we cannot eliminate the possibility that the
other PfMSRP proteins also bind; I could observe PfMSRP1-mediated nitrocefin hydrolysis
after several hours of incubation with the substrate, indicating that a small amount of this
prey was captured on SELP bait. The PfMSRP3 and PfMSRP4 prey proteins showed very
low expression levels, and thus had to be significantly concentrated, which could impact their
ability to bind SELP by AVEXIS. By concentrating cell culture supernatants, we concurrently
increase the total protein concentration alongside that of the protein of interest. Thus the preys
are incubated with the baits in a much more protein-rich environment, which could potentially
block specific interactions from occurring as efficiently.
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Figure 4.5: The N-terminus of PfMSP7 bound to SELP
A. Schematic representation of the truncations made to the full length PfMSP7 precursor. The
boundaries of each protein fragment are detailed in Table 2.3. Transitions shown represent the
proteolytic processing events believed to occur in vivo, detailed in Figure 3.1.
B. SELP bait bound the N-terminal, but not the C-terminal fragments of PfMSP7 by AVEXIS.
All PfMSP7 fragment preys bound to PfMSP1 bait. OX68 was the positive control bait (+)
and the rat Cd4 tag region was the negative control bait (-). Bars represent means +/- SD, n=3.
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Figure 4.6: SELP-binding is conserved in multiple Plasmodium MSP7s
A. SELP bait was screened against six P. falciparum MSP7 family proteins. PfMSRP2 and
PfMSRP5 preys, as well as PfMSP7, were able to interact with the SELP bait. SELP-bound
PfMSRP2 prey was able to saturate nitrocefin hydrolysis more rapidly than PfMSP7.
B. Three of the P. vivax MSP7 proteins were screened against SELP. PvMSP7_6
(PVX_082675) prey bound to SELP bait.
C. P. berghei MSP7-family preys bound to human SELP and mouse Selp bait.
In each experiment, OX68 was used as the positive control bait (+) and the rat Cd4 tag region
as the negative control bait (-). Bars represent means +/- SD, n=3.
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4.2.2.3 The MSP7-SELP interaction was conserved across Plasmodium species
To determine whether SELP binding is a conserved feature of Plasmodium MSP7s, I expressed
three of the eleven Plasmodium vivax MSP7s as prey proteins to test by AVEXIS for binding
to SELP. PvMSP7_6 prey bound to SELP at sufficient levels to saturate nitrocefin hydrolysis
within an hour, whilst no binding was evident when using PvMSP7_1 or PvMSP7_9 preys
(Figure 4.6B). I also cloned and expressed the ectodomain of mouse Selp and screened it
against the three MSP7 paralogues found in Plasmodium berghei (Figure 4.6C). Human SELP
and mouse Selp bait bound sufficient PbMSRP1 prey to saturate nitrocefin hydrolysis within
one hour, which is a good indication that this P. berghei protein interacts with mammalian
P-selectin. Similarly, nitrocefin hydrolysis was saturated when I screened PbMSRP2 prey
against human SELP. Nitrocefin hydrolysis was also observed, although it was not as rapid,
when I used mouse Selp bait. This indicates that PbMSRP2 binds to both selectin baits but
possibly does not bind to mouse Selp as strongly as it does to the human protein. However it
is also possible that a lower proportion of the recombinant mouse Selp bait is correctly folded
and fully functional. PbMSP7 prey expression levels were very low, and the cell culture
supernatant was concentrated significantly to optimise and standardise prey activity. I did not
observe any nitrocefin hydrolysis when screening PbMSP7 prey against mouse Selp bait, but
saw a colour change when using human SELP bait. In summary, I found evidence that P.
berghei MSRPs bind to selectin but I do not have enough evidence to suggest that PbMSP7
binds.
4.2.3 Investigating the influence of PfMSP7 on known binding interac-
tions of SELP
4.2.3.1 PfMSP7 blocked the interaction between sLeX and SELP
There is currently no defined biological role ascribed to the N-terminal fragments of PfMSP7.
It is likely that PfMSP7’s N-terminal fragment(s) are released into the blood stream upon
pRBC lysis[158], where they could potentially interact with a myriad of host proteins. One
hypothesis concerning the role of PfMSP7’s N-terminus is that an interaction with SELP could
act to prevent its normal role in the host’s anti-parasite immune response. To start to investigate
whether PfMSP7 could potentially modulate the normal binding functions of SELP, I tested
whether PfMSP7 could block the interaction between immobilised SELP and a sLeX-alkaline
phosphatase conjugate. By incubating immobilised SELP with pentameric PfMSP7 and then
introducing the sLeX reagent, I was able to block the interaction between SELP and sLeX
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Figure 4.7: PfMSP7 could block the SELP/sLeX interaction
The interaction between SELP bait and a sLeX-alkaline phosphatase conjugate was detected
using absorbance at 405nm produced by the activity of a phosphatase substrate. The inter-
action was blocked completely by incubating the SELP bait with 0.1µM PfMSP7 pentamers.
Bars represent means +/- SD, n=3.
(Figure 4.7). This indicated that it is theoretically possible for PfMSP7 to interfere with the
interactions that SELP makes with proteins involved in normal immune functionality.
4.2.3.2 PfMSP7 could block cellular adhesion to SELP
To further establish whether it would be theoretically possible for PfMSP7 to prevent the inter-
actions by which leukocytes adhere to endothelium, I developed an assay based on monocytic
cells binding a receptor coated-surface (see 2.4.2). I observed that THP1 cells could bind to
both SELP and an anti-PSGL1 antibody (but not negative controls) immobilised on the surface
of a microtitre plate. This showed that the cells had maintained expression of PSGL1 recep-
tors in culture and also verifies that recombinant SELP is able to bind native ligands such as
PSGL1 on leukocytes (Figure 4.8A).
To determine whether PfMSP7 could prevent the SELP-mediated binding of THP1 cells, I
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Figure 4.8: PfMSP7 could block the adhesion of THP1 cells to SELP
A. THP1 cells adhered specifically to immobilised SELP and anti-PSGL1 antibodies. The
interaction between cells and SELP could be blocked by pre-incbating the bait proteins with
the CLB-thromb/6 anti-SELP monoclonal antibody. THP1 binding via anti-PSGL1 was unaf-
fected by CLB-thromb/6 antibody. Error bars represent means +/- SD, n=3.
B. Pre-incubation of SELP bait with PfMSP7 could prevent the binding of THP1 cells. As a
positive control (+), cells were captured using SELP bait which was not subsequently incu-
bated with any other recombinant prey. As a negative control (-) Cd200, to which the cells
should not bind, was used as a bait protein. Cd200 pentamer (used instead of PfMSP7) could
not block the interaction. This experiment was performed three times, each using an indepen-
dent PfMSP7 prey preparation, once in duplicate and twice in triplicate. Error bars represent
means +/- SD, n=8.
102 Biochemical characterisation of the interactions between SELP and Plasmodium MSP7s
incubated the SELP receptors with serial dilutions of PfMSP7 prey3 prior to the addition of
cells. I observed a modest, incremental decrease in adhesion with increasing concentrations
of PfMSP7 above approximately 2.5µM, but even 20µM PfMSP7 did not completely block
the binding of cells. Using the highest concentrations of PfMSP7 possible (around 35µM or
7µM (700pmoles) of pentameric protein) from three independent preparations, I was able to
block the interaction from occurring (Figure 4.8B). The requirement for such a high concentra-
tion of PfMSP7 pentamer to achieve a blockade of leukocyte binding is surprising, especially
since a theoretical maximum of just 20pmoles of SELP protein can be immobilised in a single
well. Significantly lower quantities of PfMSP7 (2pmoles of pentamer, effectively 10pmoles of
PfMSP7 monomer) were required to block the interaction between SELP and sLeX-AP (Fig-
ure 4.7). This discrepancy might reflect differences in the proportion of functional proteins
in the preparations, such that a lower proportion of SELP and/or a higher proportion of the
PfMSP7 used in Figure 4.7 participated in binding interactions compared to the preparations
used in these experiments using THP1 cells. However the relative difficulty in blocking the
interaction between SELP and THP1 cells might lie in part with the strength of the interactions
involved; the interaction between individual sLeXand SELP proteins is of relatively low affin-
ity, with estimations ranging between 0.1 and 7.8mM [33, 171, 268], whereas the interaction
between SELP and PSGL1 and the interaction between SELP and neutrophils are of substan-
tially higher affinity, with calculated KDs of 3-320nM and 70nM respectively [63, 213, 342].
As a consequence it is likely to be more challenging to use PfMSP7 to block the interaction
between SELP and THP1 cells than it is to block the interaction between SELP and isolated
sLeX. These in vitro data show that it is theoretically possible for PfMSP7 to prevent the
SELP-mediated interactions between leukocytes and endothelia, but, given the high affinity of
the SELP/PSGL1 interaction, this may require a high local concentration of PfMSP7 proteins.
4.3 Discussion
4.3.1 Further evidence that the PfMSP7-SELP interaction is biologically
relevant
The data presented in this chapter further validate that recombinant PfMSP7 and SELP in-
teract. The interacting domains on both proteins can be isolated (Figures 4.2A & 4.5) and
the interaction can be replicated using variant SELP proteins, though PfMSP7 is unable to
3for 90 minutes, after which unbound protein removed by washing
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bind to the potentially mis-folded A156T SELP variant4 (Figure 4.4). Combined with the
evidence that PfMSP7 prey cannot bind to SELP in the presence of EDTA (Figure 4.2B),
which changes the conformation of the binding domain, this indicates that PfMSP7 can only
bind to functionally active recombinant SELP. AVEXIS data indicate that SELP-binding is a
conserved property of MSP7 proteins in multiple parasite species (Figure 4.6); these MSP7
proteins are diverse in sequence yet maintain the ability to bind SELP. Whilst this may not be
the sole function of the MSP7 family, the ability of the proteins to bind SELP - an important
adhesion molecule and component of the host immune system - may be part of the reason a
repertoire has been conserved in Plasmodium parasite species. By demonstrating that PfMSP7
is able to block the interaction of SELP with sLeX and, albeit less potently, with leukocytes
(Figures 4.7 & 4.8), I have shown that there is a possible in vivo function for SELP/MSP7
interactions, whereby MSP7 prevents the binding of SELP to its human ligands (see 4.3.3).
4.3.2 The SELP-PfMSP7 interaction is unlikely to be involved in RBC
invasion
The true test of the importance of this biochemical data will be if we can demonstrate an in
vivo function for this interaction. Existing knowledge about PfMSP7 has implicated the pro-
tein in merozoites’ entry into host RBCs[159, 164, 327]. It is unlikely that the interaction
between SELP and PfMSP7 is involved in the invasion process for two main reasons. Firstly,
SELP is not known to be present in the RBC proteome[262] and was not detected on the cell
surface (Figure 4.9). Secondly, our data indicate that it is the N-terminus of PfMSP7 that is
involved in SELP binding, and this part of the protein is not detected on the merozoite surface.
To further investigate the role and localisation of PfMSP7, I purified His-tagged PfMSP7 to
immunise rabbits and produce anti-PfMSP7 polyclonal antibodies. These antibodies bound
specifically and sensitively to recombinant PfMSP7, as observed by ELISA and Western blot
(Figure 4.10A). However, they were not able to replicate the invasion-blocking effect previ-
ously reported for anti-PfMSP7 polyclonal antibodies[164]. The levels of invasion observed
when this antibody was added into an RBC invasion assay were 99.5% (+/- 3.345) of that ob-
served when no antibody was added5. Despite being able use this antibody to detect very small
quantities of recombinant PfMSP7 by Western blotting, I was unable to detect any PfMSP7 in
the lysate from Percoll-purifed cultured P. falciparum schizonts (Figure 4.10B). This is sur-
prising as PfMSP7 fragments are expected to be abundant on the surface of, and secreted from
4It is possible that this variant is a sequencing error in the database.
5This assay was performed by Dr Leyla Bustamante and is described in Theron et al., (2010)[330]. The assay
was performed in triplicate
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Figure 4.9: Selectins were not detectable on the RBC surface
A. Monoclonal antibodies against a range of RBC surface proteins and selectins with an
Alexa488-conjugated secondary could not detect selectins on the RBC surface. Positive
control proteins Glycophorin A (present at approximately 106 copies/cell), Basigin (104
copies/cell) and Sema7A (103 copies/cell) were all detected. 2000 events were counted.
schizont-stage parasites. However, I was also unable to detect PfEBA175 or PfMSP1 in this
lysate using polyclonal antibodies in the same manner. This might indicate that this lysate
is not a reliable source of intact merozoite proteins. Whilst our invasion assay results imply
that PfMSP7 does not play an important role in RBC invasion, we cannot use these data to
eliminate this possibility as we cannot be certain that the antibody is able to bind to PfMSP7
of parasite origin.
4.3.3 SELP-binding may have anti-inflammatory function
The binding of endothelial SELP to leukocyte PSGL1 is thought to enhance inflammation and
promote phagocytic activity of immune effector cells. This process is potentially deleterious
to the parasite as it results in the deployment of cytokines such as TNFα , which has known
parasite-killing activity. An attractive hypothesis concerning the role of the SELP/PfMPS7
interaction is that the N-terminus of PfMSP7 acts as an anti-inflammatory mediator, binding
SELP, blocking its interaction with PSGL1 and preventing the downstream enhancement of
the anti-parasite immune response (see Figure 4.11). The evidence that PfMSP7 can block
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Figure 4.10: PfMSP7 was not detected schizont lysate
A. Polyclonal anti-PfMSP7 antibodies were used to detect even picogram quantities of
PfMSP7. The antibodies were specific to PfMSP7 as no bands were observed when 100ng
PfEBA175 was transferred to the membrane.
B. The same antibodies were not able to detect PfMSP7 fragments in Percoll-purified schizont
lysate.
the interaction SELP makes with sLeX and potentially leukocytes is an encouraging first step
towards demonstrating that PfMSP7 has an anti-inflammatory role. We have collaborated with
another research group who have developed an assay to measure SELP-dependent leukocyte
rolling on endothelial-derived cells[74]. We hypothesised that by incubating the endothelial
cells with PfMSP7 we would see a reduction in rolling when flowing leukocytes over the cell
monolayer. In preliminary assays we did not observe a reduction in rolling, in fact both the
PfMSP7 and Cd200 negative control seemed to increase rolling. The assay conditions are
optimised for using antibodies to block protein interactions involved in rolling, and may need
to be refined further for using pentameric proteins. I would like to revisit these assays in the
future.
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Figure 4.11: Hypothesised anti-inflammatory activity of PfMSP7
A. Prior to infection the endothelium is in a resting state.
B. Early in infection, the endothelium is activated and rapidly presents surface SELP. This
results in the rolling adhesion of leukocytes via sLeX-containing ligands such as PSGL1. This
interaction can promote cytokine production and phagocytosis in leukocytes.
C. Aggregated pRBCs sequester on the endothelium, where they may be targeted by immune
effectors.
D. The pRBCs rupture, releasing merozoites and PfMSP7 fragments into the blood stream.
Free merozoites are vulnerable to the host immune response.
E. PfMSP7 N-terminal fragments bind endothelial SELP and prevent endothelium-leukocyte
interactions. This dampens the immune response and allows more merozoites to successfully
re-invade new RBCs.
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4.3.4 Interactions between SELP and MSP7s could modulate a range of
other cellular processes, including cytoadhesion.
Inflammation is not the only process in which an interaction between SELP and PfMSP7 could
play a part. For instance, SELP is also an important player in blood coagulation[7, 51, 90].
Given the precedent set by blood-borne bacteria for pathogens producing anti-coagulant me-
diators to avoid being confined by a growing thrombus[318] it is possible that PfMPS7 could
perform a role of this kind. The previous implication of Selp and PbMSP7 in the genera-
tion and severity of cerebral malaria in mouse models, such that the absence of either gene
mitigates ECM, is particularly striking[59, 313]. It is possible that the binding of MSP7 pro-
teins to SELP directly or indirectly contributes to blood-brain barrier damage, and/or affects
the accumulation of leukocytes (in ECM) or RBCs in cerebral microvasculature. SELP is
amongst the repertoire of endothelial receptors suggested to bind to PfEMP1 on the surface of
the pRBC[302, 367]. This interaction is thought to enhance the sequestration of pRBCs but
is not essential for the process to occur. By virtue of its potential binding to PfEMP1, SELP
has also been implicated in platelet-mediated clumping of pRBCs[259]. It is plausible that
MSP7s could affect either of these SELP-mediated adhesive processes, either by preventing
them from occurring or by exacerbating them. In the hypothetical case whereby MSP7s en-
hance, rather than block, these cytoadhesive processes this phenomenon could contribute to
explaining the deleterious effect of the presence of PbMSP7 on the outcome of infection for
the host. The experimental work required to accurately define the function of the SELP/MSP7
interactions observed in vitro will be discussed in 6.3.2.

Chapter 5
Development of a biochemical
co-purification assay to detect interactions
between Plasmodium merozoite proteins
and human serum proteins
5.1 Introduction
This chapter describes the development and application of a method using recombinant P.
falciparum protein-coated paramagnetic beads to co-purify interacting proteins from human
serum, with the aim of identifying novel, potentially immunomodulatory, interactions involved
in the pathogenesis of malaria.
5.1.1 Plasmodium merozoites are exposed to human serum
During the blood stage of infection, Plasmodium parasites are predominantly intracellular and
are thus largely shielded from the body’s immune defences. Between cycles of erythrocyte
invasion, however, free merozoites are exposed to immune effectors, perhaps more so than at
any other point in the parasites’ life cycle. Plasmodium parasites are highly adept at immune
evasion, such that true sterile immunity is probably never achieved, even in highly exposed
individuals[185]. With a multitude of mechanisms at work to eliminate the parasite from the
blood, it is very likely that a number of P. falciparum’s 5,300 genes - the majority of which
have as-yet undetermined functions - are involved in manipulating the immune system. One
such example whereby a parasite-secreted molecule subverts the functioning of leukocytes has
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been identified[320] and in this laboratory we have recently determined that certain proteins
belonging to the PfMSP3 family are able to bind IgM, in another possibly immunomodulatory
mechanism. We hypothesise that Plasmodium parasites possess a large repertoire of these
defences and that merozoite proteins in particular play a key role in immune evasion.
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5.1.2 A modified biochemical co-purification assay to discover novel merozoite-
serum interactions
As a starting point to identify novel immunomodulatory mechanisms, I developed a screen-
ing approach for detecting interactions between merozoite proteins and human serum com-
ponents. Human serum is a complex mixture of over 1000 proteins including antibodies,
cytokines and complement proteins, as well as many others involved in homeostasis. It there-
fore represents an abundant (and readily obtainable) source of potential interacting partners to
screen against merozoite proteins. In brief, the modified biochemical co-purification assay is
a six-step process (Figure 5.2). The first step in this process involves creating a paramagnetic,
multivalent Plasmodium protein reagent via the interaction of N-terminally biotinylated ’bait’
proteins and streptavidin coated super-paramagnetic beads. Unbound proteins are removed by
the isolation of the beads using a magnet. The beads are resuspended in buffer and re-isolated
to wash. These reagents are then incubated with human serum and subsequently washed to
remove proteins that have bound to the beads non-specifically. Proteins remaining bound to
the beads are eluted, denatured and separated by SDS-PAGE for further analysis1.
5.2 Assay development
5.2.1 Requirements of a sensitive assay
In order to recover sufficient material to identify a protein from an SDS-PAGE gel band us-
ing mass spectrometry, I aimed to pull down at least 100ng of protein from a single assay. To
achieve this, the assay must fulfill three main criteria. In the first instance, sufficient serum pro-
tein must be bound to the merozoite protein-loaded beads following incubation. This means
that interaction detection will be dependent on the successful capture of the merozoite pro-
tein on the bead and subsequently the strength of the interaction between the protein-coated
bead and the serum component. Second, there must be sufficient serum protein left bound to
the beads after washing. This will require a washing procedure that is sufficient to remove
non-specifically bound proteins, but not so stringent as to remove the bound serum protein-
of-interest. Finally, the elution process must release at least 100ng bound serum protein from
the beads, which will be dependent on the previous two criteria, as well as the rigour of the
elution process itself. In developing this assay I worked through each stage to optimise pro-
1For more details of the method see 2.7.
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Figure 5.2: A biochemical co-purification assay for the discovery of merozoite-serum
protein interactions
A. Biotinylated proteins are incubated with streptavidin-coated paramagnetic beads (not to
scale).
B. Binding reagents are isolated using a magnet.
C. Binding reagents are incubated with human serum.
D. Binding reagents and their interacting proteins are isolated using a magnet.
E. Reagents are washed to remove loosely-bound proteins.
F. Interacting proteins are eluted from the beads, resolved by SDS-PAGE and identified by
mass spectrometry.
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cesses where protein losses could occur and to determine the theoretical range of interactions
that could be detected.
5.2.2 Ensuring specific capture of biotinylated merozoite proteins
To create merozoite protein-conjugated ’bait’ reagents on which to capture interacting serum
proteins, I coupled biotin-tagged merozoite proteins to streptavidin-coated paramagnetic beads.
To ensure that the beads were saturated with merozoite proteins, I incubated the beads with
purified biotinylated proteins for 30 minutes, isolated the beads and performed ELISAs to
detect biotinylated proteins (as described in Section 2.3.1.1) in the supernatant. If biotiny-
lated protein was successfully captured on the beads, I observed a decrease in the amount of
protein recovered from the supernatant when compared with an equivalent amount of input
protein (Figure 5.3A). To achieve the highest sensitivity for the assay I would ideally capture
the maximum amount of merozoite proteins on the beads2. Hence, it was important to en-
sure that sufficient amounts merozoite proteins were incubated with the beads to saturate their
biotin-binding capacity. I demonstrated saturation of this binding by recovering biotinylated
protein from the supernatant following the isolation of protein-coated beads from 30-minute
incubations of beads and biotinylated proteins (Figure 5.3A). Before every biochemical co-
purification experiment, these ELISA-based bead saturation assays were performed, so as to
determine the amount of protein required to completely coat the bead surface. The interac-
tion between biotin and streptavidin has a very high affinity[69], such that merozoite proteins
bound to the beads via this interaction will not be removed by even very stringent wash steps.
It was therefore important to confirm that the merozoite proteins were binding to the beads
specifically via the biotin-streptavidin interaction, and not via weak, transient interactions that
would not withstand the subsequent steps of the assay. To demonstrate this, I pre-incubated
the beads with biotin prior to adding the biotinylated proteins. This should block the avail-
able sites for the biotinylated merozoite proteins to bind and hence prevent their capture. By
performing ELISAs on the supernatant following isolation of the beads after their 30-minute
incubation with biotinylated PfMSP3.4, I was able to demonstrate that saturating the beads
with biotin could completely block subsequent capture of biotinylated protein, indicating that
merozoite proteins are indeed being captured specifically via their biotin tag (Figure5.3B).
2In theory 100µL beads can bind 40pmoles of biotinylated protein, which, for example, would be 2µg of a
50kDa protein
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Figure 5.3: Biotinylated merozoite proteins were specifically captured on paramagnetic
beads
A. ELISA-based analyses on the supernatants from the protein/bead incubations demonstrated
saturable capture of biotinylated protein. The absorbance readings reflect the amount of bi-
otinylated protein captured from the supernatant after 33µL beads were incubated with the
indicated biotinylated proteins. Where beads had been incubated with insufficient biotinylated
protein to saturate the bead surface, very little biotinylated protein remained in the supernatant,
reflected in negligable turnover of phosphatase substrate and consequent low-level absorbance
at 405nm (A405) in ELISAs (magenta squares). These signals can be compared to the cyan
data series, which shows the ELISA A405 readings for the equivalent amount of each protein
without incubation with the beads. Where beads had been incubated with an excess of biotiny-
lated proteins, protein could be recovered from the supernatant following bead isolation, and
A405 signals were observed by ELISA (blue triangles).
B. Capture of biotinylated PfMSP3.4 can be blocked by preincubation of beads with biotin.
20µL beads were incubated with biotin prior to incubation with 10µg PfMSP3.4. A405 read-
ings reflect the amount of PfMSP3.4 that could be re-isolated from the beads (i.e. that which
could not bind to the biotin-blocked beads).
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Figure 5.4: Identification of appropriate elution buffers
SDS-PAGE analysis of the eluate from biochemical co-purifications using a range of elution
reagents indicated that Glycine-HCl or SDS solutions were appropriate elution buffers. Bio-
chemical co-purifications were performed using 100µL PfMSP3.4-coated beads, 1mL serum
and three 60-second washes. Proteins were eluted by five minute incubations with the indi-
cated solutions.
5.2.3 Optimising elution efficiency
Using effective elution conditions, it should be possible to release a high proportion of bound
protein from the beads. There are various types of solutions that can be used to disrupt protein-
protein interactions including those with high salt concentrations, low or high pH and denatur-
ing reagents. To test the compatibility of various elution buffers with the proposed biochemi-
cal co-purification method, I performed a series of preliminary experiments using the known
interaction between PfMSP3.4 and human serum IgM (see Figure 5.4).
High salt solutions (5M NaCl and 4M MgCl2) were not compatible with the assay, as they
did not allow a particularly clear resolution of bands and also distorted the running of the
surrounding lanes on the gel. Low pH and SDS solutions successfully brought down proteins
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of the correct size to be the IgM heavy chain. SDS also brought down a band of the correct
size to be the input PfMSP3.4, indicating that the denaturing conditions may be strong enough
to dissociate the streptavidin-biotin interaction. However PfMSP3.4, like other members of
the PfMSP3 family, is thought to oligomerise[118], so this band may also be PfMSP3.4 that is
covalently associated to the beads via a PfMSP3.4 homotetrameric interaction, as opposed to
via its biotin tag. Hence I chose SDS for the assay’s elution buffer, as it returned the highest
yield of PfMSP3.4-interacting protein.
5.2.4 Optimising washing steps
Serum is a complex matrix from which to isolate proteins, so it is important that the washing of
the beads following incubation with serum is sufficiently stringent to remove non-specifically
bound serum proteins. However, this needs to be balanced against washing away the interact-
ing proteins and losing the beads themselves between wash steps, which will reduce the yield
of any interacting proteins. To advise the number and type of wash steps, I performed a series
of theoretical calculations. Assuming first-order dissociation kinetics during wash steps, mass
(in g) of interacting protein bound to the beads declines in a time-dependent manner such that
mass(t) =mass(0)×e−λ t , where mass(t) is the mass of serum protein bound to the beads after
t seconds of washing, mass(0) is the mass of serum protein bound prior to washing and λ is
the dissociation rate constant, which is inversely related to the interaction half life (λ = ln2t 1
2
).
The mass of bound serum protein required prior to washing can therefore be found using the
following equation:
mass(0) =
mass(t)
e−λ t
By applying this equation to a range of bead-serum protein interaction half-lives, I could esti-
mate the mass(0) required to ensure mass(t) > 10−7 , i.e. the mass of serum protein present
prior to washing necessary to leave 100ng for elution, as a function of washing time (Figure
5.5A). These calculations indicate that this method cannot be expected to detect interactions
that dissociate rapidly during washing; those with a half-life in the order of seconds are un-
likely to be detectable, but the method has promise to detect those with a half-life in the order
of minutes. As serum is a complex mixture of proteins, many of which are highly abun-
dant (see Figure 5.1), multiple wash steps will be required to remove proteins that are bound
non-specifically to the protein-coated beads. By iterative application of exponential decay cal-
culations, I estimated mass(0) required to isolate 100ng serum protein after a succession of
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Figure 5.5: Theoretical assessment of wash-step dependency of interaction detection
A. The minimum required mass(0) - the amount of a 50kDa serum protein bound to the beads
prior to washing to ensure that 100ng can be recovered from co-purifications using 100µL
beads and 1mL serum - was plotted against as a function of washing time, assuming first-
order dissociation kinetics, for a range of given interaction half-lives.
B. The minimum required mass(0) was plotted as a function of the number of successive
60-second wash steps.
60-second wash steps3 (Figure 5.5B). These calculations indicate that the requirement for re-
peated washing will only slightly increase the threshold interaction half-life needed to ensure
detection.
To investigate the effectiveness of washing for removing non-specifically bound proteins, it
was necessary to perform some additional preliminary biochemical co-purification assays. I
observed that the beads had a tendency to adhere to the walls of the polypropylene tubes in
which they were being handled, so I tested whether transferring the resuspended beads to a
3Note that a washing time of less than 60s is impractical, as at least 45s are required for the magnetic separa-
tion of the beads for the supernatant
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Figure 5.6: Experimental optimisation of washing steps using negative and positive con-
trol bait proteins
A. 100µL beads coated with the Cd4 tag region were used in preliminary co-purification as-
says with 1mL serum and the indicated number of 60-second wash steps. On the left-hand
panel the same tube was used for all wash steps, whereas in the right-hand picture the beads
were transferred to a fresh tube between each wash step. In either case, only albumin was re-
covered after three washes. The approximate locations of other common contaminating serum
proteins, identified in Figure 5.1 are indicated on the right.
B. PfMSP3.4-coated beads were used in similar preliminary co-purification assays. At least
two washes were required to remove contaminating serum proteins. IgM remained stably
bound to the beads during washing, though IgM yields were slightly decreased after multiple
washes when fresh tubes were used for each wash.
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fresh tube between 60 second washes stood to increase the purity of eluted protein, without
compromising the yield. To systematically determine the optimum number and type of wash
steps, I performed a series of co-purifications using a rat Cd4 domains 3&4 bait, which we do
not expect to bind serum proteins (Figure 5.6A), and the PfMSP3.4 bait which we know to
bind IgM (Figure 5.6B). The results of these preliminary experiments demonstrated that:
• Even after five washes, it is not feasible to remove all non-specifically bound albumin
protein, shown by the consistent presence of a 65kDa band in all lanes in Figure 5.6.
• There is no significant increase in the purity of the eluted IgM after four washes, shown
in Figure 5.6B.
• Exchanging tubes between wash steps does not significantly impact the purity of the
eluted IgM (Figure 5.6B).
• Losses of the interacting IgM are more noticeable when changing tube between washes.
This is most easily observed by examining the light chain band in Figure 5.6B.
• Higher levels of non-specifically bound proteins are observed when performing the bio-
chemical co-purification using PfMSP3.4-coated beads than the Cd4-coated beads (as
seen by comparing Figure 5.6B with Figure 5.6A). This might mean that serum proteins
have a greater propensity to interact with other proteins than with the beads themselves,
or the comparatively small Cd4-tag region.
• Recurring contaminant bands likely represent the most abundant serum proteins, which
are summarised in Figure 5.1. The hypothesised identities of some of these bands are
indicated in Figure 5.6A.
Based on these observations, pull down assays were subsequently performed using four 60-
second wash steps, without exchanging the tube between each.
5.2.5 Theoretical assessment of assay sensitivity
For a receptor-ligand interaction R+L ⇀↽ RL, at equilibrium
KD =
[R][L]
[RL]
And if a is the concentration of Plasmodium protein added into serum, and x the initial con-
centration of the ligand in serum, then
a = [RL]+ [R]
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and
x = [RL]+ [L]
Combining these equations gives
KD =
(x− [RL])(a− [RL])
[RL]
where [RL] can be determined from mass(0) in the wash-step dependency calculations in Sec-
tion 5.2.4. By applying this formula to a hypothetical experiment using 100µL beads and 1mL
human serum, and involving a medium-sized (50kDa) serum protein, it is possible to approx-
imate the ranges of interaction affinities and target protein abundances into which detectable
interactions would fall (Figure 5.7). These rough calculations indicate that this method could
detect interactions with a KD in the micromolar range, provided the concentration of serum
protein is in the micromolar, or even the high nanomolar range. Using these calculations we
can speculate that an assay using 100µL beads and 1mL human serum would be well suited to
the detection of interactions:
• with half-lives in the order of minutes, so as not to be lost during washing (Figure 5.5);
• with KDs in the micromolar range, or lower
• provided their serum binding partner is present at high nanomolar concentrations, or
higher. At least 30 serum proteins can be expected to be present in this concentration
range [131]4.
However, these calculations are highly simplified and make several assumptions, and are
thereby likely to underestimate the potential this screening approach has to discover novel
interactions. The calculations have been based on biochemical co-purification assays using
1mL of serum and 100µL of beads; by increasing the amount of beads used in the assay, the
amount of serum protein that can be captured also increases so number of interacting serum
proteins that we can hope to detect will rise5. These calculations also assume that proteins are
interacting monovalently. In reality a number of serum proteins, including IgM, are multimeric
and may thus interact with the merozoite protein-coated beads with a high avidity, increasing
the sensitivity of the detection system. Perhaps the biggest flaw with these calculations is the
4As proteins are denatured prior to detection, the abundance of the particular interacting chain of multimeric
proteins will also be important. See Figure 5.1.
5Taking into account the assumptions made in the above calculations, doubling the amount of beads would
theoretically double the maximum detectable KD for a given concentration of serum protein
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Figure 5.7: Theoretical determination of the range of detectable interactions
For given interaction half lives (during washing), the maximal KD that would allow the recov-
ery sufficient serum protein is shown as a function of the protein’s original concentration in the
serum. The interaction between serum IgM and PfMSP3.4 falls well within the predicted de-
tectable range. The indicated BSG concentrations correspond to those used in the experiment
depicted in Figure 5.10.
simplification that the proteins are interacting in free solution, when in fact they are interact-
ing around the surface of a bead. This may significantly increase the effective half-life of the
bead-serum protein interaction, as there is a very high local concentration of Plasmodium bait
protein. This way, when an interacting serum protein dissociates from an individual Plasmod-
ium bait it can readily re-associate with a neighbouring bait protein and remain bound to the
bead surface for longer than would be expected for an interaction between free, monomeric
proteins. This single simplification may mean that assuming exponential decay during wash
steps massively underestimates the range of half-lives of detectable interactions, and also that
lower-affinity interactions have a higher chance of detection than the calculations suggest.
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5.3 Results
5.3.1 The optimised assay reproducibly detected the interaction between
PfMSP3.4 and IgM
In developing the assay, I used the previously-identified interaction between PfMSP3.4 and
serum IgM. In a biochemical co-purification assay using PfMSP3.4 bait, we would therefore
expect to elute 72kDa and 25kDa proteins corresponding to the heavy and light chains of IgM.
We might also expect to recover the 115kDa PfMSP3.4 protein. These three species were all
observed by SDS-PAGE (Figure 5.6B). To support the assumption that the identity of bands
are as expected, I ran purified IgM, biotinylated PfMSP3.4 and bovine serum albumin (BSA,
which is almost identical in size to human serum albumin) alongside the eluate by SDS-PAGE
(Figure 5.8); each band of the eluate was identical in size to their purified expected counterpart.
To confirm the identity of the IgM heavy chain, I extracted peptides from the appropriate
bands from PfMSP3.4 and PfMSP3.8 biochemical co-purification assays and submitted them
for in-house tandem mass spectrometry analysis (LC-MS/MS). The most abundant peptides
identified from these bands mapped to human IgM, indicating that this protocol can be used
to accurately determine the identity of eluted interacting serum proteins (Tables 5.1 & 5.2).
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Figure 5.8: Identification of IgM from PfMSP3.4 biochemical co-purification experiments
Purified BSA, biotinylated PfMSP3.4 and IgM were resolved by SDS-PAGE alongside eluates
from serum biochemical co-purification experiments using Cd4- and PfMSP3.4-coated beads.
The biochemical co-purification protocol was also performed using PfMSP3.4-coated beads,
replacing serum with purified IgM in 5% BSA (far-right lane).
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Protein Example Uniprot ID Unique peptides
IgM heavy chain constant region P01871 54
Keratin P35527 37
Complement C4 B0UZ83 27
Ig heavy chain variable region P01765 24
Heat shock protein P07900 6
RNA-binding protein H3BPE7 6
Desmoplakin P15924 6
IgG heavy chain constant region P01857 4
Dermicidin P81605 4
Serotransferrin P02787 4
Arginase 1 P05089 3
Desmoglien 1 Q02413 1
Caspase 14 P31944 1
Coagulation factor V P12259 1
Table 5.1: Peptides identified by mass spectrometry from hypothesised IgM heavy chain
band from PfMSP3.4 biochemical purification In this experiment, the β chain of Comple-
ment C4 was a significant contaminant, which is perhaps unsurprising as it as an abundant
component of human serum and is equivalent in mass to the IgM heavy chain (Figure 5.1).
Protein Example Uniprot ID Unique peptides
IgM heavy chain constant region P01871 57
Ig heavy chain variable region P10766 22
Keratin P35527 8
IgG heavy chain constant region P01857 3
Complement C4 B0UZ83 1
Table 5.2: Peptides identified by mass spectrometry from hypothesised IgM heavy chain
band from PfMSP3.8 biochemical purification
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5.3.2 The PfMSP3.4 bait could be used to co-purify IgM with a very high
sensitivity
To test the sensitivity of the optimised IgM co-purification assay, I performed it using serial
dilutions of serum. I diluted the serum in PBS containing 5% BSA, such that the albumin
content of the dilutions remained approximately constant, but the concentration of IgM was
reduced (Figure 5.9A). The interaction between recombinant PfMSP3.4 (in its oligometric
form) and IgM has an estimated KD of 0.3nM, determined by SPR. According to the theoretical
calculations in 5.2.5, this high-affinity means that the PfMSP3.4 should be able to purify IgM,
even if the antibody is present at very low levels (Figure 5.7). IgM can still be detected when
serum is diluted 1000-fold, when its expected concentration would be approximately 2µg/mL.
I performed the same assay replacing serum with purified IgM diluted in PBS + 5% BSA
(Figure 5.9B). Using the purified IgM it was possible to detect the interaction when only
200ng of IgM was added, approximating to a 1 in 10,000 dilution of serum. According to the
manufacturers instructions, SYPRO staining can be used to detect as little as 4ng of protein in
an SDS-PAGE band, so when 20ng was added to the biochemical co-purification assay, this is
probably at the very limit of detection of the assay6. We might expect to be able to detect IgM
at a 1 in 10,000 dilution of serum, when the IgM concentration is thought to be 200ng/mL,
however IgM bands are not present for this dilution in Figure 5.9A. Despite this, IgM bands
are seen in Figure 5.9B when 200ng purified IgM was present, indicating that the assay is a
highly sensitive method to detect this interaction.
5.3.3 The biochemical co-purification assay was capable of detecting a
low affinity interaction
IgM interacts with PfMSP3.4 with a high affinity, but the interactions we wish to identify
may not be so strong. To experimentally determine whether the optimised assay is capable
of detecting low affinity interactions, I tested it using the interaction between PfRH5 and
BSG, which has a micromolar affinity[64]. Even under equilibrium binding conditions, the
interaction between monomeric proteins has a half-life of only a few seconds[347], so if the
assumption that exponential decay occurs during washing is correct, it may not be possible
to detect the interaction (Figure 5.5). BSG is not a known component of human serum, so I
added a range of concentrations of purified BSG into the serum before use in the assay using
6only 25µL of the 100µL elutant was analysed by SDS-PAGE
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Figure 5.10: PfRH5-coated beads could be used to co-purify BSG
The biochemical co-purification assay was performed using 100µL PfRH5-coated beads in
1mL serum spiked with purified human BSG. When sufficient BSG was added, a enhancement
of SYPRO staining is seen in the 55kDa region of the SDS-PAGE resolved eluate from co-
purifications using PfRH5-coated beads when compared with that using Cd4-coated beads.
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PfRH5 as the bait protein (Figure 5.10). Even if BSG remains bound to the PfRH5 beads
following washing, these concentrations are at the very limits of the expected detection range
for this interaction, given its micromolar KD (indicated in Figure 5.7). High concentrations of
BSG were required to be able to see an appropriately-sized band in the PfRH5 biochemical
co-purification. When 100µg BSG was added into 1mL serum, there was a clear differential
between the elution profiles when using Cd4- and PfRH5-coated beads, such that a 55kDa
band corresponding to BSG was specifically observed in the PfRH5 lane. This implies that the
stability of the BSG/bead interaction is higher than anticipated, and that the assay is potentially
more sensitive than the above calculations suggest (as discussed in Section 5.2.5).
5.3.4 Serum interaction screens using purified merozoite baits
To screen for novel merozoite-serum interactions, I initially selected a range of merozoite pro-
teins that are known to be exposed to the bloodstream. This shortlist included proteins known
to be cleaved from the surface of the merozoite during the invasion process. PfMSP1, and
hence the peripherally associated fragments of PfMSP6 and PfMSP7, as well as PfAMA1 are
released as the parasite enters the host blood cells via the activity of the PfSUB2 [135]. PfM-
TRAP has also been implicated in RBC invasion and is potentially cleaved from the surface by
a rhomboid protease upon the parasite’s entry into the cell[12, 22]. PfRH5 was also included
because it is of particular interest to vaccine research taking place within the laboratory, and
elsewhere[41]. The elution profiles obtained appeared to contain a number of bands specific
to the Plasmodium protein used to coat the beads. However, the majority of the bands were the
correct size to be those of the input Plasmodium protein (indicated by grey circles in Figure
5.11). The elution profile when using PfAMA1 protein initially indicated that the protein was
interacting with a serum component consisting of 75 and 25kDa fragments, but analysis of the
protein size and re-sequencing of the expression plasmid revealed that the protein was in fact
PfMSP3.8. We can therefore safely assume that these bands correspond to the heavy and light
chains of IgM. The elution profile using PfRH5 bait also looked potentially interesting, as three
unique bands were observed. SDS-PAGE analysis of the input recombinant PfRH5 showed
that each of these bands were in fact fragments of the full-length PfRH5 precursor (Figure
5.11C). Proteolytic processing of recombinant PfRH5 has been previously reported[41, 277],
so it is likely that we are observing a similar phenomenon in these preparations.
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In two additional screens, all members of the PfMSP3 family and six members of the PfMSP7
family were loaded onto beads and incubated with human serum. These multi-gene families
are enigmatic in that multiple members are preserved in parasite genomes, yet the reason for
this is unclear. Most of the members of these families have no currently-identified function.
We already know that PfMSP3.4 and PfMSP3.8 bind serum IgM in a potential immunomodu-
latory mechanism; however none of the other PfMSP3 family members appear to demonstrate
the same antibody-binding behavior, nor did I reproducibly identify any other serum proteins
to which PfMSP3 proteins could additionally bind (Figure 5.12). Recognising that the sen-
sitivity of the assay may be limited by the amount of serum used, I repeated the assay using
serum volumes up to 15mL. I also increased the bead volume to 200µL so as to expand the
range of interactions that could potentially be discovered. Neither of these enhancements,
individually or in combination, resulted in any novel bands in SDS-PAGE analyses of their
eluates. Similarly, biochemical co-purification assays did not identify any serum protein bind-
ing partners for PfMSP7 proteins (Figure 5.13).
5.3.5 High-throughput screening of the merozoite protein library
In the screens described above, the major limitation on the throughput of the assay was
the need to purify the recombinant biotinylated merozoite proteins with which to coat the
beads. Although purified protein is preferable (as it can be more easily quantified and quality
checked), it should be possible to use transfected HEK293E cell culture supernatant7 as a di-
rect source this biotinylated protein to coat the beads. To test whether this would be a viable
approach, I selected a panel of eight merozoite protein baits for a pilot screen. I incubated
100µL beads with 1.5mL cell culture supernatant for 30 minutes, isolated the beads and per-
formed ELISAs on the resulting supernatant. In most cases 1.5mL cell culture supernatant
was insufficient to clearly saturate the binding capacity of 100µL beads, such that that no bi-
otinylated protein could be detected following isolation of the beads. Where this occurred I
re-incubated the partially coated beads with a further 1.5mL cell culture supernatant for 30
minutes and repeated the bead saturation ELISA. If I was still unable to observe saturation,
I repeated the incubations with 1.5mL culture supernatant until unbound biotinylated protein
could be detected by ELISA (Figure 5.14). Having demonstrated that bead saturation was
possible without the use of purified proteins, I screened these proteins against human serum
7Dialysed as described in 2.1.2.3 to remove excess D-biotin
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Figure 5.12: PfMSP3-family serum biochemical co-purification screen revealed no novel
interactions
A SDS-PAGE elution profiles from biochemical co-purification assays using eight PfMSP3
family baits. Grey dots to the left of bands indicate that the band corresponds to the input
Plasmodium protein. Pink dots indicate bands corresponding to the heavy or light chain of
IgM, and yellow dots are placed to the left of bands that are potentially unique and do not
correspond to the input bait protein or IgM. The three gels are a selection from six sets of
biochemical co-purification experiments, each using a different batch of human serum.
B. SDS-PAGE analysis of the nickel-purified proteins incubated with the beads to produce the
binding reagents. Grey dots indicate the expected protein sizes.
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Figure 5.13: PfMSP7-family serum biochemical co-purification screen revealed no novel
interactions
A SDS-PAGE elution profiles from biochemical co-purification assays using six PfMSP7 fam-
ily baits. Grey dots to the left of bands indicate that the band corresponds to the input Plas-
modium protein.
B. SDS-PAGE analysis of the nickel-purified proteins incubated with the beads to produce the
binding reagents. Grey dots indicate the expected protein sizes.
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as before, but without the bait protein purification step used originally. Encouragingly, the
interaction between PfMSP3.4 and IgM was still readily detectable, as I reliably observed a
clear band corresponding to the IgM heavy chain. A few bands appeared to be specific to the
input bait protein, thus representing potential ’hits’ in this screen. A proportion of these were
of the correct size to be the bait protein itself, but a number of them were not. Of these, no
single specific band was observed reproducibly in three independent screens. Following this
pilot screen, I produced 32 additional proteins from the P. falciparum merozoite for to screen
for interactions with human serum. I coated the beads by 3 successive 30-minute incubations
with 1.5mL filtered, dialysed transfected cell culture supernatant, retaining the supernatant
from the final incubation to confirm bead saturation by ELISA. I screened panels of up to
ten proteins using 100µL beads and 1.5mL serum, and did so at least twice, using a different
batch of serum on each occasion. I used these high throughput screens to select candidates
for screening using 250µL beads and 5mL serum (Figure 5.17). None of the unique bands
observed in Figures 5.15 & 5.16 were repeated or validated using this approach.
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Figure 5.14: Recombinant protein from HEK cell culture supernatant could saturate
beads
Bead-saturation ELISA measurements were performed on the supernatants following the iso-
lation of 100µL beads after 30 minute incubations with 1.5mL filtered, dialysed HEK293 cell
culture supernatants. The cyan data series shows the phosphatase substrate turnover, measured
by absorbance at 405nm, resulting from the capture of biotinylated protein from the cell cul-
ture supernatant prior to its incubation with the beads. The remaining data series show the
detection of biotinylated proteins following the indicated number of successive incubations of
1.5mL supernatants with 100µL beads. Error bars repesent the mean +/- SD, n=2.
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5.4 Discussion
5.4.1 Strengths of the assay
This assay is capable of detecting interactions with a wide range of affinities, and can be com-
bined with mass spectrometry to determine the identity of binding partners for Plasmodium
proteins. Serum is an extremely protein-rich medium to sample for interactions (Figure 5.1),
yet this assay is able to yield elution profiles with fairly low levels of contaminating proteins
(Figures 5.6 & 5.8). Whilst the screens using 56 P. falciparum bait proteins did not lead to the
identification of any novel interactions (Figures 5.11, 5.12, 5.13, 5.15, 5.16 & 5.17), there are
still many more serum-exposed Plasmodium proteins that have yet to be screened. Hence this
assay could be a useful tool for screening proteins for which there is a rational basis to assume
that they might interact with a component of human serum. Serum is not the only matrix
that can be screened using this approach; the method can be used to sample any other fluid.
For instance I used SELP-coated beads to try to detect PfMSP7 fragments in parasite culture
supernatant. In summary the assay has demonstrated potential for interaction detection, and
could be used to discover novel interactions between recombinant proteins and partners in
serum and beyond.
5.4.2 Potential improvements to the assay
Despite these successes, the assay is limited by the low abundances of certain serum proteins
and the potentially transient nature of many host-pathogen interactions. However, there are a
number of steps that could be taken to overcome these challenges.
• Increase volumes: Interaction detection capacity is certainly limited by the amount of
serum protein that can be captured, either due to a low abundance of protein present
in serum or a low interaction affinity that means that fewer molecules of interacting
protein are bound to beads at equilibrium. As serum is abundantly available, it is very
straightforward to increase its volume, although it is more cumbersome experimentally.
Increasing the volume of beads has no negative effect on running the experiment, but is
associated in a significantly increased cost. I performed the PfMSP3-family biochemical
co-purification assay using 200µL beads and 15mL serum to see whether this would re-
veal any additional bands, but recovered very similar elution profiles to those presented
in Figure 5.12.
• Further increase the avidity and stability of interactions: Coating Plasmodium bait pro-
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P. falciparum bait Accession number Tags Mass (kDa) Plasmid constructor
AARP PF3D7_0423400 Bio 43.1 Dr C. Crosnier
AMA1 PF3D7_1133400 Bio 82.7 Dr C. Crosnier
ASP PF3D7_0405900 Bio 103 Dr C. Crosnier
CyRPA PF3D7_0423800 Bio, His 64.5 Dr Z. Zenonos
EBA140 PF3D7_1301600 Bio 152 Dr C. Crosnier
EBA165 PF3D7_0424300 Bio 178 Dr Z. Zenonos
EBA175 PF3D7_0731500 Bio 186 Dr C. Crosnier
EBA181 PF3D7_0102500 Bio 192 Dr C. Crosnier
EBL1 PF3D7_1371600 Bio 318 Dr C. Crosnier
ETRAMP10.2 PF3D7_1033200 Bio 26.5 Dr C. Crosnier
GAMA PF3D7_0828800 Bio 103 Dr C. Crosnier
MSP1 PF3D7_0930300 Bio, His 216 A. J. Perrin
MSP2 PF3D7_0206800 Bio 45.9 Dr C. Crosnier
MSP3.1 PF3D7_1035400 Bio, His 62.4 A. J. Perrin
MSP3.2 PF3D7_1035500 Bio, His 65.5 A. J. Perrin
MSP3.3 PF3D7_1035600 Bio, His 70.5 A. J. Perrin
MSP3.4 PF3D7_1035700 Bio 100 Dr C. Crosnier
MSP3.4 PF3D7_1035700 Bio, His 102 A. J. Perrin
MSP3.5 PF3D7_1035800 Bio, His 104 A. J. Perrin
MSP3.6 PF3D7_1035900 Bio, His 87.8 A. J. Perrin
MSP3.7 PF3D7_1036000 Bio, His 68.7 A. J. Perrin
MSP3.8 PF3D7_1036300 Bio, His 110 A. J. Perrin
MSP4 PF3D7_0207000 Bio 49.1 Dr C. Crosnier
MSP5 PF3D7_0206900.1 Bio 50.1 Dr C. Crosnier
MSP7 PF3D7_1335100 Bio, His 63.1 A. J. Perrin
MSP8 PF3D7_0502400 Bio, His 89.0 Dr Z. Zenonos
MSP9 PF3D7_1228600 Bio 107 Dr C. Crosnier
MSP10 PF3D7_0620400 Bio 78.5 Dr C. Crosnier
MSRP1 PF3D7_1335000 Bio, His 65.4 A. J. Perrin
MSRP2 PF3D7_1334800 Bio, His 55.2 A. J. Perrin
MSRP3 PF3D7_1334600 Bio, His 57.4 A. J. Perrin
MSRP4 PF3D7_1334400 Bio, His 59.0 Dr Z. Zenonos
MSRP5 PF3D7_1334300 Bio, His 76.8 Dr Z. Zenonos
MTRAP PF3D7_1028700 Bio 73.1 Dr C. Crosnier
Pf12 PF3D7_0612700 Bio 56.7 Dr C. Crosnier
Pf12p PF3D7_0612800 Bio 61.4 Dr C. Crosnier
Pf34 PF3D7_0419700 Bio 57.0 Dr C. Crosnier
Pf38 PF3D7_0508000 Bio 58.8 Dr C. Crosnier
Pf41 PF3D7_0404900 Bio 63.6 Dr C. Crosnier
Pf92 PF3D7_1364100 Bio 110 Dr C. Crosnier
Pf112 PF3D7_1436300 Bio 133 Dr C. Crosnier
Pf113 PF3D7_1420700 Bio 130 Dr C. Crosnier
Table 5.3: P. falciparum merozoite proteins screened against human serum
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P. falciparum bait Accession number Tags Mass (kDa) Plasmid constructor
PF10_0166 PF3D7_1017100 Bio, His 58.8 Dr Z. Zenonos
PF11_0373 PF3D7_1136200 Bio 94.4 Dr C. Crosnier
PF13_0125 PF3D7_1321900 Bio, His 76.9 Dr Z. Zenonos
PF14_0293 PF3D7_1431400 Bio 133 Dr C. Crosnier
PFA0135w PF3D7_0102700 Bio, His 57.1 Dr Z. Zenonos
PFA0210c PF3D7_0104200 Bio, His 76.1 Dr Z. Zenonos
PFF0335c PF3D7_0606800 Bio 55.0 Dr C. Crosnier
RAMA PF3D7_0707300 Bio 122 Dr C. Crosnier
RAP1 PF3D7_1410400 Bio 111 Dr C. Crosnier
RH5 PF3D7_0424100 Bio, His 85.2 A. J. Perrin
RhopH3 PF3D7_0905400 Bio 125 Dr C. Crosnier
RON6 PF3D7_0214900 Bio 133 Dr C. Crosnier
SPATR PF3D7_0212600 Bio 49.7 Dr C. Crosnier
TLP PF3D7_0616500 Bio 173 Dr C. Crosnier
TRAMP PF3D7_1218000 Bio 56.0 Dr C. Crosnier
Table 5.4: P. falciparum merozoite proteins screened against human serum (continued)
teins onto paramagnetic beads has the dual purpose of facilitating the isolation of inter-
acting proteins and increasing the stability of interactions with serum proteins. It may be
possible to increase the strength of binding interactions further by changing the way that
merozoite bait is arrayed on the surface of the bead. For instance, it might be possible
to coat the bead surface with pentamerised proteins, so as to increase the number and
density of receptors on the surface of the bead. Stabilisation of interactions could also
be achieved by chemically cross-linking beads and interacting proteins prior to washing,
although this might also compromise the purity of the eluate.
• Improve quality of serum: Serum was purchased as frozen, pooled isolates from a num-
ber of healthy donors. However, even before performing any assays with the serum,
there was observable variation between the batches received. For instance, some batches
were seen to contain large, visible protein aggregates upon thawing. I removed these ag-
gregates by centrifugation and subsequent filtration, but in doing so could have removed
an important source of serum protein that could potentially interact with one (or even
many) of the merozoite baits. I expect that variability in the serum batches might ac-
count for differences in backgrounds of the serum screens, for example in Figures 5.11,
5.12 and 5.13. In the future it may be possible to improve the source of serum, such that
steps can be taken to reduce protein aggregation and increase the consistency of screens.
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• Alter elution conditions: The experiment shown in Figure 5.4 indicated that SDS or
Glycine-HCl would be appropriate elution buffers for the assay. The main difference
between these buffers was that SDS was able to elute PfMSP3.4 as well as IgM from
PfMSP3.4/serum biochemical co-purification experiments. Knowing that PfMSP3.4
oligomerises in vitro I had hypothesised that the best elution process would bring down
IgM and the PfMSP3.4 that was peripherally associated with the beads (i.e. not via the
biotin-streptavidin interaction). However, given the appearance of input protein in the
elution profiles of each screen (Figures 5.11, 5.12 and 5.13), I expect that the denatur-
ing conditions used are able to dissociate the biotin-streptavidin interaction that binds
the merozoite protein to the beads. By using an acidic elution buffer, such as pH 1.5
Glycine-HCl, the biotin-streptavidin interaction may remain intact and only serum pro-
teins may be eluted. This would remove the input protein bands from the gels, making
the presence of additional interesting bands more immediately identifiable.
• Decrease stringency: These experiments were designed with the intention of observing
a single, unique band in a denaturing gel electrophoresis-based analysis of the eluate
from washed beads. This way the protein-of interest could be specifically isolated from
the gel and identified by tandem mass spectrometry. This is perhaps an unrealistically
stringent expectation and, as mass spectrometry techniques advance, it might be possible
to compare more of the eluate from a large numbers of biochemical co-purifications and
identify human proteins that are specifically enriched when particular merozoite baits
are used[261], without an SDS-PAGE step.
Chapter 6
General discussion
6.1 Summary of results
In this work I have employed a range of techniques using recombinant Plasmodium proteins to
identify host-pathogen protein-protein interactions occurring in malaria. These have included
the use of established methodologies such as AVEXIS and surface plasmon resonance, and
the development of flow cytometry and biochemical purification approaches.
High-throughput screening using AVEXIS enabled the identification of an interaction between
human SELP and PfMSP7, which I demonstrated in several experimental systems and char-
acterised in detail, identifying the interacting regions of both recombinant proteins. I subse-
quently tested a range of PfMSP7 homologues and discovered that this SELP-binding prop-
erty is a conserved feature of multiple members of the MSP7 family, across at least three
Plasmodium species. Given the known role of SELP in human immunity, I have investigated
the hypothesis that MSP7 proteins could have an important immunomodulatory role. The
observation that PfMSP7 can block the interaction between SELP and sLeX, and potentially
SELP and leukocytes, in vitro provides encouragement that the interaction could modulate the
normal in vivo interactions between SELP and its sLeX-containing ligands.
Screening using other approaches did not lead to the identification of any new receptors for
Plasmodium proteins.
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6.2 Implications of SELP/MSP7 interactions
6.2.1 A possible mechanism underlying MSP7-knockout phenotypes
The molecular mechanisms underlying the observed reduction in pathology in PbMSP7-knockout
parasites compared to their wild-type counterparts in rodent models are currently unknown.
These data regarding the interactions between MSP7 proteins and SELP might contribute to
explaining these observations. Gomez et al. demonstrated that rodents infected with PbMSP7-
knockout parasites were somewhat protected from death and they hypothesised that an im-
munomodulatory function for PbMSP7 underlay this phenomenon[117]. It is possible that an
interaction with Selp that prevents its recruitment and activation of leukocytes (as described
in 4.11) could provide a molecular basis for these results.
In addition to the data that suggest an immunomodulatory function for PbMSP7, Spaccapelo
et al. showed that PbMSP7-knockout parasites induced less cerebral pathology than wild
type parasites in experimental cerebral malaria models[313]. This is particularly interesting
when combined with the data that show that Selp-knockout mice are completely protected
from cerebral malaria[53, 59]. Whilst there may be distinct mechanisms underlying these two
observations1, it is noteworthy that when either binding partner (PbMSP7 or Selp) are lacking
from experimental malaria in an ECM-susceptible mouse, cerebral pathology is significantly
reduced. In terms of a mechanism by which an interaction between Selp and PbMSP7 could
interact to exacerbate ECM symptoms, it is tempting to suggest that PbMSP7 binds to Selp
and prevents the adhesion of leukocytes in the mouse brain. However, leukocyte adhesion
in the brain is not thought to be affected in infected Selp-knockout mice, which makes this
mechanism less likely[53].
Endothelial SELP is thought to preferentially recruit Th1 cells which are associated with the
production of pro-inflammatory cytokines, including TNF, IFNγ and lymphotoxin[10, 30],
which have all been implicated in exacerbating cerebral malaria[6, 85, 105, 122, 169, 177,
287, 364]. With this is mind, a hypothesis that unifies the data discussed above on the pathol-
ogy of mice infected with PbMSP7 knockout parasites would be that an interaction between
Selp and PbMSP7 prevents the recruitment and activation of Th1 cells, dampening the inflam-
matory response so as to reduce circulating levels of cytokines that control infection but also
exacerbate cerebral pathology.
It is important to note that I did not observe a Selp/PbMSP7 interaction using AVEXIS (Figure
4.6C), which makes it highly speculative to correlate the observed features of infections with
1For example increased blood-brain barrier stability in Selp-knockout mice may be responsible for their
protection from ECM[155]
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PbMSP7-knockout parasites with the parasites’ ability to bind Selp. However, the data de-
scribed in 4.2.2.2 and Figure 4.6C do not eliminate the possibility that PbMSP7 interacts with
Selp; the levels of PbMSP7 expression were consistently very low, which made it difficult to
ensure that sufficient amounts of sufficient-quality PbMSP7 protein were used in experiments.
6.2.2 Implications for vaccine development
Antibodies against PfMSP7 have recently been associated with protective immunity in a co-
hort of Tanzanian children[273]. This evidence, combined with the abundance of the MSP1
complex on the merozoite surface[115], data suggesting immunisation with P. yoelii MSRP2
protects mice, and the documented ability of anti-MSP7 antibodies to impair RBC invasion[164,
357], makes PfMSP7 an attractive vaccine antigen. When designing a vaccine based on any
particular protein target, it is informative to determine the precise epitopes that confer pro-
tective immunity. More antibodies were detected against PfMSP722 than PfMSP7-N in S.
E. Asian serum samples, suggesting that the humoral immune response against the PfMSP7
components that are present on the merozoite surface might be more dominant, though it is
not known whether or which of these antibodies provided protection from malaria[349]. Since
the work described in this thesis indicates that PfMSP722/PfMSP719 and the N-terminal frag-
ments of PfMSP7 perform distinct functions, it will be important to determine the respective
benefits to the host of immune responses against each PfMSP7 fragment. It is likely that anti-
bodies against PfMSP722 can confer protection by preventing merozoite-RBC interactions or
by inhibiting the shedding of the MSP1 complex[164, 357], but there is currently insufficient
evidence to know whether anti-PfMSP7-N responses would be complementary or deleterious
to the host. On one hand, in vivo evidence from mice infected with PbMSP7-knockout para-
sites indicates that the presence of MSP7 enhances pathology in the host[117, 313], such that
antibodies that eliminate the function(s) of MSP7 might be expected to be protective. On the
other hand, if PfMSP7’s N-terminal fragment(s) play an anti-inflammatory role, which might
limit immunopathology in the host, it might be advantageous to exclude these regions from
protein-based vaccines so as to preserve this potentially beneficial function.
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6.3 Summary of potential future experiments
6.3.1 Biochemical details of SELP/MSP7-family protein-protein interac-
tions
Whilst the interaction between recombinant PfMSP7 and SELP has been demonstrated in
multiple experiments, there are still some biochemical details of this interaction that remain to
be clarified. The following experiments could help to do so:
1. Further validate the interaction by demonstrating that PfMSP7 binds to native SELP:
Given our concerns about the non-specific interaction behaviour of recombinant SELP,
it will be important to verify that the interaction can occur using native SELP. We could
do this by re-designing the flow cytometry platelet-binding experiment (Figure 3.12) so
as not to use the anti-FLAG antibody, potentially by using recombinant PfMSP7 directly
fused to a fluorescent reporter protein.
2. Determine the molecular basis of PfMSP7 oligomerisation: We hypothesise that the in
vitro assembly of PfMSP7 could enhance its binding to SELP. Having confirmed that
oligomerisation is a property the SELP-binding N-terminus of PfMSP7 molecule, it
would be informative to further narrow down the region(s) involved in oligomerisation
using truncated PfMSP7 proteins in size-exclusion chromatography (SEC) experiments
and/or by using synthetic peptides to prevent oligomerisation[144]. Techniques such
as size exclusion chromatography with multi-angle light scattering (SEC-MALS)[290],
X-ray solution scattering (SAXS)[272] or atomic force microscopy[309] could be used
to determine the number and conformation of PfMSP7 monomers in each of these com-
plexes, and in complex with SELP. Amino acid analysis of the SELP/PfMSP7 complex
could also reveal the stoichiometry of the interaction[288]. This information could help
us determine how the complexes form in vitro and whether complexes are likely to form
in vivo.
3. Accurately determine kinetic parameters of the SELP/PfMPS7 interaction using SPR:
Our initial SPR experiments suggest that larger PfMPS7 complexes bind more strongly
to SELP. To separate the increase in SPR signal due to increased complex binding from
that due to the increased size of the binding species, we would have to determine bind-
ing constants for each species. This would involve producing sufficient quantities of
PfMSP7 to saturate binding to immobilised SELP, measuring the binding signal pro-
duced at a range of lower concentrations, creating an equilibrium binding curve and
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using this to determine the KD. Given the difficulties experienced in performing these
analyses by SPR, it might be necessary to seek an alternative method to calculate bio-
physical parameters. Free-solution methods such as isothermal titration calorimetry[67]
or back-scattering interferometry (discussed in 6.3.3.3) may be appropriate methods.
4. Systematically characterise the oligomerisation and binding behaviour of the MSRPs:
AVEXIS data indicate that SELP-binding is not limited to PfMSP7. We could back up
these data by observing the interactions by SPR or in the HEK-cell based flow cytometry
assay (described in 2.6.2, 3.2.4 & Figure 2.4). It would be interesting to use SEC to
determine whether the PfMSRPs also self-associate and whether this is necessary to
promote their binding to selectins. If disordered regions in PfMSP7 are responsible for
its oligomerisation, we might anticipate that the P. falciparum MSRP proteins would
display similar behaviour, as all are predicated to be disordered, particularly at their N-
termini (Figure 6.1A & B). Of the SELP-binding PfMSRP proteins, PfMSRP2 appears
to be the least disordered (Figure 6.1A, B & C), and thus perhaps the most amenable to
analysis by SPR. Early indications are that PfMSRP2 binding to SELP may indeed be
easier to characterise, as an SEC-elution profile of purified material gave a monodisperse
peak, with little evidence of significant oligomerisation (Figure 6.1D).
6.3.2 Determination of the function of the SELP/MSP7 interaction
Functional assays will be required to determine the potential in vivo role of the PfMSP7-SELP
interaction. The following assays could be used to test our hypotheses as to the function of the
interaction (introduced in 4.3):
1. Leukocyte rolling assays: Our initial attempts to use PfMSP7 in rolling assays[74] did
not provide us with conclusive data to support or reject the hypothesis that PfMSP7
can modulate the rolling of leukocytes on endothelial cells. Having demonstrated that
PSGL1-expressing THP1 cells can adhere to a SELP coated surface, and that PfMSP7
can be used to block this interaction, we hope to revisit and optimise these assays, as
they represent a closer proxy for in vivo leukocyte-endothelial cell interactions than our
existing plate-based assays.
2. Inflammation assays: We could test the hypothesis that PfMSP7 can behave as an anti-
inflammatory molecule using Selp-dependent mouse model of inflammation. In one
model system, inflammation is measured by counting blood and peritoneal neutrophils
following injection of thioglycollate into the peritoneal cavity[206]. If PfMSP7-N can
148 General discussion
Figure 6.1: Predicted disorder is common to all P. falciparum MSP7-family proteins but
lower in PfMSRP2
A. IUPred prediction of disordered residues in the P. falciparum MSP7 family. Regions corre-
sponding to PfMSP722, PfMSP7-N, the 25kDa C-terminal region of PfMSRP2 downstream of
a validated SUB1 cleavage site (PfMSRP225) and the remaining portion (excluding the signal
peptide) of its N-terminus (PfMSRP2-N) are indicated.
B. Disopred3 prediction of disordered residues in the P. falciparum MSP7-family
C. Summary of number and proportion of disordered residues predicted in P. falciparum
MSP7-family, proteins.
D. SEC analysis of a single PfMSRP2 protein preparation gave a monodisperse peak. This
might mean that SPR analyses using PfMSRP2 stand to be more successful than those using
PfMSP7 (described in Chapter 3).
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behave as an anti-inflammatory molecule, we might expect to see a reduced influx of
neutrophils in mice that have been injected with PfMSP7 prior to thioglycollate in-
troduction. This would constitute very convincing evidence that PfMSP7 has an im-
munomodulatory role
3. Other adhesion assays: To investigate whether PfMSP7 can affect other SELP-mediated
adhesion events in disease it would be possible to introduce PfMSP7 into sequestration
assays[101, 367] and RBC clumping assays[259]. We could test the hypothesis that
PfMPS7 might modulate haemostasis by adding PfMSP7 into an appropriate assay to
measure thrombus formation[281].
6.3.3 Expansion and improvement of screening for interactions occur-
ring between Plasmodium proteins and human receptors
AVEXIS has been successful in identifying a number of host-pathogen interactions, including
those between SELP and MSP7 proteins, that could contribute to our understanding of malar-
ial pathology at the molecular level[19, 64]. However, this approach cannot be used exhaus-
tively to screen all potential host receptors against our recombinant P. falciparum proteins; for
instance there are many host proteins that we cannot produce recombinantly at sufficient lev-
els, or with the appropriate post-translational modifications2. This makes it advantageous to
screen for interactions using native sources of human receptor proteins, for instance in serum
or on the surface of intact cells. Using receptors on the surface of intact cells has the particular
advantage of conserving the native environment of the receptor proteins such that interactions
involving protein complexes or proteins that traverse the membrane multiple times, can be
studied.
The following approaches could potentially facilitate the identification of novel host-pathogen
interactions that could in turn help to elucidate the molecular mechanisms involved in the
pathogenesis of malaria:
1. Screen more proteins for interaction with human serum: In Chapter 5, I screened 56 P.
falciparum proteins for interactions with human serum. There are many more serum-
exposed Plasmodium proteins, including some included in our own existing protein
expression libraries; I expressed at least 20 proteins that I did not screen, as their levels
2For example, we have been unable to produce recombinant Glycophorin A that is sufficiently sialylated to
bind to PfEBA175. Recombinant PSGL1 was also unable to bind to SELP, which could very plausibly mean that
HEK293E cells did not reproduce the post-translational addition of sLeXto PSGL1 that occurs in leukocytes in
vivo.
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in cell culture supernatants were insufficient to saturate the protein-binding capacity
of the paramagnetic beads. By scaling-up the production of these bait proteins, and
enhancing their concentration by purification, it would be possible to screen more P.
falciparum candidate bait proteins.
2. Improve the sensitivity of the biochemical purification approach: Despite screening a
large number of proteins, the biochemical co-purification approach did not reveal any
novel host-pathogen protein-protein interactions. This may be a consequence of the
high stringency, and hence insufficient sensitivity, of this approach. By making the
improvements identified in 5.4.2, and in particular by increasing the avidity and stability
of interactions whilst decreasing the stringency of the detection method, the power of
this method to detect novel interactions could be enhanced.
3. Develop back-scattering interferometry (BSI) for the discovery and quantification of
Plasmodium protein-host interactions: BSI, described in Figure 6.2A, is a relatively
new technique that can be used to measure binding events. In very recent years, the
Bornhop laboratory has developed BSI as a highly sensitive method for studying bi-
ological interactions in free solution3. Various examples of simple protein-protein or
protein-small molecule interactions have been studied using BSI[31] and it is also pos-
sible to use cell membrane preparations instead of isolated proteins in this system[13],
which makes BSI an exciting new tool for studying interactions occurring at the cell
surface. In the course of this work, we have been collaborating with the Bornhop labo-
ratory to determine whether BSI can be used to study interactions occurring between our
recombinant P. falciparum proteins and the RBC surface; preliminary data has indicated
that BSI is a very sensitive method that can be used to accurately determine the kinetic
parameters of interactions occurring between known P. falciparum invasion ligands and
their receptors on intact human RBCs (Figure 6.2B). Thus, this method has great po-
tential as a screening tool for the discovery of novel interactions between parasite and
RBC surface proteins. Since BSI has also been applied to the detection of molecules
in more complex matrices, including serum[175], it might also be possible to use this
technique to screen our recombinant Plasmodium proteins against human serum; BSI
could represent a highly sensitive detection method for serum-binding proteins, whose
receptors could be subsequently be identified using biochemical purification and mass
spectrometry approaches discussed in Chapter 5.
3In its earlier stages BSI used immobilised receptors on the surface of the chip, in a similar manner to SPR
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Figure 6.2: BSI as a method to discover and measure protein-RBC interactions
A. Schematic representation of the BSI methodology. In brief, a helium-neon laser beam is directed onto a
microfluidic chip containing the sample. Photons take different paths through the matrix, being reflected in
complex patterns from the walls of the channel such that they are out-of-phase (and thus interfere) upon their
exit from the channel. This results in the formation of a visible interferometric fringe pattern. The fringe pattern
can be recorded using a CCD camera, then analysed. An increase in the refractive index of the solution will
proportionately decrease the speed at which the photons travel through the matrix, meaning that their phase upon
exit from the channel will be different. Consequently, the waves interfere with each other differently and the
position of the fringe pattern changes. BSI can be used to measure tiny shifts in the position of the fringes and
infer a change in the refractive index of the solution. Biomolecular binding events can bring about profound
changes to the organisation of molecules in solution, and hence cause refractive index changes. The formation of
a new complex in the solution has been shown to induce measurable phase shifts in the fringe pattern detected by
BSI, even at very low concentrations of the binding species. Figure from Bornhop et al., (2007)[31]. Reproduced
with permission from AAAS.
B. BSI was used to measure the interaction of purified recombinant PfRH5 and BSG receptors on the suface
of intact RBCs. In brief, RBCs were incubated with a range of PfRH5 concentrations for one hour and the
phase of the interference fringe pattern was measured using the BSI instrument. Phase change was calculated
by subtracting this reading from that using negative control RBCs that had been pre-incubated with anti-BSG
antibody, to prevent PfRH5 binding. These data allowed the plotting of a saturation binding curve and the
estimation of the KD at around 1µM, which is almost identical to that calculated for the interaction between
recombinant PfRH5 and BSG by SPR by Crosnier et al., (2011)[64]. Error bars represent mean +/- SEM, n=7.
Data courtesy of Phoonthawee Saetear, Vanderbilt University.
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6.4 Concluding remarks
Whilst the main result of this work is the discovery of a set of interactions occurring in vitro
between human SELP and Plasmodium MSP7 proteins, I have also developed and optimised
experimental techniques that can be used more broadly for the discovery and characterisation
of protein-protein interactions. Going forward, the interactions between SELP and MSP7s
require further validation and functional analyses so as to precisely define their role in the
pathogenesis of malaria. Concurrently, the further use, development and refinement of inter-
action detection methodologies such as those discussed in this thesis could lead to the iden-
tification of additional host-pathogen interactions. The processes of validation, biochemical
characterisation and functional analysis, as described for SELP/MSP7 interactions, could then
contribute to our existing knowledge about the molecular details of the interactions Plasmod-
ium parasites make with their hosts. These insights could contribute to the rational design of
drugs and vaccinations, to combat the global burden of malaria.
Appendix A
Glossary
A.1 Abbreviations Used in this work
ADP: adenine diphosphate
AP: alkaline phosphatase
APC: antigen-presenting cell
AVEXIS: Avidity-based extracellular interaction screening
BBB: blood-brain barrier
BSA: bovine serum albumin
BSI: Back-scattering interferometry
cDNA: complementary DNA
COS: A simian cell line, CV-1 in Origin, and carrying the SV40 virus genetic material
CTL: C-type lectin
DC: dendritic cell
DNA: deoxyribonucleic acid
dNTPs: deoxyribonucleotide triphospates
EBV: Epstein-Barr Virus
ECM: experimental cerebral malaria
EDTA: ethylenediaminetetraacetic acid
ELISA: enzyme-linked immunosorbant assay
FACS: fluorescene-associated cell sorting
FCS: foetal calf serum
FITC: fluorescein isothiocyanate
FLAG: DYKDDDDK octapeptide tag
GPI: glycophosphatidylinositol
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GST: glutathione S-transferase,
HBS: HEPES-buffered saline
HBST: HBS containing 0.2% Tween
HEK: Human Embryonic Kidney
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HRP: Horseradish peroxidase
HSPG: heparan sulphate proteoglycan
HUVEC: human umbilical vien endothelial cell
IMAC: immobilised metal ion affinity chromatography
ITN: insecticide-treated net
IRS: indoor residual spraying
LB: Luria broth
mAB: monoclonal antibody
MWCO: molecular weight cut-off
PAGE: polyacrylamide gel electrophoresis
PAMP: pathogen-associated molecular pattern
PBS: phosphate-buffered saline
PCR: polymerase chain reaction
PEI: polyethylenimine
PMA: Phorbol 12-myristate 13-acetate
PPI: protein-protein interaction
pRBC: parasitised red blood cell
PRP: platelet-rich plasma
PVDF: Polyvinylidene fluoride
RBC: red blood cell
SDS: sodium dodecyl sulphate
SEC: size-exclusion chromatography
sLeX: Sialyl-LewisX
SMA: severe malarial anaemia
SNP: single nucleotide polymorphism
SPR: surface plasmon resonance
TM: transmembrane
WHO: World Health Organsiation
Y2H: yeast two-hybrid
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A.2 Protein names
AMA1: Apical membrane antigen 1 (P. falciparum)
APLP2: Amyloid precursor-like protein 2 (H.sapiens)
ASP: Apical sushi protein (P. falciparum)
BirA: Biotin protein ligase (E. coli)
BSG: Basigin (H.sapiens)
CD: Cluster of differentiation protein (H.sapiens, R.norvegicus)
COMP: Cartilage oligomeric matrix protein (H.sapiens)
CR1: Complement receptor 1 (H.sapiens)
CSA: Chondroitin sulfate A (H.sapiens)
CSP: Circumsporozoite protein (H.sapiens)
EBA: Erythrocyte-binding antigen (P. falciparum)
EBL1: Erythrocyte binding ligand 1 (P. falciparum)
EBNA1: Epstein Barr Nuclear Antigen 1 (Epstein Barr virus)
EGF: Epidermal growth factor (H.sapiens)
EMP: Erythrocyte membrane protein (P. falciparum)
EPCR: Endothelial protein C receptor (H.sapiens)
ESAM: Endothelial cell-selective adhesion molecule (H.sapiens)
GFP: Green fluorescent protein (A. victoria)
GLURP: Glutamate rich protein (P. falciparum)
GYPA: Glycophorin A (H.sapiens)
ICAM: Intercellular adhesion molecule (H.sapiens)
IFN: Interferon (H.sapiens)
LAMP2: Lysosome-associated membrane protein 2 (H.sapiens)
MIF: Macrophage migration inhibitory factor (H.sapiens)
MSP: merozoite surface protein (P. falciparum, P.vivax, P. berghei)
MSRP: MSP7-related protein (P. falciparum, P. berghei)
MTRAP: merozoite TRAP-like protein (P. falciparum)
PECAM1: Platelet endothelial cell adhesion molecule 1 (H.sapiens)
PMIF: Plasmodium macrophage migration inhibitory factor (P. falciparum)
PSGL1: P-selectin glycoprotein ligand 1 (H.sapiens)
RH: Reticulocyte binding-like homologue (P. falciparum)
SCARF2: Scavenger receptor class F member 2 (H.sapiens)
SEA1: Schizont egress antigen 1 (P. falciparum)
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SELE: E-selectin (H.sapiens)
SELL: L-selectin (H.sapiens)
SELP: P-selectin (H.sapiens, M. musculus)
SELPLG: P-selectin ligand (H.sapiens)
SEMA7a: Semaphorin 7a (H.sapiens)
SERA: Serine repeat antigen (P. falciparum)
SPATR: Sporozoite protein with an altered thrombospondin repeat (P. falciparum)
STARP: Sporozoite threonine-asparagine-rich protein (P. falciparum)
TLR: Toll-like receptor (H.sapiens)
TNF: Tumour necrosis factor (H.sapiens)
TRAP: Thrombospondin-related adhesive protein (P. falciparum, P.berghei)
TRSP: Thrombospondin-related sporozoite protein (P. falciparum)
A.3 Weblinks
1000 genomes sequencing database: www.1000genomes.org
dbSNP database: www.ncbi.nlm.nih.gov/SNP
Disopred3: Found at bioinf.cs.ucl.ac.uk/psipred
Disprot: www.disprot.org/pondr-fit.php
IUPred:iupred.enzim.hu
Pfam database: pfam.xfam.org
PlasmoDB: plasmodb.org/plasmo/
PrDOS:prdos.hgc.jp/cgi-bin/top.cgi
T-COFFEE multiple protein sequence alignment: www.ebi.ac.uk/Tools/msa/tcoffee
Uniprot: www.uniprot.org
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